Report Sections

See All Reports

  • drug1150: Convalescent plasma
  • Placebo (610) Hydroxychloroquine (101) Standard of Care (44) Azithromycin (39) Tocilizumab (36) Placebo oral tablet (34) Questionnaire (33) Remdesivir (32) Standard of care (29) Convalescent Plasma (28) No intervention (24) Favipiravir (23) Ivermectin (23) Convalescent plasma (22) Placebos (17) placebo (17) Enoxaparin (16) Survey (16) Methylprednisolone (15) Nitazoxanide (15) Control (14) Vitamin C (14) Colchicine (13) Blood sample (12) Dexamethasone (12) Hydroxychloroquine Sulfate (12) Anakinra (11) Questionnaire Administration (11) Saline (11) Usual Care (11) Vitamin D (11) Questionnaires (10) Ruxolitinib (10) Standard care (10) blood sample (10) no intervention (10) Camostat Mesilate (9) Losartan (9) questionnaire (9) Baricitinib (8) Blood sampling (8) Lopinavir/ritonavir (8) Nasopharyngeal swab (8) Zinc (8) survey (8) Chloroquine (7) Clazakizumab (7) Gam-COVID-Vac (7) LY3819253 (7) Normal saline (7) Oseltamivir (7) Prednisone (7) Quality-of-Life Assessment (7) Saliva collection (7) Standard treatment (7) DAS181 (6) Interferon beta-1a (6) Lung ultrasound (6) Normal Saline (6) Prone position (6) Rivaroxaban (6) Sarilumab (6) Standard Care (6) Vitamin D3 (6) blood sampling (6) convalescent plasma (6) Acalabrutinib (5) Ad26.COV2.S (5) Aspirin (5) Best Practice (5) COVID-19 (5) COVID-19 Convalescent Plasma (5) COVID-19 convalescent plasma (5) Camostat (5) Cholecalciferol (5) Cyclosporine (5) Doxycycline (5) Famotidine (5) Hydroxychloroquine (HCQ) (5) Interview (5) Lopinavir / Ritonavir (5) Mepolizumab (5) Midazolam (5) Nafamostat Mesilate (5) Online Survey (5) Online survey (5) Placebo Administration (5) Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (5) Standard Medical Treatment (5) Standard of Care (SOC) (5) UC-MSCs (5) Usual care (5) hydroxychloroquine (5) questionnaire assesment (5) Alirocumab (4) Ascorbic Acid (4) Association atezolizumab + BDB001 + RT (4) BCG Vaccine (4) BCG vaccine (4) BNT162b2 (4) Best Supportive Care (4) Blood draw (4) CELLECTRA® 2000 (4) Colchicine Tablets (4) Dapagliflozin (4) Data collection (4) Evolocumab (4) HCQ (4) Heparin (4) Hydrocortisone (4) Ibrutinib (4) Interferon Beta-1A (4) LY3832479 (4) Lopinavir/Ritonavir (4) Matching placebo (4) Mavrilimumab (4) Melatonin (4) Methotrexate (4) Nitric Oxide (4) Observational (4) Online questionnaire (4) Ontamalimab (4) Opaganib (4) Oxygen (4) Ozanimod (4) Peginterferon beta-1a (4) Povidone-Iodine (4) Presatovir (4) Prone positioning (4) RLS-0071 (4) Reslizumab (4) Rifampin (4) Rosuvastatin (4) SARS-CoV-2 (4) SARS-CoV-2 convalescent plasma (4) Sargramostim (4) Survey Administration (4) Telemedicine (4) Telerehabilitation (4) Yoga (4) anti-SARS-CoV-2 convalescent plasma (4) standard care (4) 0.9% saline (3) 3D Telemedicine (3) ACE inhibitor (3) AG0302-COVID19 (3) AZD1222 (3) AZD7442 (3) Abatacept (3) Allocetra-OTS (3) Allopurinol (3) Anti-SARS-CoV2 Serology (3) Apremilast (3) Atorvastatin (3) BAY1817080 (3) BCG-Denmark (3) BI 764198 (3) BI 894999 (3) BNT162b1 (3) Biospecimen Collection (3) Blood samples (3) COVID-19 RT-PCR (3) COViage (3) Carboplatin (3) Chloroquine or Hydroxychloroquine (3) Chloroquine phosphate (3) Clinical assessment (3) Clinical data (3) Clopidogrel (3) Cognitive Behavioral Therapy (3) Control group (3) DWRX2003 (3) Deferoxamine (3) ECG (3) EIDD-2801 (3) Echocardiography (3) Eltrombopag (3) Exercise (3) Exercise program (3) Fremanezumab (3) GSK3640254 (3) INO-4800 (3) Inactivated SARS-CoV-2 Vaccine (Vero cell) (3) Interferon Beta-1B (3) Interferon beta-1b (3) Itraconazole (3) Lenzilumab (3) MEDI3506 (3) Mesenchymal Stromal Cells (3) Mesenchymal stromal cells (3) Mindfulness (3) Naltrexone (3) Niclosamide (3) Nitric Oxide Gas (3) Nivolumab (3) No Intervention (3) No intervention, observational study (3) Observation (3) PLACEBO (3) Pembrolizumab (3) Pentoxifylline (3) Phase 2 (3) Placebo oral capsule (3) Plasma (3) Povidone-Iodine Nasal Spray and Gargle (3) Probiotic (3) Prone Positioning (3) Prospective study with two measurement points investigating the impact of viral mitigation protocols on mental health (3) REGN10933+REGN10987 combination therapy (3) RT-PCR (3) Ravulizumab (3) Recombinant new coronavirus vaccine (CHO cells) placebo group (3) Relamorelin (3) Remestemcel-L (3) Ribavirin (3) Saline Placebo (3) Selinexor (3) Serological test (3) Siltuximab (3) SnPP Protoporphyrin plus Sunlight exposure (3) Standard of care (SOC) (3) Supportive Care (3) Suspension of heat killed (autoclaved) Mycobacterium w (3) TY027 (3) Telmisartan (3) Unfractionated heparin (3) VPM1002 (3) Venetoclax (3) Verinurad (3) Vitamin Super B-Complex (3) blood donation SMS (3) exhaled breath sampling (3) mRNA-1273 (3) observational (3) placebo for risankizumab (3) risankizumab IV (3) risankizumab SC (3) self-administered questionnaire (3) standard of care (3) standard therapy (3) 0.9% Saline (2) 100 mg/mL Virazole (2) 2D Telemedicine (2) 300 mg of omega3-FA (2) 50 mg/mL Virazole (2) ADCT-301 (2) AG0301-COVID19 (2) ARB (2) AT-100 (2) ATI-450 (2) AVIGAN 200 MG Film Tablets (2) AZD2693 (2) AZD5718 (2) AZD9977 (2) Abidol hydrochloride (2) Acalabrutinib Treatment A (2) Acalabrutinib Treatment B (2) Acalabrutinib Treatment C (2) Acebilustat (2) Aeonose (2) Aerobic Exercise Training (2) Alteplase 50 MG [Activase] (2) Ampion (2) Angiotensin 1-7 (2) Angiotensin II (2) Angiotensin converting enzyme inhibitor (2) Angiotensin-(1-7) (2) Antibiotics (2) Apixaban 2.5 MG (2) Appendectomy (2) Arbidol (2) Assessment of behavioral response to emotional stimulation (2) Assessment of work-related stress (2) Association atezolizumab + BDB001+ RT (2) Atezolizumab (2) Attention Placebo (2) Ayurveda (2) Azithromycin Tablets (2) BI 474121 (2) BIIB091 (2) Bacille Calmette-Guérin (BCG) (2) Baloxavir Marboxil (2) Baricitinib Oral Tablet (2) Behavioral Activation SSI (2) Bemiparin (2) Bevacizumab Injection (2) Bicalutamide 150 Mg Oral Tablet (2) Biological data (2) Biological sample collection (2) Blood test (2) Blood tests (2) Breath Biopsy face masks with removable filters and fitted PVA strip (2) Brequinar (2) Brief cognitive intervention (2) Bucillamine (2) CFTR Modulators (2) COVID Convalescent Plasma (2) COVID-19 Serology (2) COVID-19 Therapeutic Biologics - Spike-GM-CSF Protein Lactated Ringer's Injection (2) COVID-19 exposure (2) COVID-19 pandemic (2) COVID-19 patients (2) COVID-19 survey (2) CT-P59 (2) CT-Scan (2) CYT107 (2) Cabotegravir Tablets (2) Camostat Mesylate (2) Canakinumab (2) Candin (2) Cannabidiol (2) Cardiac and electrodermal recordings (2) ChAdOx1 MERS (2) ChAdOx1 nCoV-19 (2) Chemotherapy (2) Chlorhexidine Gluconate (2) Chloroquine Sulfate (2) Chloroquine or hydroxychloroquine (2) Ciclesonide (2) Clinical Examination (2) Cognitive training (2) Convalescent COVID 19 Plasma (2) Convalescent Plasma (CP) (2) Convalescent Plasma (anti-SARS-CoV-2 plasma) (2) Convalescent Plasma Transfusion (2) Conventional treatment (2) Corticosteroid (2) Daclatasvir (2) Data Collection (2) Data record (2) Defibrotide (2) Dexamethasone injection (2) Diagnostic test (2) Disulfiram (2) Dornase Alfa Inhalation Solution [Pulmozyme] (2) Double-Trunk Mask (2) Durvalumab (2) Duvelisib (2) EC-18 (2) EDP1815 (2) EXO 1 inhalation (2) EXO 2 inhalation (2) Early-Dexamethasone (2) Ebselen (2) Eculizumab (2) Electronic questionnaire (2) Enhanced Usual Care (2) Enoxaparin 40 Mg/0.4 mL Injectable Solution (2) Ensifentrine (2) Etoposide (2) Exebacase (2) Exercise training (2) Exposure (2) Expressive writing (2) Famotidine 20 MG (2) Favipiravir Placebo (2) Fiberoptic Endoscopic Evaluation of Swallowing (2) Fisetin (2) Flow cytometric analysis (2) Fluoxetine (2) Follow up (2) Fostamatinib (2) Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale (2) GLPG3970 (2) GLS-5300 (2) Growth Mindset SSI (2) Guduchi Ghan Vati (2) HB-adMSCs (2) HFNC (2) Hepatitis A vaccine (2) High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule (2) Home exercise (2) Human biological samples (2) Human immunoglobulin (2) Hydroxychloroquine + azithromycin (2) Hydroxychloroquine - Weekly Dosing (2) Hydroxychloroquine 200 Mg Oral Tablet (2) Hydroxychloroquine Sulfate 200 MG (2) Hydroxychloroquine Sulfate 200 MG [Plaquenil] (2) Hydroxychloroquine Sulfate Loading Dose (2) Hydroxychloroquine Sulfate Regular dose (2) Hydroxychloroquine Sulfate Tablets (2) Hydroxychloroquine and Azithromycin (2) Hyperbaric oxygen (2) Hypothermia (2) ICU treatment (2) IMU-838 (2) IVIG (2) Icosapent ethyl (2) Imlifidase (2) Infliximab (2) Interleukin-7 (2) Intramuscular injection (2) Iodine Complex (2) Ion Mobility Spectrometry (IMS) (2) Ivermectin Oral Product (2) Ivermectin Pill (2) Ivermectin and Doxycycline (2) Ixazomib (2) KB109 + Self Supportive Care (SSC) (2) Ketogenic diet (2) L-ascorbic acid (2) Lanadelumab (2) Lazertinib (2) Leflunomide (2) Lemborexant 10 mg (2) Leronlimab (700mg) (2) Lopinavir-Ritonavir (2) Low Dose Radiation Therapy (2) Low Dose Radiotherapy (2) Low Oxalate Diet (2) Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule (2) Low molecular weight heparin (2) M5049 (2) MAS825 (2) MSC (2) MW33 injection (2) MW33 injection placebo (2) MagPro X100 Stimulator, B70 Fluid-Cooled Coil (2) Matched Placebo (2) Matching Placebo (2) Meaning Centered Psychotherapy for Latinos (2) Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients (2) Meditation (1 x 20-minute guided audio training) (2) Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule (2) Meplazumab for Injection (2) Metformin (2) Methylprednisolone Sodium Succinate (2) Mindfulness Based Intervention (2) Mobocertinib (2) Molnupiravir (2) Moxifloxacin (2) Multivitamin (2) N-Acetyl cysteine (2) N-acetylcysteine (2) NORS (Nitric Oxide Releasing Solution) (2) Narrative Writing (2) Nasal swab (2) Nasopharyngeal swabs (2) Neuromuscular Blocking Agents (2) Niclosamide Oral Tablet (2) Nigella Sativa / Black Cumin (2) Nitrogen gas (2) Observational study (2) Olokizumab 64 mg (2) Online Questionnaire (2) Other (2) PLX-PAD (2) PUL-042 Inhalation Solution (2) Paracetamol (2) Parent Education (2) Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances (2) Peginterferon Lambda-1A (2) Peripheral blood draw (2) Phase 1 (2) Phone call (2) Physical exercise training (2) Physiotherapy (2) Pirfenidone (2) Placebo (NaCl 0.9%) (Group 2D) (2) Placebo Comparator (2) Placebo capsules (2) Placebo inhalation (2) Placebo on a 0- and 28-day schedule (2) Postcard (2) Pozelimab (2) Practice details (2) Prazosin (2) Pre-assessment questionnaire (2) Psychoeducation (2) Pulmonary Rehabilitation (2) Pulmozyme (2) RECOP unit patient (2) RELX ENDS Menthol Flavor (2) RELX ENDS Tobacco Flavor (2) RLF-100 (aviptadil) (2) RO6889450 (2) RTB101 (2) RTH258/Brolucizumab (2) Rabeprazole (2) Radiation therapy (2) Radiotherapy (2) Rapamycin (2) Recombinant new coronavirus vaccine (CHO cell) low-dose group (2) Recombinant new coronavirus vaccine (CHO cells) high-dose group (2) Remdesivir placebo (2) Rifampicin (2) Rilpivirine Tablets (2) Risankizumab (2) Rituximab (2) Routine care for COVID-19 patients (2) Ruxolitinib Oral Tablet (2) SAB-185 (2) SARS-CoV-2 PCR (2) SARS-CoV-2 diagnostic rapid test (2) SARS-CoV-2 rS/Matrix-M1 Adjuvant (2) SARS-Cov2 testing (2) SCTA01 (2) SEL-212A (2) SEL-212B (2) SOC (2) SOC + Placebo (2) Saline solution (2) Saliva sample collection (2) Sample collection (2) Sampling (2) Self Supportive Care (SSC) Alone (2) Semi-directive interview (2) Seraph 100 (2) Serology test for COVID-19 (2) Serum testing (2) Sevoflurane (2) Simple cognitive task intervention (2) Simvastatin (2) Single Dose of Hydroxychloroquine (2) Sirolimus (2) SivoMixx (200 billion) (2) Spesolimab (2) Spirometry (2) Standard Therapy (2) Standard of Care (SoC) (2) Standard of Care Treatment (2) Standard of care treatment (2) Stellate Ganglion Block (2) Supportive Therapy SSI (2) T3011 (2) TD-0903 (2) Taking blood samples (capillary and venous), saliva sampling and nasopharyngeal sampling. (2) Telehealth (2) Telisotuzumab vedotin (2) Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg (2) Tezepelumab (2) Therapeutic Plasma Exchange (2) Therapeutic anticoagulation (2) Throat swab (2) Thymalfasin (2) Tildrakizumab (2) Tocilizumab (TCZ) (2) Tocilizumab Injection (2) Tofacitinib (2) Tofacitinib 10 mg (2) Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit (2) Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 (2) Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 (2) Two doses of placebo at the schedule of day 0,28 (2) Virtual Reality (2) Volatile Organic Compounds analysis (2) Volitional help sheet (2) Vonoprazan (2) Xanomeline and Trospium Chloride Capsules (2) basic treatment (2) blood draw (2) blood samples (2) blood test (2) conjunctival swab (2) digoxin (2) human monoclonal antibody DZIF-10c (Group 1A-2D) (2) lung ultrasound (2) nasopharyngeal swab (2) online survey (2) other (2) oxygen therapy (2) pregnant women with laboratory-confirmed 2019-n-CoV (2) prone position (2) retrospective analysis (2) rhTPO (2) serology (2) survey work (2) tabelecleucel (2) tocilizumab (2) unfractionated Heparin (2) venous ultrasound (2) vv-ECMO + cytokine adsorption (Cytosorb adsorber) (2) vv-ECMO only (no cytokine adsorption) (2) "Calm" is a mindfulness meditation mobile app (1) "Sham"-block with Placebo (Isotone NaCl) (1) "Vernonia amygdalina" (1) (Standard of Care) SoC (1) - Synthetic anti-malarial drugs (1) 0.075% Cetylpyridinium Chloride (1) 0.12% Chlorhexidine Gluconate (1) 0.12% Chlorhexidine Gluconate Mouth Rinse (1) 0.12% Chlorhexidine oral/nasal rinse (1) 0.5% Povidone Iodine (1) 0.5% Povidone/Iodine oral/nasal rinse (1) 0.9% (w/v) saline (1) 0.9% Normal Saline (1) 0.9% Sodium Chloride (Placebo) (1) 0.9% Sodium-chloride (1) 0.9% sodium chloride (normal saline) (1) 0.9%NaCl (1) 0.9%sodium chloride (1) 1% Hydrogen Peroxide (1) 1% w/v Povidone-iodide (1) 1. Characterize the immune response after infection with SARS-CoV-2 (1) 1.5-2% w/v Hydrogen Peroxide (1) 10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse (1) 11C-ER176 (1) 12 weeks of bicycle exercise (1) 12-page health warning leaflet (1) 12-week FMS Intervention (1) 14C-lazertinib (1) 150 ppm Nitric Oxide delivered through LungFit Delivery System (1) 18F-DX600 PET/CT (1) 18F-Florbetaben (1) 18F-GP1 PET CT (1) 18F-MK-6240 (1) 18F-αvβ6-BP (1) 1: ILT101 (1) 1: Naproxen (1) 1: Prone positioning (1) 1: Usual practice (1) 1: discontinuation of RAS blocker therapy (1) 1D (1) 20 Mg Prednisone for 14 days (1) 20 mg MitoQ (1) 2019-nCoV IgG/IgM Rapid Test Cassette (1) 2019-nCoV PCR (1) 21% Ethanol plus essential oils (1) 24 hour Holter ECG (1) 25-OH cholecalciferol (1) 2: No instruction regarding positioning (1) 2: Placebo Comparator (1) 2: Standard of care (1) 2: Usual practice + SYMBICORT RAPIHALER (1) 2: continuation of RAS blocker therapy (1) 3 Wishes Project (1) 30 Gy over 3 weeks (1) 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients) (1) 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients ) (1) 38 questions questionnaire (1) 38-questions questionnaire (1) 3D (1) 40-Steps-test (1) 40mg of MitoQ (1) 40ml blood sample (1) 4Plants/Azythromycin (1) 5-ALA-Phosphate + SFC (5-ALA + SFC) (1) 50 Gy Radiation Therapy (1) 55 Gy Radiation Therapy (1) 5Fluorouracil (1) 6 minute walk test (1) 60 Gy Radiation Therapy (1) 68Ga-DX600 PET/CT (1) 7-day exposure therapy via self-developed app according to (Haberkamp et al., submitted) (1) 80 ppm Nitric Oxide delivered through LungFit Delivery System (1) A $10 Survey Incentive (1) A $20 Survey Incentive (1) A short video intervention (1) A vignette intervention (1) AAZ Covid-19 rapid test (1) ABBV-47D11 (1) ABBV-951 (1) ABC/3TC (1) ABPM (1) ABTL0812 (1) ABX464 (1) ACE Inhibitors and Calcium Channel Blockers (1) ACE inhibitor, angiotensin receptor blocker (1) ACEI (1) ACEI/ARB (1) ACEIs (1) ACP Decisions Video Program (1) ACT-1014-6470 (1) ACT-20-CM (1) ACT-20-MSC (1) ACT-541478 10 mg (1) ACT-541478 100 mg (1) ACT-541478 1000 mg (1) ACT-541478 30 mg (1) ACT-541478 300 mg (1) ACT-541478 dose E1 (1) ACT-541478 high or low dose (or placebo) (1) ADAM Sensor (1) ADM03820 (1) AI model (1) AIRVO (1) AK119 (1) ALLOCETRA-OTS (1) ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS (1) ALX148 (1) ALZT-OP1 (cromolyn and ibuprofen) ALZT-OP1a (cromolyn) and ALZT-OP1b (ibuprofen) (1) AMA Acknowledgement Drug Pricing (1) AMY-101 (1) AN69-Oxiris (1) AN69-Standard (1) ANNE One (1) APL-9 (1) APPS (1) ARALAST NP (1) ARBIDOL 100 MG KAPSUL (1) ARBOX (1) ARBs and/or ACE inhibitors (1) ARCT-021 Dose 1 (1) ARCT-021 Dose 2 (1) ARCT-021 Dose 3 (1) ARCT-021 Dose 4 (1) ARCT-021 Dose Regimen 1 (1) ARCT-021 Dose Regimen 2 (1) ARDSNet (1) ARFC mask (1) ARGX-117 (1) ARGX-117 + rHuPH20 (1) ASC09/ritonavir group (1) ASC09F+Oseltamivir (1) ASP0367 (1) ASP2390 (1) ASP7317 (1) ASSIST (1) ASTX660 (1) AT-001 (1) AT-527 (1) ATAFENOVIR 200 MG KAPSUL (1) ATI-1777 (1) ATYR1923 1 mg/kg (1) ATYR1923 3 mg/kg (1) AUDIT score interpretation sheet adapted from the Department of Health of Hong Kong (1) AUP1602-C (1) AV-COVID-19 (1) AVICOD 200 MG Film Tablet (1) AVIGAN (1) AVIGAN 200 mg FT (1) AVIGAN 200 mg Film Tablets (1) AVM0703 (1) AVP 4 (1) AVP I (1) AVP II (1) AWARD advice (1) AWARD plus COVID-specific advice (1) AZD1390 (1) AZD1402 (1) AZD1656 (1) AZD3427 (1) AZD5069 (1) AZD8154 Monodose DPI presented in capsules (1) AZD8154 Placebo Monodose DPI presented in capsules (1) AZD8154 nebuliser (1) AZD9567 (1) AZD9833 Oral Solution (1) AZD9833 film-coated tablet A Dose 1 (1) AZD9833 film-coated tablet A Dose 2 (1) AZD9833 film-coated tablet B Dose 1 (1) AZD9833 film-coated tablet B Dose 2 (1) Abdominal ultrasound (1) Abidol Hydrochloride combined with Interferon atomization (1) Abiraterone Acetate (1) Abivertinib (1) Ablative Fractional 2940 nm Laser (1) Absolute Pro LL stent (1) Acacia Senegal (1) Acalabrutinib Treatment D (1) Acceptability questionnaire (1) Acceptance and Commitment Therapy (1) Access to training facility (1) Accuchek Inform II platform (1) Acetazolamide + supplemental oxygen + PAP therapy (1) Acetyl L-Carnitine (1) Acetylsalicylic acid (1) Acknowledgement Racial Injustice AMA (1) Actigraph (1) Active COVID-19 disease (1) Active Choice (1) Active Comparator (1) Active Comparator: Control (1) Active Control (1) Active PBMT/sMF (1) Active control condition (1) Active control:Healthy Living (1) Active nudge text feedback (1) Activity (1) Activity plan to break up sitting time (1) Acyclovir (1) Ad26.ZEBOV (1) Ad5-nCoV (1) Ad5FGF-4 (1) Adalimumab (1) Additional and minimal collection of products of the human body carried out during a sample for standard of care (1) Additional biological samples (1) Adenosine (1) Adenovirus Type-5 Vectored COVID-19 Vaccine (1) AdimrSC-2f (1) Adipose tissue (1) Administration of Equine immunoglobulin anti SARS-CoV-2 (1) Admission to ICU for COVID-19 (1) Adsorbed COVID-19 (inactivated) Vaccine (1) AeroEclipse II Breath Actuated Nebulizer (1) Aerobic Exercises (1) Aerobic training (1) Aerolized Hydroxychloroquine Sulfate (1) Aerosol Box (1) Aerosol-reducing Mask (1) Aerosolized 13 cis retinoic acid (1) Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone (1) Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg (1) Aerosolized All trans retinoic acid (1) Aerosolized All-Trans Retinoic acid plus oral Tamoxifen (1) Aerosolized Isotretinoin plus Tamoxifen (1) African American Sender Acknowledgement (1) African American Sender in Informational Videos. (1) After COVID-19 Pandemic (1) AirFLO2 (1) AirGo Respiratory Monitor (1) Airwave Oscillometry (1) Airway pressure release ventilation (1) Albendazole (1) Albuterol - Control (1) Albuterol - Experimental (1) Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic) (1) Alcohol (1) Alcohol brief intervention (1) Alexa Amazon (1) Alferon LDO (1) Algorithm-based recommendation (1) Alisporivir (1) AlloStim (1) Allogeneic NK transfer (1) Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells (1) Allogenic pooled olfactory mucosa-derived mesenchymal stem cells (1) Almitrine (1) Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C (1) Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose (1) Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment (1) Alprazolam 1mg XR (1) Alteplase (1) Alternating face-to-face medical visits and video medical consultations (1) Aluminum adjuvant (1) Aluminum hydroxide (1) Aluminum hydroxide adjuvant (Alhydrogel®) (1) Alvelestat (1) Ambrisentan (1) Amiodarone (1) Amlodipine (1) Amlodipine 2.5 mg/indapamide 1.25 mg (1) Amoxicillin-clavulanate (1) An auto-questionnaire comprising three psychometric scales (1) Anakinra +/- Ruxolitinib (stages 2b/3) (1) Anakinra 100Mg/0.67Ml Inj Syringe (1) Anakinra 149 MG/ML Prefilled Syringe [Kineret] (1) Anakinra Prefilled Syringe (1) Anakinra alone (stages 2b/3) (1) Anakinra and Ruxolitinib (Advanced stage 3) (1) Anakinra and Ruxolitinib (overcome stage 3) (1) Anakinra and Zinc (1) Anakinra plus oSOC (1) Analogs, Prostaglandin E1 (1) Analysis of cytokine response, innate and adaptive immune response, complement activation, and serum neurofilaments as a marker of neurological damage. (1) Anatomic Pulmonary Resection (1) Anger message (1) Angiography (1) Angiography scanner (1) Angiotensin II Receptor Blockers (1) Angiotensin Receptor Blockers (1) Angiotensin receptor blocker (1) Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin II Receptor Blockers (ARB) (1) Anluohuaxian (1) Anthocyanins (1) Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients (1) Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients (1) Anti- SARS-CoV-2 Plasma (1) Anti-COVID-19 human immunoglobulin (1) Anti-Human Thymocyte Immunoglobulin, Rabbit (1) Anti-SARS-CoV-2 Human Convalescent Plasma (1) Anti-SARS-CoV-2 IgT seropositivity (1) Anti-SARS-CoV-2 convalescent plasma (1) Anti-SARS-CoV-2 equine immunoglobulin fragments (INOSARS) (1) Anti-SARS-CoV-2 immunoglobulin (1) Anti-SARS-CoV2 serological controls and serum neutralization (1) Anti-Sars-CoV-2 Convalescent Plasma (1) Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients (1) Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients (1) Antibody Test (1) Antibody test (SARS-CoV2) (1) Antibody testing (1) Antibody titration (1) Antibody-Rich Plasma from COVID-19 recovered patients (1) Anticoagulant Therapy (1) Anticoagulation Agents (Edoxaban and/or high dose LMWH) (1) Antihemophilic Factor (Recombinant) (1) Antihypertensive Agents (1) Antioxidation Therapy (1) Antithrombin III (1) Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19 (1) Antroquinonol (1) Anxiety Reduction Training (1) Any drug used to treat Covid-19 (1) Apilimod Dimesylate Capsule (1) Apixaban (1) Apixaban 5MG (1) Apo-Hydroxychloroquine (1) Appeals (1) Apple Watch Series 5 (1) Application of tele-rehabilitation (1) Apramycin injection (1) Aprepitant injectable emulsion (1) Aprotinin (1) Arbidol Hydrochloride Granules (1) Argatroban (1) Arm exercise electrocardiographic stress test (1) Artemesia annua (1) ArtemiC (1) Artemisia Annua Leaf (1) Artemisinin / Artesunate (1) Arterial Blood Gas test (ABG) (1) Artesunate (1) Artesunate-amodiaquine (1) Artificial tear MDI - 101 (1) Ascorbic Acid and Zinc Gluconate (1) Ashmolean Website (1) Aspirin 100mg (1) Aspirin 75mg (1) Aspirin 81 mg (1) Assembled mask (1) Assessing antibody responses, neutralizing capacity and memory B-cell function (1) Assessing impact of COVID19 (1) Assessment of Dietary Changes in Adults in the Quarantine (1) Assessment of cardiovascular diseases and cardiovascular risk factors (1) Assessment of coagulopathy, Platelets activation and Platelets-Neutrophils interplay (1) Assessment of lung mechanics and heart-lung interactions (1) Assessment of postnatal depression using the the Edinburgh questionnaire between 4 and 6 weeks after delivery (1) Assessment of ventilator-associated pneumonia criteria (1) Assigned Strategies: Active Choice (1) Assigned Strategies: Enhanced Active Choice (1) Assigned Strategies: Opt-in (1) Association of diltiazem and niclosamide (1) Asthma controller therapies (incl. prednisone/prednisolone) (1) Asthma reliever therapies (1) AstroStem-V (1) Asunercept (1) Asynchronies detection (1) Asynchronous self-directed digital training (1) Atazanavir (1) Atazanavir and Dexamethasone (1) Atomoxetine hydrochloride (1) Atorvastatin 20 Mg Oral Tablet (1) Atorvastatin 20mg (1) Atorvastatin 40mg (1) Atovaquone/Azithromycin (1) Attention Bias Modification (ABM) (1) Attention Control Group (1) Attention Control Intervention 4 (1) Attention Control Text Messaging (1) Attention Training Program (1) Attention control (1) Audio-Visual Triage System (AVT) (1) Audit and Feedback (1) Auditory Evoked Potentials (AEP) (1) Augmentin (ES)-600 (1) Auricular neuromodulation (1) Auricular percutaneous neurostimulation (1) Auscul-X (1) Auto-questionnaires (patients co infected HIV Sras-CoV-2) (1) Autologous Adipose MSC's (1) Autologous Bone Graft (1) Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) (1) Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells (1) Autologous fat cell transplantation (1) Automated oxygen administration - FreeO2 (1) Autophagy inhibitor (GNS651) (1) Auxora (1) Avdoralimab (1) Aviptadil 67μg (1) Aviptadil by intravenous infusion + standard of care (1) Awake Prone Positioning (1) Awake Proning (1) Awake prone positioning (1) Awake proning (1) Ayurvedic Kadha (1) Azacitidine (1) Azacytidine (1) Azinc (1) Azithromycin (Azithro) (1) Azithromycin 250 MG (1) Azithromycin 250 MG Oral Capsule (1) Azithromycin 500 milligram (mg) oral Tablet (1) Azithromycin 500Mg Oral Tablet (1) Azithromycin Capsule (1) Azithromycin and hydroxychloroquine (1) Azithromycin with amoxicillin/clavulanate (1) Açaí palm berry extract - natural product (1) BACMUNE (MV130) (1) BAT (1) BAT + Calcifediol (1) BAT2020 (1) BAX 888 (1) BAY1211163 Dose 1 (1) BAY1211163 Dose 2 (1) BAY1211163 Dose 3 (1) BAY1211163 Dose 4 (1) BAY1211163 Dose 5 (1) BAY1237592 (1) BAY2328065 LSF (1) BAY2328065 tablet (1) BBV152 (1) BBV152A - Phase I (1) BBV152A - Phase II (1) BBV152B - Phase I (1) BBV152B - Phase II (1) BBV152C - Phase I (1) BCG (1) BCG GROUP (1) BCG vaccine (Freeze-dried) (1) BCG-10 vaccine (1) BDB-001 Injection (1) BGB DXP593 (1) BGB-DXP593 (1) BI 1015550 (1) BI 1323495 (1) BI 1358894 (1) BI 1569912 (1) BI 425809 (1) BI 706321 (1) BI 730357 (1) BI 764198 - Formula A (1) BI 764198 - Formula B (1) BI 764198 - Formula C (1) BI 764198 - Formula D (1) BIIB107 (1) BIIB133 (Dapirolizumab pegol) (1) BIKTARVY Tablets (BIK) (1) BIO 300 Oral Suspension (1) BIO101 (1) BIOMARKERS IN THE LONG TERM IMPACT OF CORONAVIRUS INFECTION IN THE CARDIORRESPIRATORY SYSTEM (1) BIOVITALS (1) BLAfit® (1) BLD-2660 (1) BLZ945 (1) BM-Allo.MSC (1) BM-MSCs (1) BMS program (1) BMS-986253 (1) BMS-986256 (1) BMS-986259 (1) BMS-986322 (1) BMS-986322 Placebo (1) BMS-986337 (1) BMS-986337 Placebo (1) BNT162a1 (1) BNT162b3 (1) BNT162c2 (1) BRIDGE Therapy Program (1) BRII-196 (1) BRII-198 (1) BTL-TML-COVID (1) BVA-100 (1) BVRS-GamVac (1) BVRS-GamVac-Combi (1) Bacillus Calmette-Guerin (BCG) (1) Back Side of the Moon (1) Background questionnaire (1) Bactek-R (1) Bacterial species isolated (1) Baking Soda (1) Balance exercise (1) Bamlanivimab (1) Bardoxolone methyl (1) Bariatric procedures (1) Bariatric surgery (1) Baricitinib (janus kinase inhibitor) (1) Baricitinib 4 MG Oral Tablet (1) Baricitinib or Anakinra (1) Barrier box (1) Base therapy (1) Baseline and during hospitalization blood samples (1) Baseline blood sample (1) Baseline message (1) Basic Body Awareness Therapy (1) Basic Go NAPSACC (1) Beck Depression Inventory (BDI) (1) Bedside lung ultrasound (1) Behavioral Activation in real-life (1) Behavioral activation, evidence-based sleep strategies including sleep restriction, exposure-based strategies, promotion of physical activity and recuperating activities, psychoeducational material (1) Behavioral: OCAT (1) Behavioral: OCAT-sham (1) Behaviour Change Technique Intervention to Improve Quality of Life (1) Behavioural Experiments for Intolerance of Uncertainty (1) Being Brave (1) Bemiparin sodium (1) Bemotrizinol (1) Bempegaldesleukin (1) Benlysta (1) Berberine (1) Bereavement Virtual Support Group (1) Berzosertib (1) Best Available Therapy (1) Best Available Therapy (BAT) (1) Best Message + Augmented Message or Implementation Strategy (1) Best Message Alone (1) Best Standard of Care (1) Best Standard of Care + CARDIO (1) Best available care (1) Best available treatment (1) Best standard of care (1) Best supportive care" which includes antivirals /antibiotics/ hydroxychloroquine; oxygen therapy (1) Bevacizumab (1) Bicalutamide 150 mg (1) Bimekizumab (1) Bintrafusp alfa (1) BioMedomics COVID-19 IgM-IgG Rapid Test (1) Bioarginina® (1) Biobehavioral Tele-rehabilitation Sessions (1) Biocollection (1) Biocontainment Device For Aerosol Generating Procedures (Biobox) (1) Biological (1) Biological Sample Collection (1) Biological collection (patients co infected HIV Sras-CoV-2) (1) Biological collection with nasopharyngeal samples, saliva, blood, stool and urine (1) Biological sample and clinical data collection (1) Biological samples specific to research (1) Biological sampling (1) Biological test (1) Biological/Vaccine: Angiotensin peptide (1-7) derived plasma (1) Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group (1) Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group (1) Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) placebo group (1) Biological: COVID-19 convalescent plasma (1) Biological: mRNA-1273: 100 mcg (1) Biological: mRNA-1273: 50 mcg (1) Biological: oral polio vaccine (1) Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT) (1) Biomarkers expression (1) Biosensor (1) Biosensors (1) Biospecimen collection (1) Bivalirudin Injection (1) Blackmores Omega Daily (4 1g capsules per day) (1) Bleomycin and Vincristine (BV) (1) Blink and Masseter Inhibitory Reflex (1) Blood Collection (1) Blood D-dimer assay (1) Blood Draw (1) Blood Sample (1) Blood Test (1) Blood Transfusion (1) Blood analysis (1) Blood and derivatives. (1) Blood collection (1) Blood collection at Day 8, Day 16, Day 24, Month 6 and Month 12 after first symptoms from SARS-CoV-2 infection (1) Blood collection on admission and longitudinally (1) Blood collection on their first consultation and 10 to 14 days later (1) Blood donation from convalescent donor (1) Blood for anti-drug antibody (ADA) (1) Blood for pharmacokinetic samples (1) Blood for research purposes (1) Blood group determination (1) Blood plasma (1) Blood sample and data record (1) Blood sample collection (1) Blood sample for serological test (1) Blood sample for serology to measure past infection with SARS-CoV-2 (1) Blood sample for whole genome sequencing (1) Blood samples (collection of 5 mL of blood in a dry tube) (1) Blood samples collection (1) Blood sampling (venesection) (1) Blood test for IgG antibodies against SARS-CoV-2 (1) Blood tests sputum, nasal lavage and brushing (1) Bloodwork (1) Body Project (BP) (1) Bolus placebo (1) Bolus vitamin D3 (1) Bone Marrow Harvest (1) Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment (1) Bone conduction headphones (1) Botox (1) Bovine Lactoferrin (1) Bovine Lipid Extract Surfactant (1) Brain Health Education (BHE) (1) Brain MRI (1) Brain MRI scan (1) Brainstem Responses Assessment Sedation Score (BRASS) (1) Brazilian Green Propolis Extract (EPP-AF) (1) Breastfeeding (1) Breastfeeding Support Provided to Mothers Through WhatsApp Messaging Application (1) Breastfeeding self-efficacy (BSE) (1) Breath Biopsy (1) Breath Biopsy Analysis (1) Breath Test & Cheek Swab (1) Breath biopsy sampling using the ReCIVA Breath Sampler (1) Breath sample (1) Breath test (1) Breathing exercise, intensive spirometry use, supported cough, progressive mobilisation and ambulation (1) Brensocatib 10 mg (1) Brensocatib 25 mg (1) Brexanolone (1) Bridge therapy (1) Brief Behavioral Activation Treatment (1) Brief Behavioral Activation with Mental Imagery (1) Brief Interpersonal Telepsychotherapy (1) Brief Psychiatric Rating Scale (1) Brief Skills for Safer Living (1) Brief cognitive behavioral therapy (1) Brief educational video (1) Brief informational infographic (1) Bromhexine 8 MG (1) Bromhexine Hydrochloride (1) Bromhexine Hydrochloride Tablets (1) Bromhexine Oral Tablet and/or hydroxychloroquine tablet (1) Bromhexine and Spironolactone (1) Broncho-Vaxom® (1) Bronchoalveolar Lavage (BAL) (1) Budesonide (1) Budesonide Nasal (1) Budesonide dry powder inhaler (1) Buprenorphine Sublingual Product (1) Burnout (1) Buspirone + PAP therapy (1) Buspirone 10 Mg Oral Tablet (1) Butterfly (1) Butterfly iQ (1) C-reactive protein (1) C21 (1) C2Rx (1) C3+ Holter Monitor (1) CAG length <22 (1) CAG length >=22 (1) CALY-002 (1) CAM2038 (1) CAP-1002 (1) CAP-1002 Allogeneic Cardiosphere-Derived Cells (1) CAPABLE Transitions (1) CAStem (1) CBD Isolate (1) CBT Text Messaging (1) CBT-OSA (1) CCP (1) CCTP (1) CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc (1) CD24Fc (1) CD55 (1) CDX-0159 (1) CE-Iohexol (1) CELLECTRA™ 2000 (1) CERC-002 (1) CETA Short Session (CSS) (1) CFZ533 (1) CGB-S-100 (1) CH505TF gp120 (1) CHAMindWell (1) CHEST CT SCAN (1) CHLORPROMAZINE (CPZ) (1) CHMI (1) CHX0.12+CPC0.05 oral rinse (PerioAidActive Control) (1) CICI - Feasibility trial study group (1) CIG Axial (1) CIG Tilted (1) CK0802 (1) CLBS119 (1) CLIA of IgG and IgM against SARS-Cov-2 (1) CM4620-IE (Injectable Emulsion) (1) CME (active control) (1) CMP-001 (1) CMR with T1 and T2 mapping (1) CNM-ZnAg (1) CNS magnetic resonance imaging (MRI) imaging (1) COM-COVID anonimous survey (1) COMPASS (1) CONTROL GROUP (1) CONVALESCENT PLASMA (1) COPAN swabbing and blood sample collection (1) CORVax (1) COSH Self-help smoking cessation booklet (1) COVI-AMG (1) COVI-GUARD (1) COVI-VAC (1) COVICU (1) COVID 19 Convalescent Plasma (1) COVID 19 Diagnostic Test (1) COVID 19 Self-Questionnaire (1) COVID 19 diagnostic test by PCR (1) COVID 19 impact (1) COVID 19 serology (1) COVID WHELD (1) COVID Watch (1) COVID positive via testing (1) COVID visitation restrictions (1) COVID-19 Androgen Sensitivity Test (CoVAST) (1) COVID-19 Antibody testing (1) COVID-19 Antigen/Antibody Rapid Testing, mobile device image capture and telemedicine support (1) COVID-19 Breastfeeding Support (1) COVID-19 Convalescent Plasma (CCP) (1) COVID-19 Convalscent Plasma (1) COVID-19 Diagnostic and Assessment Tests (1) COVID-19 FACILITY (1) COVID-19 IgG / IgM rapid test (whole blood, serum, plasma) (1) COVID-19 IgG/IgM Rapid Test Cassette test (Healgen Scientific, Houston, Texas, USA) (1) COVID-19 PCR (1) COVID-19 PCR Swab (1) COVID-19 PCR and Serology (1) COVID-19 PCR and serology testing (1) COVID-19 Pandemic (1) COVID-19 Pneumonia (1) COVID-19 Specific T Cell derived exosomes (CSTC-Exo) (1) COVID-19 Swab (1) COVID-19 and Intensive Care (1) COVID-19 antibodies testing (1) COVID-19 antibody point of care test kit (1) COVID-19 barrier box (1) COVID-19 convalescent hyperimmune plasma (1) COVID-19 convalescent plasma (CCP) plus standard of care (SOC) (1) COVID-19 convalescent plasma treatment (1) COVID-19 diagnostic PCR (1) COVID-19 diagnostic test (1) COVID-19 e-package: Psychological wellbeing for healthcare workers (1) COVID-19 experience surveys (1) COVID-19 infection (1) COVID-19 infection status (1) COVID-19 positive via testing (1) COVID-19 related health warning leaflet (1) COVID-19 standard care (1) COVID-19 swap test PCR (1) COVID-19 test (1) COVID-19 test, polymerase chain reaction for SARS-CoV-2 (1) COVID-19 testing (1) COVID-19 treatment (1) COVID-19 treatments (1) COVID-19+ observational (1) COVID-HIGIV (1) COVID-VIRO® test (1) COVID-surgRES questionaire (1) COVID19 (1) COVID19 convalescent plasma infusion (1) COVID19 vaccine (1) COVIDSeq Test (1) COVSurf Drug Delivery System (1) CPAP (1) CPAP treatment (1) CPI-006 (1) CRESTOR® (1) CRI management (1) CSL324 (1) CSL760 (1) CT of the chest (1) CT score (1) CT-P59/Placebo (1) CT-V (1) CT-imaging (1) CT-scan (1) CT-scan with minimal invasive autopsy (1) CTUS examination (1) CUROSURF® (poractant alfa) (1) CVL-865 High dose (1) CVL-865 low dose (1) CVnCoV (1) CVnCoV 12 μg (1) CVnCoV 12μg (1) CVnCoV 6 μg (1) CVnCoV Vaccine (1) CYNK-001 (1) CYP 450 Substrates (1) CYP-001 (1) Cabotegravir 200 mg/mL (1) Cabotegravir 400 mg/mL (1) Cabotegravir Injectable Suspension (CAB LA) (1) Cabotegravir extended release suspension for injection (long-acting) (1) Cabotegravir sodium (Oral Lead In) (1) Caffeine 200 mg (1) Calcium Channel Blockers (1) Calm Meditation App (1) Cambridge Validated Viral Detection Method (1) Camidanlumab Tesirine (1) CanSwab (1) Canakinumab 150 MG/ML [Ilaris] (1) Canakinumab Injection 300mg (1) Canakinumab Injection 600mg (1) Candesartan (1) Canine odor detection of Volatile Organic Compounds (1) Cannabidiol, pharmaceutically produced with < 5 ppm THC (1) Cannabidivarin (1) Cannabis, Medical (1) Capillary Collection & Testing (1) Capillary and salivary sampling (1) Caption AI (1) Cardiac CT (1) Cardiac MRI (1) Cardiac Magnetic resonance imaging (1) Cardiac rehabilitation (1) Cardiac surgery (1) Cardiopulmonary resuscitation (1) Cardiorespiratory Exercise (1) Cardiovascular Magnetic Resonance (CMR) Imaging (1) Care with C-reactive protein assay in micro method (1) Caring Contacts (1) Carotid Artery Reactivity Testing (1) Carrageenan nasal and throat spray (1) Carrimycin (1) Case fatality rate (1) Cash transfer (1) Ceftaroline (1) Ceftriaxone (1) Cell therapy protocol 1 (1) Cell therapy protocol 2 (1) Cell-culture based influenza vaccines (1) Cellectra 2000 Electroporation (1) Cellular response (1) Cemdisiran (1) Cenicriviroc (1) Cenicriviroc (CVC) (1) Cenobamate (1) Centricyte 1000 (1) Centrum Adult (under 50) multivitamin (1) Ceralasertib (1) Cerebral compliance and hemodynamics monitoring (1) Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies (1) Certified cloth face mask plus preventive information (1) ChAd155-RG (1) ChAdOx1 nCoV-19 (Abs 260) (1) ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost (1) ChAdOx1 nCoV-19 (qPCR) (1) ChAdOx1 nCoV-19 0.5mL boost (1) ChAdOx1 nCoV-19 0.5mL prime plus boost (1) ChAdOx1 nCoV-19 full boost (1) ChAdOx1 nCoV-19 half boost (1) ChAdOx1 nCoV-19 single dose + paracetamol (1) ChAdOx1 nCoV-19 two dose + paracetamol (1) ChAdOx1-HPV (1) Change in knowledge, motivation, skills, resources (1) Change in preference to surgery under COVID-19 pandemic. (1) Chat-based instant messaging support (1) Chat-based support (1) Chest MRI (1) Chest computed tomography (CT) (1) Chest physiotherapy using a non-invasive oscillating device (1) Chinese Herbal Medicine (1) Chinese medicine treatment (1) Chiropractic care (more than one visit) (1) Chiropractic care (one visit) (1) Chloroquine Diphosphate (1) Chloroquine Phosphate Tablets (1) Chloroquine diphosphate (1) Chlorpromazine (1) Choice of Assignment: Active Choice (1) Choice of Assignment: Enhanced Active Choice (1) Choice of Assignment: Opt-in (1) Choices and judgements (1) Chronic Disease Self-Management Program (1) Chronic Hypersensitivity Pneumonitis Health Related Quality of Life Survey Instrument (1) ChulaCov19 mRNA vaccine (1) Ciclesonide Inhalation Aerosol (1) Ciclesonide Metered Dose Inhaler [Alvesco] (1) Cimetidine (1) Cisplatin (1) Clarithromycin (1) Clarithromycin 500mg (1) Clazakizumab 12.5 mg (1) Clazakizumab 25 mg (1) Clevudine (1) Clinical Observation (1) Clinical diagnosis of COVID-19 by a health care professional (1) Clinical examination (1) Clinical interview (1) Clinical, functional and radiological lung involvement evolution (1) Clinical, laboratory and imaging characteristics of pneumonia (1) Cliniporator (1) Clinolipid (1) CloSYS mouthwash (1) Clofazimine (1) Clonidine HCl Mucoadhesive Buccal Tablet (1) Clopidogrel 75mg (1) Closed face shield with Surgical face mask use (1) Closed-loop control of oxygen supplementation by O2matic (1) Cloth Face Mask (1) Clungene rapid test cassette (1) Co-created intervention (1) Co-formulated Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) (1) Co-mestring (co-coping) (1) CoYoT1 Care (1) Coala Heart Monitor (1) Cobicistat (1) Cocoa extract (1) Cocoa extract placebo (1) Cod liver oil (1) Cognitive Behavior Therapy (1) Cognitive Behavioral Brief-Telepsychotherapy (1) Cognitive Behavioural Group Therapy for Perinatal Anxiety (1) Cognitive Behavioural Therapy for Insomnia (1) Cognitive Behavioural Therapy with Mindfulness classes (1) Cognitive Stimulation (1) Cognitive Training (1) Cognitive and behavioral intervention. (1) Cognitive behavioral therapy (CBT) (1) Cognitive testing (1) Cohort (1) Colchicine 0.5 MG (1) Colchicine 1 MG Oral Tablet (1) Colchicine Pill (1) Colchicine plus symptomatic treatment (paracetamol) (1) ColdZyme® mouth spray (1) Coldamaris lozenges (1) Colgate Peroxyl mouthwash (1) Colgate Total mouthwash (1) Colgate periogard mouthwash (1) Collagen-Polyvinylpyrrolidone (1) Collection of Biological Samples (1) Collection of blood samples in order to create a biocollection (1) Collection of blood, salivary and nasopharyngeal samples. (1) Collection of breath sample (1) Collection of odour samples (1) Collection of samples (1) Collection of tears and saliva. (1) Colonoscopy (1) Colorectal resection (1) Colorectal resections (1) Combination (1) Combination of Lopinavir /Ritonavir and Interferon beta-1b (1) Combination of oral polio vaccine and NA-831 (1) Combined ART/hydroxychloroquine (1) Combined use of a respiratory broad panel multiplex PCR and procalcitonin (1) Commercial membrane for Extracorporeal Blood Purification Therapy (EBPT) (1) Common Elements Toolbox (1) Common Elements Toolbox- Adult version (COMET-A) (1) Communication (1) Communication type (1) Community Referral as appropriate (1) Community based combination HIV prevention package (1) Community identity recruitment (1) Community interest message (1) Community popular opinion leader (POL) based intervention (1) Community-driven messages to promote COVID-19 testing (1) Comparable Placebo (1) Comparable Placebo of Oral Polio Vaccine and Placebo of drug (1) Comparable Placebo of drug (1) Comparative Observational Cohort Study (1) Comparator (1) Comparator full face mask 1 (1) Comparator full face mask 2 (1) Comparator full face mask 3 (1) Compassion focused intervention (1) Complement dosage (1) Complete thrombophilic profile testing by multiplex PCR (1) Completion of post telemedicine encounter survey (1) Completion of pre-pandemic survey (1) Completion of survey after peak of pandemic (1) Complex diagnostic panel (1) Comprehensive treatment (1) Computed Tomography (CT) (1) Computer Based Response Training Weight Loss Intervention (1) Computer task questionnaires (1) Computerized Talking Touchscreen (1) Conestat alfa (1) Conexiones (1) Confinement and Communication During the COVID-19 Pandemic (1) Conjunctival swab and nasopharyngeal swab (1) Connected devices measurements (1) Connor-Davidson Resilience Scale 10 items (CD-RISC 10) (1) Contain COVID Anxiety SSI (1) Continuation of ACEi/ARB (1) Continuation of ARB/ACEI (1) Continuation of anti-TNF treatment (1) Continuous Glucose Monitor (CGM) (1) Continuous Positive Airway Pressure (1) Continuous renal replacement therapy (1) Continuous vital sign monitoring - Isansys Patient Status Engine (1) Contrast-enhanced CMR (1) Control (albumin 5%) (1) Control (standard clinical practice) (1) Control Blend (1) Control Group (1) Control Group (pharmacotherapy and/or psychotherapy, n=10) (1) Control Intervention (1) Control Period (1) Control Test (1) Control arm (1) Control for aerosol generating procedures (1) Control message (1) Control patients (1) Control swab (1) Control-EDI (1) ConvP (1) Convalescent Immune Plasma (1) Convalescent Plasma 1 Unit (1) Convalescent Plasma 2 Units (1) Convalescent Plasma Infusion (1) Convalescent Plasma as Therapy for Covid-19 patients (1) Convalescent Plasma from COVID-19 donors (1) Convalescent Plasma of patients with COVID-19 (1) Convalescent SARS COVID-19 plasma (1) Convalescent Serum (1) Convalescent anti-SARS-CoV-2 MBT Plasma (1) Convalescent anti-SARS-CoV-2 MBT plasma (1) Convalescent anti-SARS-CoV-2 plasma (1) Convalescent plasma (CP) (1) Convalescent plasma transfusion (1) Convalesscent Plasma (1) Conventional CPR training (1) Conventional N95 respirator (1) Conventional Oxygen Therapy (1) Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) (1) Conventional medicines (Oxygen therapy, alfa interferon via aerosol inhalation, and lopinavir/ritonavir) and Traditional Chinese Medicines (TCMs) granules (1) Conventional oxygen therapy (1) Conventional physical therapy (1) Conventional therapy first (1) Cooking Training (1) Coping strategies video (1) Cord Tissue Mesenchymal Stromal Cells (1) Cordio App (1) Core Warming (1) Corn oil (placebo) (1) CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test (1) CoronaVac (1) Coronary artery calcium score and cardiac computed tomographic angiography (1) Coronavirus Anxiety Scale , COVID-19 Phobia Scale (1) Coronavirus Disease 2019 (1) Corticosteroid injection (1) Corticosteroid with or without colchicine (1) Corticosteroids and Derivatives (1) Cosentyx (1) Cospherunate/Azythromycine (1) Cospherunate/Phytomedicine/Azythromycien (1) Cost-Benefit Frame (1) Counseling Services Alone (1) Counter Attitudinal Therapy (1) Couples' Intervention (1) CovX (1) Covax-19™ (1) Covid ICU containment measures (1) Covid-19 + patients (1) Covid-19 Antibody testing (IgG and IgM) (1) Covid-19 PCR , IGM (1) Covid-19 Rapid Test Kit (RAPG-COV-019) (1) Covid-19 Standard of Care (1) Covid-19 presto test (1) Covid-19 swab PCR test (1) Covid19 (1) Covidfree@home (1) Covigenix VAX-001 (1) Covigenix VAX-001 placebo (1) Crest Pro-Health Multi-Protection mouthwash (1) Crisis intervention therapy (1) Crisis management coaching (1) Crizanlizumab (1) Cross Sectional study using scientifically validated psychometric Scales (1) Cross-sectional observational study (1) Cross-sectional study examining the impact of information sources to obtain information about COVID-19 on depression and anxiety symptoms (1) Cross-sectional study investigating the association of NPIs with mental health (1) Cross-sectional survey (1) Curently used therapy for COVID-19 non-critical patients (1) Current care per UCLA treating physicians (1) Customized questionnaire (1) Cyclophosphamide injection (1) Cyclosporin A (1) CytoSorb (1) CytoSorb 300 mL device (1) CytoSorb-Therapy (1) Cytochrome P450 (CYP) Substrates (1) Cytokine Adsorption (1) Cytokines dosage (1) Cytokines measurement (1) D-1553 (1) D-beta-hydroxybutyrate-(R)-1,3 butanediol monoester (1) D-dimer,CBC.ESR,CRP, (1) DAS181 COVID-19 (1) DAS181 OL (1) DASS-21 instrument (depression and anxiety) (1) DAXI for injection Dose HIGH DOSE (1) DAXI for injection dose LOW DOSE (1) DAXI for injection dose MEDIUM DOSE (1) DB-001 (1) DFV890 (1) DIG Axial (1) DIG Tilted (1) DPPFit (1) DUR-928 (1) DWJ1248 (1) Dabigatran etexilate (1) Dabigatran etexilate + BI 1323495 (1) Daclatasvir 60 mg (1) Daily Coping Toolkit (1) Daily Monitoring (1) Daily Vitamin D3 (1) Daily placebo (1) Danoprevir+Ritonavir (1) Dapagliflozin 10 MG (1) Dapagliflozin 10 mg (1) Daprodustat (1) Darunavir (1) Darunavir and Cobicistat (1) Darunavir/Cobicistat (1) Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC (1) Darunavir/Ritonavir (DRV/RTV) (1) Darvadstrocel (1) Data Collection: Clinical Care Assessments (1) Data collection and clinical testing of subjects (1) Data collection and rhinopharyngeal swab (1) Data collection from blood draw (1) Data collection from lumbar puncture (1) Data collection from medical files (1) Data collection up to 1 year (1) Data monitoring for 48h within the first 12 hours of admission for COVID-19 (1) Data registry (1) Data research, database analysis (1) Ddrops® products, 50,000 IU, Oral (1) Decidual Stromal Cells (DSC) (1) Decitabine (1) Deep Breathing training (1) Deep Venous Disease Diagnostic (1) Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days (1) Defibrotide Injection (1) Degarelix (1) Delayed diagnostics Anyplex TMII RV16 Detection (1) Delivery of iStride™ device gait treatment using telemedicine (1) DeltaRex-G (1) Dental pulp mesenchymal stem cells (1) Depression, Anxiety and Stress Scale (1) Descartes 30 (1) Description of groups caracteristics (1) Desferal 500 MG Injection (1) Desidustat (1) Detection of anti-COVID-19 antibody level (1) Determination of physical activity, quality of life, stress levels of isolated people at home with the danger of coronavirus. (1) Device used to record voice for screening (1) Dexamethasone (high dose) (1) Dexamethasone 2 MG/ML (1) Dexamethasone and Hydroxychloroquine (1) Dexcom G6 (1) Dexmedetomidine Injectable Product (1) Dexmethylphenidate (1) DiaNose (1) Diabetes type 2 (1) Diagnosis of SARS-Cov2 by RT-PCR and : IgG, Ig M serologies in the amniotoc fluid, the blood cord and the placenta (1) Diagnostic Laboratory Biomarker Analysis (1) Diagnostic Test: serology test for COVID-19 (1) Diagnostic examination for venous thromboembolism (1) Diagnostic mammography (1) Diagnostic test Covid-19 (1) Diagnostic test for SARS-Cov2 for patients and health staff (1) Diagnostic test for detection of SARS-CoV-2 (1) Dialectical Behavioral Therapy (DBT) Skills (1) Dialyzable Leukocyte Extract (1) Diet tracking and survey (1) Dietary Intervention (1) Dietary Supplement containing resistant starch (1) Dietary advice (1) Dietary advice and advice on timing (1) Dietary counselling on Food Groups according to IYC Feeding practices, WHO (1) Dietary intake, body composition, lifestyle, and CVD risk factors (1) Dietary program (1) Differences in triage (1) Differential Leucocyte Count (CLDC) device and algorithm (1) Difficulties lived by disabled children's parents in the period of COVID-19 pandemic (1) Diffusing capacity of carbon monoxide (1) DigiVis visual acuity app (1) Digital Health Literacy Intervention (1) Digital Health Online Platform (1) Digital cardiac Counseling (1) Digital intervention (1) Digital oximeter monitoring (1) Digoxin (1) Digoxin 0.25 mg (1) Diphenhydramine (1) Dipyridamole (1) Dipyridamole 100 Milligram(mg) (1) Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care (1) Direct Antigen Tests for COVID-19 (1) Direct laryngoscope (1) Direct laryngoscopy (1) DirectCAM (1) Discontinuation of ACEi/ARB (1) Discontinuation of ARB/ACEI (1) Discontinuation of anti-TNF treatment (1) Discussion Board for Social Support +Basic Feedback (1) Discussion Board for Social Support+Personalized Feedback (1) Disease-modifying antirheumatic drugs (DMARDs) (1) Distilled water (1) Docetaxel (1) Dociparastat sodium (1) Doctella telehealth monitoring (1) Doctor Spot (1) Doctorgram Patient Kit (1) Doing What Matters in Times of Stress: An Illustrated Guide (1) Dolutegravir (1) Doppler Echo (1) Dornase Alfa (1) Dornase Alfa Inhalation Solution (1) Dose Finding Phase (MTD) (1) Dose of Tinzaparin or Dalteparin (1) Dose of tinzaparin or dalteparin (1) Double-Blind NT-I7 (1) Double-Blind Placebo (1) Dove Confident Me Indonesia Single Session (1) Doxycyclin (1) Doxycycline Hcl (1) Drug COVID19-0001-USR (1) Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment (1) Drug: GS-5734 - 1.00 mg/kg (1) Drug: GS-5734 - 2.00 mg/kg (1) Drug: Isotretinoin plus Tamoxifen (1) Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) (1) Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole (1) Drug: NA-831 (1) Drug: NA-831 - 0.10 mg/kg (1) Drug: NA-831 - 0.20 mg/kg (1) Drug: Standard treatment Standard treatment (1) Drugs and supportive care (1) Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) (1) Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg) (1) DuACT (1) Duo Venous Stent System (1) Duodenal biopsy (1) Dupilumab (SAR231893/REGN668) (1) Duplex ultrasound and Computed Tomography Angiography (1) During COVID-19 Pandemic (1) Dutasteride (1) Dutasteride 0.5 mg (1) Duty Frame (1) DynamX Bioadaptor (1) Dynamic 3D bone motion capture (1) Dysphagia Handicap Index (DHI) (1) E-cigarette ad exposure (1) EBV gp350-Ferritin Vaccine (1) ECCO2R (1) ECG from handheld device (1) ECG-Holter (1) ECMO Implantation (1) EDP-938 (1) EEG (1) EG-HPCP-03a (1) EG-HPCP-03a Placebo (1) EHR-based Clinician Jumpstart (1) EIT-Group (1) ELISA (1) ELISA and Rapid test to detect antibodies against COVID-19 (1) ELISPOT (1) ELIZA, Extraction of nucleic acid ,Determination of viral genome by using PCR, Quantitative real-time PCR to assess viral load ,Immunohistochemistry analysis of EMB. (1) ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY (1) ELMO PROJECT AT COVID-19: STUDY IN HUMANS (1) EMDR (1) EMPOWER (1) ENT exam (1) EP (1) EPDS (Edinburgh Postnatal Depression Scale) (1) EPIC risk score display (1) EQ001 (1) EQ001 Placebo (1) ESOGER (1) ESPRIMO (1) ESPRIT™ BTK Device (1) EU-approved RoActemra (1) EUROIMMUN assay (1) EXN407 (1) EXTRA-CVD Virtual Care (1) EarSats Pulse Oximeter Probe (1) Early Aggressive Therapy or Traditional Therapy (1) Early rehabilitation (1) EasyCov POC (1) Eating habits (1) Echo-Doppler (1) Economic benefit message (1) Economic freedom message (1) Edinburgh Postnatal Depression Scale (EDPS) (1) Edoxaban Tablets (1) Education (1) Education sessions (1) Educational Program on Air Pollution as a Health Risk Reduction Strategy (1) Educational meetings and visual prompts (1) Educational outreach (1) Effects of a 2-week DASH/SRD intervention vs. control diet on HFpEF functional cardiovascular risk factors (1) Effortful Control Camp (1) Egg based influenza vaccines (1) Eicosapentaenoic acid gastro-resistant capsules (1) Ejaculated semen sample (1) Elaborative Reminiscence (ER) (1) Elagolix (1) Elective Cancer Surgery (1) Electric pad for human external pain therapy (1) Electrical Impedance Tomography (EIT) (1) Electrical Impedance tomography (1) Electrocardiogram (ECG) (1) Electrocardiogram, telemetry, echocardiogram, laboratory values (1) Electrocardiogram, transthoracic echocardiography and clinico-biological parameters in routine care (1) Electrocautery Ablation (EC) (1) Electroencephalogram with EKG lead (1) Electronic Health Record Review (1) Electronic Survey questionnaire (1) Electronic survey (1) Electrotherapy group (1) Elisa-test for IgM and IgG to SARS-CoV-2 (1) Emapalumab (1) Embarrassment message (1) Emergency Laparotomy (1) Emergency Ventilator Splitter (1) Emergency surgery (1) Emotion Regulation Training via Telehealth (1) Emotion- and Relationship-Focused Therapeutic Interview (1) Emotional Freedom Technique (1) Emotional Support Plan (1) Emphasis of Academic Researchers Involvement (1) Emphasis of Government Involvement (1) Emtricitabine/Tenofovir Alafenamide (1) Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet (1) Emtricitabine/tenofovir (1) Emtricitabine/tenofovir disoproxil (1) Enbrel (1) End tidal breath sample (1) Endoscopic intervention (1) Endoscopic management according to standard of care (1) Endoscopic procedure (1) Endothelial damage and angiogenic biomarkers (1) Endothermal Ablation (ETA) (1) Endotracheal intubation (1) Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19 (1) Enhanced Chronic Disease Self-management program (1) Enhanced Go NAPSACC (1) Enhanced Milieu Teaching (1) Enhanced hygiene measures (1) Enhanced linkage (1) Enhanced supervised fitness training (1) Enoxaparin 1 mg/kg (1) Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml (1) Enoxaparin Higher Dose (1) Enoxaparin Prefilled Syringe [Lovenox] (1) Enoxaparin Prophylactic Dose (1) Enoxaparin sodium (1) Enoxaparin/Lovenox Intermediate Dose (1) Enriched Survey Feedback (1) Ensifentrine Dose 1 (1) Entinostat (1) Entrée: Behavioral skills (1) Entrée: Cognitive skills (1) Entrée: Interpersonal skills (1) Environmental Decontamination (1) Environmental exposure and clinical features (1) Enzalutamide (1) Enzalutamide 40 MG (1) Enzalutamide Pill (1) EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) (1) Equipment with smartwatch throughout hospital stay on the general ward (1) Ergoferon (1) Eritoran (1) Erlotinib (1) Escin (1) Esflurbiprofen hydrogel patch 165 mg (EFHP) (1) Esomeprazole 20mg (1) Esophageal temperature monitoring probe (1) Essential Oil Blend (1) Essential oils (1) Estradiol patch (1) Estrogen Therapy (1) Ethanol with Asprin (1) Etoposide (ET) (1) Etravirine (ETR) (1) Etripamil (1) Evaluate HACOR score effectivity in this patients (1) Evaluation of changes in the diagnostic-therapeutic pathway for patients affected by pancreatic cancer (1) Evaluation of clinical, instrumental and laboratory diagnostics tests (1) Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2) (1) Ex vivo expanded Wharton's Jelly Mesenchymal Stem Cells (1) Examinations for the research: (1) Examine the impact of COVID-19 during pregnancy (1) Exercise Group (1) Exercise Intervention (1) Exercise Testing and Training (1) Exercise Training Only (1) Exercise and Cognitive Training (1) Exercise booklet (1) Exercise brochure (1) Exercise capacity (1) Exercise physiology (1) Exercise test ECG (1) Exercise training group (1) Experiences in Close Relationship Scale questionnaire (ECR-S) (1) Experimental 1 (1) Experimental 2 (1) Experimental Group (1) Experimental drug (1) Experimental: PIVOT with MI (1) Experimental: Questionnaire without precaution information (1) Experts consensus (1) Expiratory training device (1) Exposed to the novel coronavirus disease 2019 (1) Exposure (not intervention) - SARS-CoV-2 infection (1) Exposure Therapy (1) Exposure to the Dutch measures due to the Covid-19 pandemic. (1) Exposure to the SARS-CoV-2 (1) Exposure to the SARS-CoV-2 and its consequences (1) Exposure: Covid-19 infection (1) Expression of receptors and activating proteases (1) Extended Vision IOL (1) Extended sampling and procedures (1) Extra blood sample (1) Extracorporeal Membrane Oxygenation (1) Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter (1) Extracorporeal left hemicolectomy anastomosis (1) Extracorporeal membrane oxygenation (1) Extravascular Lung Water Index (1) Eye Movement Desensitisation and Reprocessing Recent traumatic Event Protocol (1) Eye Movement Desensitization and Reprocessing (EMDR) (1) EyeQue Insight (1) F-652 (1) F-FMISO PET/CT Scan (1) FAVICOVIR 200 mg Film Tablet (1) FAVIR 200 MG FT (1) FAVIRA 200 MG Film Tablet (1) FBT (1) FBT+Variety (1) FCR001 (1) FEIBA (1) FFP (1) FFP2 (1) FITSTART+ PBI (1) FLOW intervention (1) FLT3 Ligand (CDX-301) (1) FMD (1) FNC dummy tablet+Standard of Care (1) FNC+Standard of Care (1) FOY-305 (1) FS120 (1) FSD201 (1) FT516 (1) FTC/TAF (1) FTX-6058 oral capsule(s) - Two dosing periods (1) FTX-6058 oral capsule(s) / Midazolam Syrup (1) FTX-6058/placebo oral capsule(s) (1) FX06 (1) Face Mask + Soap (1) Face mask (1) Face mask awareness (1) Face mask sampling (1) Face-to-face medical visits (1) Face-to-face training (1) Facebook Ads on the importance of staying safe during the Thanksgiving holiday (1) Facial fractures reduction or osteosynthesis (1) Facial mask (1) Family Nurture Intervention (FNI) (1) FamilyChildCare (provisional name of app) (1) Farmalarm (1) Fast dissolving film (1) Favipiravir (3200 mg + 1200 mg) (1) Favipiravir (3200 mg + 1200 mg) combined with Azithromycin (1) Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine (1) Favipiravir (3600 mg + 1600 mg) (1) Favipiravir + Currently used therapy (1) Favipiravir + Standard of Care (1) Favipiravir Combined With Tocilizumab (1) Favipiravir and Hydroxychloroquine (1) Favipiravir plus Nitazoxanide (1) Favipiravir tablets (1) Fecal Microbiota Therapy (FMT) (1) Feeling Good Digital App (1) Fenofibrate (1) Ferric maltol capsule (1) Ferric maltol suspension (1) Fiberoptic Bronchoscopy (FOB) (1) Fibreoptic Endoscopic Evaluation of Swallowing (FEES) (1) Fibrin generation markers assays (1) Fidaxomicin (1) File Scanning (1) File scanning (1) Filgotinib (1) FilmArray PCR on respiratory samples (1) FilmArray Pneumonia (1) Filtration Test (1) Fingerstick (1) Fingolimod 0.5 mg (1) Fit test (1) Five-days oseltamivir (1) Fixed Anchoring Strategy (1) Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration (PH FDC SC) (1) Fixed-duration Hydrocortisone (1) Fixed-duration higher dose Hydrocortisone (1) Flexitouch Plus with Cellular Connectivity (FT-CC) (1) Flotetuzumab (1) Flow controlled ventilation (Evone-ventilator) (1) Flow cytometry (1) Flu shot (1) FluBlok (1) Flucelvax (1) Flurbiprofen 100 mg (1) Fluvirin (1) Fluvoxamine (1) Fluzone High Dose (1) Flywheel exercise (1) Focus Group Interviews (1) Focused/Targeted Message (1) Foldax Tria Aortic Valve (1) Folfirinox (1) Folic Acid (1) Follow up calls (1) Follow-up at 14 days (1) Follow-up of patients with COVID-19 (1) Follow-up phone call (1) Follow-up visit (1) Fondapariniux (1) Fondaparinux (1) Food Ads (1) Forced expiratory technique and induced sputum (1) Formulation without Active Drug (1) Fosfomycin disodium (1) Fourth Trimester Mobile Tool (1) Freestyle Libre 14 day CGM system (1) Fremanezumab-Vfrm (1) Froben 100 mg comprimidos revestidos (1) Fruquintinib (1) Full Spectrum CBD Oil (1) Functional MRI (1) Furosemide Injection Solution for subcutaneous administration (80 mg) (1) Furosemide Injection, USP (1) Fuzheng Huayu Tablet (1) Fuzheng Huayu tablet (1) GAD-7 (7-item Generalized Anxiety Disorder) (1) GAD-7 (General Anxiety Disorder) scale (1) GAD-7 General anxiety disorder scale (1) GAMUNEX-C (1) GC4419 (1) GC5131 (1) GENETIC (1) GENUS device (Active Settings) (1) GENUS device (Sham Settings) (1) GLA-SE adjuvant (1) GLPG3667 (1) GLPG4399 capsules (1) GLPG4399 oral suspension (1) GLS-1027 (1) GLS-1200 (1) GM-CSF (1) GNS561 (1) GNX102 (1) GO2 PEEP MOUTHPIECE (1) GPs reports of potential patient safety incidents, non-COVID-19 related (1) GRAd-COV2 (1) GSK2982772 (1) GSK3494245 (1) GSK3640254 200 mg (1) GSK3640254 Oral tablet (1) GSK3739937 (1) GSK3858279 (1) GSK3858279 IV (1) GSK3858279 SC (1) GSK3882347 (1) GSK3915393 Capsules (1) GSK3915393 Solution for Infusion (1) GSK3923868 (1) GX-19 (1) Gabapentin Enacarbil (1) Gait Retraining (1) Galidesivir (1) Gam-COVID-Vac Lyo (1) Gamification (1) Ganovo+ritonavir+/-Interferon nebulization (1) Garadacimab, Factor XIIa Antagonist Monoclonal Antibody (1) Gargle/Mouthwash (1) Gas exchange measurement (1) Gas exchanges at different PEEP (1) Gastrointestinal endoscopy (1) General Communication Message (1) General Parenting Advice (1) General Public cohort (1) General health education (1) General health through IM Apps (1) Generalized Anxiety Disorder-7 (GAD 7) (1) Generalized Anxiety Disorder-7 (GAD-7) (1) Generic Response Training Control Intervention (1) Gepotidacin (1) Geriatrics Bundle (1) Gestational Age-Based Dose of Unfractionated Heparin (1) Gimsilumab (1) Global Longitudinal Strain (1) Glucarpidase (1) Glucose tablets (1) Gluten (1) Glycaemic levels (1) Glycine (1) Goal Management Training (GMT) (1) Goal-Oriented Attentional Self-Regulation (GOALS) (1) Graded exercise test (1) Graded exposure therapy (1) Grocery store gift cards (1) Group 1 (1) Group 1: Rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed (1) Group 2: control group with enoxaparin 40mg/d (1) Group A (AG0302-COVID19) (1) Group A (Placebo) (1) Group A HCQ (1) Group A: oropharygeal spray and immunostimulant (1) Group B (AG0302-COVID19) (1) Group B (Placebo) (1) Group B Control (1) Group B: Placebo oropharyngeal spray + Active principle immunostimulant (1) Group C:Active principle oropharyngeal spray + Placebo taken PO (1) Group CBT (1) Group Cognitive Behaviour Therapy for Perinatal Anxiety (CBT-PA) (1) Group D:Placebo oropharyngeal spray + Placebo taken PO (1) Group Exercise Classes (1) Group Lifestyle Balance (1) Group Lifestyle Balance™ (1) Group Social ABCs (1) Group1 (1) Growth Hormone (1) Growth Mindset (1) Guanfacine hydrochloride (SPD503) (1) Guided online support program (1) Guilt message (1) HADS (1) HADS questionnaire (1) HB-adMSC (1) HCFWO (1) HCQ & AZ (1) HCQ & AZ vs HCQ+SIR (1) HCQ+AZT (1) HERizon Project (1) HFB30132A (1) HFNO (1) HIIT (intervention) (1) HIT-exercise (1) HLCM051 (1) HLX70 (1) HLX71 (1) HOME-CoV rule implementation (1) HOPE intervention (1) HPV Vaccine Education (1) HPV vaccine, Gardasil 9 (1) HaRTC (1) Halo Oral Spray (1) Halo Placebo (1) Hand sanitizer and hand washing (1) Haptic stimulation (1) Health Care Worker Survey (1) Health Enhancement Program (1) Health Promotion Program with cartoon education for Children with Asthma (1) Health Questionnaire (1) Health and work environment information and processes (1) Health supplements (1) Health warning leaflet (1) Health-related quality of life (1) Healthy Minds Program Foundations Training (1) Healthy Weight Program (HW) (1) Healthy lifestyle advise (1) Heated Vest (1) Helmet CPAP (1) Helmet Continuous Positive Airway Pressure (CPAP) (1) Helmet non-invasive ventilation (1) Helmet non-invasive ventilation (NIV) (1) Hemanext One (1) Hemodynamics changes at different PEEP (1) Hemopurifier (1) Heparin - Prophylactic dosage (1) Heparin - Therapeutic dosage (1) Heparin Infusion (1) Heparin SC (1) Heparin sodium (1) Hesperidin and Diosmin mixture (1) Heterologous stimuli (1) Hidroxicloroquina (1) High Dose Quadrivalent Inactivated Influenza Vaccine (1) High Dose of KBP-COVID-19 (1) High Flow Nasal Oxygen (HFNO) (1) High Flow Nasal Therapy (1) High Intensity Interval Training group (1) High Intensity Resistance (HIT-RT) and Endurance exercise (HIIT) (1) High Oxalate Diet (1) High PEEP with end inspiratory pause (1) High PEEP without end inspiratory pause (1) High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule (1) High dose Interferon-beta 1a (1) High dose radiation 100 cGy (1) High flow nasal cannula (1) High flow nasal cannula HFNC (1) High intensity interval training (1) High nitrite/NDMA meals (1) High-Concentration Essential Oil (1) High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma (1) High-Titer COVID-19 Convalescent Plasma (HT-CCP) (1) High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen (1) High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen (1) High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen (1) High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen (1) High-dose placebo (18-59 years) & Three dose regimen (1) High-dose placebo (18-59 years) & Two dose regimen (1) High-dose placebo (60-85 years) & Three dose regimen (1) High-dose placebo (60-85 years) & Two dose regimen (1) High-flow nasal cannula (1) High-intensity training (1) High-titer Convalescent COVID-19 Plasma (CCP1) (1) Higher-dose (1) Hillrom (1) Home Health Agency Care (1) Home Pulse Oximetry Monitoring (1) Home Sleep Apnea Testing or In-hospital Polysomnography (1) Home exercise program (1) Home sample collection of concerning mole with physician supervision (1) Home visiting (1) Home-based exercise (1) Home-based exercise training (1) Home-based exergaming (1) Home-use Test and Follow-up Questionnaire (1) Honey (1) Hormones (1) Hospital admission (1) Hospital anxiety and depression scale (1) Hospital: DD-CA (1) Hospital: Usual Care (UC) (1) Hospitalized Patients for COVID-19 Infection (1) Huaier Granule (1) Human Amniotic Fluid (1) Human Biological samples (1) Human Coach first, then Virtual Assistant (1) Human Cord Tissue Mesenchymal Stromal Cells (hCT-MSCs) (1) Human Ezrin Peptide 1 (HEP1) (1) Human milk donors (1) Human umbilical cord derived CD362 enriched MSCs (1) Human umbilical cord mesenchymal stem cells + best supportive care (1) Humanistic Care (1) Humor/Salience (1) Humoral and cellular immunity (1) Hydrogen Oxygen Generator with Nebulizer (1) Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03 (1) Hydroxychloroquin with Azithromycin (1) Hydroxychloroquine (placebo) (1) Hydroxychloroquine + Azithromycin (1) Hydroxychloroquine + Metabolic cofactor supplementation (1) Hydroxychloroquine + Sorbitol (1) Hydroxychloroquine + azithromycin + / - tocilizumab (1) Hydroxychloroquine + lopinavir/ritonavir (1) Hydroxychloroquine + placebo (1) Hydroxychloroquine , Sofosbuvir, daclatasvir (1) Hydroxychloroquine - Daily Dosing (1) Hydroxychloroquine - Daily dosing (1) Hydroxychloroquine Only Product in Oral Dose Form (1) Hydroxychloroquine Oral Product (1) Hydroxychloroquine Pill (1) Hydroxychloroquine Pre-Exposure Prophylaxis (1) Hydroxychloroquine SAR321068 (1) Hydroxychloroquine Sulfate (HCQ) (1) Hydroxychloroquine Sulfate + Azithromycin (1) Hydroxychloroquine Sulfate + Azythromycin (1) Hydroxychloroquine Sulfate 200 milligram (mg) Tab (1) Hydroxychloroquine Sulfate 400 mg twice a day (1) Hydroxychloroquine Sulfate 600 mg once a day (1) Hydroxychloroquine Sulfate 600 mg twice a day (1) Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets (1) Hydroxychloroquine and azithromycin treatment (1) Hydroxychloroquine and azithromycin treatment arm. (1) Hydroxychloroquine as post exposure prophylaxis (1) Hydroxychloroquine combined with Azithromycin (1) Hydroxychloroquine in combination of Azithromycin (1) Hydroxychloroquine plus Nitazoxanide (1) Hydroxychloroquine plus standard preventive measures (1) Hydroxychloroquine sulfate (1) Hydroxychloroquine sulfate &Azithromycin (1) Hydroxychloroquine, Azithromycin (1) Hydroxychloroquine, Clindamycin (1) Hydroxychloroquine, Clindamycin, Primaquine - high dose. (1) Hydroxychloroquine, Clindamycin, Primaquine - low dose. (1) Hydroxychloroquine, Doxycycline (1) Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy) (1) Hydroxychloroquine/Azithromycine (1) Hydroxychloroquine/Chloroquine (1) Hydroxycloroquine and Azythromycine (1) Hyperbaric Chamber (1) Hyperbaric Oxygen (1) Hyperbaric Oxygen Therapy (1) Hyperbaric Oxygen Therapy (HBOT) (1) Hyperbaric oxygen therapy (1) Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device) (1) Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) (1) Hyperimmune plasma (1) Hyperpolarized Xe129 (1) Hyperpolarized Xenon-129 MRI of the lungs (1) Hypertension (1) Hypocaloric, low carbohydrate diet (1) Hypocaloric, moderate low fat diet (1) Hypofractionated intensity modulated radiotherapy (1) Hypothermia Via Cooling Machine- Arctic Sun 5000 (1) Hysteroscopy (1) IC14 (1) IC14, a monoclonal antibody against CD14 (1) ICU Recovery + Physical Therapy (1) ID NOW vs. Accula (1) IER-R (posttraumatic stress) (1) IGV-001 Cell Immunotherapy (1) IIBR-100 high-dose (prime) (1) IIBR-100 low-dose (prime-boost) (1) IIBR-100 medium dose (prime) (1) IIBR-100, low dose (prime) (1) IIEF-5 questionnaire (1) IL-12 plasmid (1) IMGC936 (1) IMM-101 (1) IN01 vaccine (1) INB03 (1) INC424 / Ruxolitinib (1) INM005 (1) INO-4700 (1) INOpulse (1) IO-202 Dose Escalation (1) IO-202 Dose Expansion (1) ION-827359 (1) IP-10 in CDS protocol (1) IPSS questionnaire (1) ISIS 721744 (1) IV Deployment Of cSVF In Sterile Normal Saline IV Solution (1) IV Dexamethasone (1) IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care. (1) IW-3718 (1) Ibudilast (1) Ibuprofen (1) Icatibant (1) Icosapent ethyl (IPE) (1) Identification by PCR of the SARS-COV-2 virus in samples taken from the fetus (1) Identification of genetic variants (1) IgG (1) IgG SARS CoV 2 antibodies (1) IgG SARS CoV2 (1) IgG antibodies immunoassay (1) IgG test (1) IgIV (1) IgM and IgG antibodies assay (1) IgM and IgG diagnostic kits to SARS-CoV-2 (1) Iloprost (1) Imaging (1) Imaging by thoracic scanner (1) Imaging of the lungs (1) Imatinib (1) Imatinib Mesylate (1) Imatinib tablets (1) Imetelstat (1) Immediate vs. delayed provision of antibody test results (1) Immune response study (1) Immunfluorescence (1) Immunofluorescence Imaging (1) Immunofree tablets and Reginmune capsule (1) Immunoglobulin (1) Immunoglobulin of cured patients (1) Immunoglubulins (1) Immunological profiling (1) Immunosuppressive (1) Immunosuppressive Agents (1) Impact Event Score (1) Impact of COVID-19 questionnaire (1) Impact of Event Scale-Revised (1) Implementation Facilitation (IF) (1) In Person Behaviour Modification Program (1) In-Person Default (1) In-person in clinic follow-up visit (1) In-person instruction (1) In-person postoperative visit (1) Inactivated SARS CoV 2 vaccine (Vero cell). Wuhan (1) Inactivated SARS-CoV-2 vaccine (Vero cell) (1) Inactivated convalescent plasma (1) IncobotulinumtoxinA 100 UNT Injection [Xeomin] (1) Increasing Willingness and Uptake of COVID-19 Testing and Vaccination (1) Independent Living Program for Affordable Housing. (1) Individualised Ayurveda (1) Individualized-Chinese herbal medicine (1) Indomethacin (1) Infant Mental Health-Home Visiting (1) Infectious Disease and Cardiology Clinical Consultations (1) Inflammatory cytokines and chemokines profiles of patients with dexmedetomidine administration (1) Influenza vaccination at different time points (1) Information (1) Information and referral condition (1) Information leaflet (1) Information-only intervention (1) Informational videos and social media campaigns encouraging cancer screening. (1) Informed consent (1) Infrared Energy and Dietary Supplement (1) Infusion IV of Mesenchymal Stem cells (1) Infusion of 10 mg/kg Infliximab (1) Infusion of 5 mg/kg Infliximab (1) Infusion placebo (1) Inhaled Hypertonic ibuprofen (1) Inhaled ILOPROST (1) Inhaled Supplemental Oxygen (1) Inhaled beclomethasone (1) Inhaled budesonide (1) Inhaled budesonide and formoterol (1) Inhaled nitric oxide (iNO) (1) Inhaled nitric oxide gas (1) Inhaled placebo (1) Inhaled sedation (1) Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs (1) Injection into olfactory cleft (1) Innova Lateral Flow Device (1) Inspiratory Muscle Training (1) Inspiratory training device (1) Instramuscular vaccine (1) Instrumental Activities of Daily Living Shaping (1) Insulin (1) Insulin film (1) Insulin icodec (1) Insulin regimen (1) Integrated Illness Management and Recovery (1) Interactive workshops LiPAT intervention group (1) Interferon alfa (1) Interferon-Alpha2B (1) Interferon-Beta (1) Interferon-ß-1a (1) Interferon-β 1a (1) Interferon-β1a (1) Interleukin 6 (IL6) Antagonist (1) Interleukin 6 (IL6) Antagonist and corticosteroids (1) Interleukin assessment in semen (1) Interleukin-1 receptor antagonist (1) Interleukin-6 Gene-174C detection (1) Intermediate dose thromboprophylaxis (1) Intermittent prone positioning instructions (1) Internet Cognitive Behavioral Therapy plus CHAMindWell (1) Internet-Delivered Cognitive Behavior Therapy (iCBT) (1) Internet-based Cognitive Behavioral Therapy (1) Internet-based guided self-help based on CBT principles (1) Internet-based self-help (1) Internet-based self-help after 3 weeks (1) Internet-connected computer tablet (1) Internet-delivered cognitive behavior therapy (ICBT) for dysfunctional worry related to the Covid-19 pandemic (1) Interpersonal Psychotherapy (1) Interpersonal Therapy (1) Intervention (1) Intervention App (1) Intervention for COVID-19 preventive protocols (1) Intervention for TECC Model (1) Intervention group CoronaCope (1) Intervention group_rehabilitation program (1) Intervention program (1) Intervention training: (1) Intervention, TBN (1) Intervention-EDI and health coaching (1) Interview by psychologists (1) Interviews only. (1) Intra-articular corticosteroid injection (1) Intracorporeal left hemicolectomy anastomosis (1) Intralipid (1) Intramuscular Vaccine (1) Intramuscular vaccine (1) Intranasal heparin sodium (porcine) (1) Intraosseous access (1) Intravenous Immune Globulin (1) Intravenous Immunoglobulin (1) Intravenous Infusions of Stem Cells (1) Intravenous Placebo (1) Intravenous access (1) Intravenous drug (1) Intravenous saline injection (Placebo) (1) Intravenous sedation (1) Intubation Box (1) Invasive mechanical ventilation (1) Invasive mechanical ventilation using the Unisabana-Herons Ventilator during 24 hours (1) Investigation of smell and taste disorders (1) Investigation of the prevalence of test positivity (1) Investigational Product - ViraCide (1) Invitation to participate (1) Iohexol (1) Iota carrageenan nasal spray and Ivermectin oral drops (used as buccal drops) (1) Iota-Carrageenan (1) Isocaloric Diet (1) Isoflurane Inhalant Product (1) Isoniazid, Rifampicin, Pyrazinamide and Ethambutol (1) Isoprinosine (1) Isoquercetin (1) Isoquercetin (IQC-950AN) (1) Isotonic saline (1) Isotonic saline 0.9% (1) Isotretinoin Only Product in Oral Dose Form (1) Isotretinoin(Aerosolized 13 cis retinoic acid) +standard treatment (1) Itolizumab IV infusion (1) Ivermectin (IVM) (1) Ivermectin + Doxycycline (1) Ivermectin + Doxycycline + Placebo (1) Ivermectin + Placebo (1) Ivermectin 3mg Tab (1) Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets (1) Ivermectin 5 MG/ML oral solution, Dexamethasone 4-mg injection, Enoxaparin injection. Inpatient treatment with mechanical ventilation in ICU. (1) Ivermectin 5 mg/mL oral solution, Dexamethasone 4-mg injection, Aspirin 250 mg tablets (1) Ivermectin 6 MG Oral Tablet (2 tablets) (1) Ivermectin Injectable Solution (1) Ivermectin Tablets (1) Ivermectin and Doxycyline (1) Ivermectin nasal (1) Ivermectin oral (1) Ivermectin plus Nitazoxanide (1) Ivermectin wth chloroquine (1) Ixazomib Placebo (1) JNJ-53718678 (1) JNJ-53718678 125 mg (1) JNJ-53718678 2.5 mg/kg (1) JNJ-53718678 250 mg (1) JNJ-53718678 3 mg/kg (1) JNJ-53718678 4.5 mg/kg (1) JNJ-66525433 (1) JS016 (anti-SARS-CoV-2 monoclonal antibody) (1) Janus Kinase Inhibitor (ruxolitinib) (1) KELEA Excellerated Water (1) KIR phenotype evaluation (1) KOH 10 % (1) Kagocel (1) Kaletra and beta interferon (1) Kamada Anti-SARS-CoV-2 (1) Kaplan Meier analysis (1) Ketamine (1) Ketamine Hydrochloride (1) Ketamine Injectable Product (1) Ketogenic diet with phytoextracts (1) Ketotifen 1 MG (1) Kevzara sc (1) Knowledge, Attitude, Practice, Awareness, Preference (1) Kukaa Salama: mHealth intervention (1) Kundalini Yoga and Anxiety Reduction Training (1) L-Citrulline (1) L-citrulline (1) LAMP (1) LAU-7b (1) LB1148 (1) LDAEP (1) LEAF-4L6715 (1) LIIT.CI ACT (1) LIIT.CI CFT (1) LIVE (1) LMWH (1) LNP023 (1) LSALT peptide (1) LY3127804 (1) LY3473329 (1) LYMPHOCYTE MONOCYTE RATIO (1) LYT-100 (1) Lab workup (on admission and regularly during follow up). (1) Laboratory Analyses (1) Laboratory Biomarker Analysis (1) Laboratory test positive for SARS-CoV-2 virus (1) Laboratory tests (1) Lactobaciltus rhamnosus GG (1) Lactobaciltus rhamnosus GG Placebo (1) Lactoferrin (1) Lactoferrin (Apolactoferrin) (1) Lambda 180 mcg S.C (1) Lasix® (1) Late dexamethazone (1) Late-Dexamethasone (1) Lateral Position (left and right lateral decubitus) (1) Leadership Training (1) Learning running subcuticular sutures on the Gamified Educational Network (1) Lecanemab (1) Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5. (1) Lenoxin® (1) Let It Out (LIO)-C (1) Leukapheresis (1) Levamisole (1) Levamisole Pill + Budesonide+Formoterol inhaler (1) Levamisole and Isoprinosine (1) Levamisole and isoprinosine (1) Levilimab (1) Levodopa/Carbidopa (LD/CD) (1) Lianhua Qingwen (1) Liberase Enzyme (Roche) (1) Licensed seasonal influenza vaccine (1) Licorice extract (1) Lidocaine 2% (1) Life2000® Ventilator (1) LifeSignals Biosensor 1AX* (1) Lifelight® Data Collect Blood Pressure Group (1) Lifelight® Data Collect Oxygen Saturation Group (1) Lifestyle App (1) Lifestyle change promotion program (1) Lifestyle intervention (1) Lifestyle medicine (1) Lift (1) Limbix Spark (1) Linagliptin (1) Linagliptin 5 MG (1) Linagliptin tablet (1) Liposomed polyphenols resveratrol and curcumin (1) Liquid Alpha1-Proteinase Inhibitor (Human) (1) Liquid Model (1) Liquid Peanut Extract (1) Listerine Mouthwash Product (1) LithoLyte (1) Live Long Walk Strong rehabilitation program (1) Liver function tests ,serum ferritin and PCR for COVID-19 . (1) Liver injury (1) Local Bone Autograft (1) Local standard of care (1) Lock-down and social distancing (1) Long arm full cast (1) Long arm soft cast (1) Longeveron Mesenchymal Stem Cells (LMSCs) (1) Lopinavir (1) Lopinavir / Ritonavir plus Ribavirin (1) Lopinavir / ritonavir tablets combined with Xiyanping injection (1) Lopinavir / ritonavir, alpha-interferon nebulization,Abidor Hydrochloride (1) Lopinavir 200 MG / Ritonavir 50 MG [Kaletra] (1) Lopinavir 200Mg/Ritonavir 50Mg FT Reference (1) Lopinavir 200Mg/Ritonavir 50Mg FT Test (1) Lopinavir 200Mg/Ritonavir 50Mg Tab (1) Lopinavir and Ritonavir Tablets (1) Lopinavir and ritonavir (1) Lopinavir-Ritonavir Drug Combination (1) Lopinavir/ Ritonavir (1) Lopinavir/ Ritonavir Oral Tablet (1) Lopinavir/ Ritonavir Placebo (1) Lopinavir/Ritonavir + hydoxychloroquine (1) Lopinavir/Ritonavir 200 MG-50 MG Oral Tablet (1) Lopinavir/Ritonavir 400 mg/100 mg (1) Lopinavir/ritonavir treatment (1) Losartan 50 mg and Spironolactone 25 mg pillules oral use (1) Losmapimod oral tablet (1) Loss Frame and Fear Appeals (1) Lovenox 40 MG in 0.4 mL Prefilled Syringe (1) Loving-Kindness Meditation (1) Low Dose (10 mg) Control (1) Low Dose Radiation Therapy (LD-RT) (1) Low Dose of KBP-COVID-19 (1) Low Molecular Weight Heparin (1) Low PEEP - FiO2 high (1) Low PEEP - FiO2 low (1) Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule (1) Low dose CT (1) Low dose Interferon-beta 1a (1) Low dose Low molecular weight heparin or Placebo (1) Low dose Radiotherapy (1) Low dose prednisolone (1) Low dose radiation 35 cGy (1) Low dose radiation therapy (1) Low dose whole lung radiotherapy for older patients with COVID-19 pneumonitis (1) Low fat "standard care" control breakfast (1) Low flow ECMO driving by CVVH machine (1) Low nitrite/NDMA meals (1) Low or upper respiratory tract sample (1) Low-Carb High-Fat breakfast (1) Low-Carbohydrate Diet (1) Low-Concentration Essential Oil (1) Low-Intensity Psychosocial Interventions through Telemental health (1) Low-dose Chest CT (1) Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen (1) Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen (1) Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen (1) Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen (1) Low-dose placebo (18-59 years) & Three dose regimen (1) Low-dose placebo (18-59 years) & Two dose regimen (1) Low-dose placebo (60-85 years) & Three dose regimen (1) Low-dose placebo (60-85 years) & Two dose regimen (1) Low-dose radiotherapy (1) Lower-dose prophylactic anticoagulation (1) Lucinactant (1) Lumbar Puncture (1) Lung CT (1) Lung CT scan analysis in COVID-19 patients (1) Lung Cancer Screening Decision Tool (1) Lung Function Test (1) Lung Function tests (1) Lung Low Dose Radiation (1) Lung Ultrasound (1) Lung impedance technique (1) Lung ultrasound use in patients hospitalized with COVID (1) LungFit™ (1) M201-A Injection (1) MAGEC Spine Rod (1) MANAGEMENT OF COVID-19 (1) MBCT/MBSR (1) MCC IMS (1) MCN (Methylene blue, vitamin C, N-acetyl cysteine) (1) MEDI5395 (1) MEDI7219 (1) MELT-100 (1) MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 15mcg (1) MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 45mcg (1) MF59 adjuvanted SARS-CoV-2 Sclamp vaccine 5mcg (1) MFS (1) MGA012 (1) MGC018 (1) MI-CBT (1) MK-5475 (1) MLS Laser (1) MMR vaccine (1) MORPH (1) MOVE! (1) MOVE!+gshCBT (1) MPT0B640 (1) MR or M-M-R II ® vaccine (1) MR-Pro-ADM (1) MRG-001 (1) MRI (1) MRI (heart, brain, lungs, liver) (1) MRI scans (1) MRx-4DP0004 (1) MSB11456 (1) MSC Treatment (1) MSCT (1) MSCs (1) MSCs-derived exosomes (1) MSTT1041A (1) MSTT1041A-matched Placebo (1) MT-7117 (1) MULTI-LINK 8 LL stent (1) MULTI-LINK 8 SV stent (1) MULTI-LINK 8 stent (1) MVA-BN-Filo (1) MVA-HPV (1) MVA-MERS-S_DF1 - High Dose (1) MVA-MERS-S_DF1 - Low Dose (1) MVA-SARS-2-S vaccinations (days 0 & 28) (1) MVC-COV1901 (1) MaaT033 capsule (1) Machine Learning/AI Algorithm (1) Machine learning model (1) Macrolide administered for 3-5 days (1) Macrolide administered for up to 14 days (1) Magnetic Resonance Imaging (1) Magnetic Resonance Imaging (MRI) (1) Magnetic Resonance Spectroscopy (MRS). (1) Maintenance or reduction of immunosuppression (1) MakAir (1) Making Mindfulness Matter© (M3) (1) Male Sexual Health Questionnaire (MSHQ) (1) Maltodextrin (1) Mannitol (1) Manremyc (1) Maraviroc (1) Maraviroc + Currently used therapy (1) Maraviroc 300 mg (1) Maraviroc+Favipiravir+CT (1) Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol) (1) Masimo, LidCO (1) Masitinib (1) Masked Saline Placebo (1) Maslach Burnout Inventory (MBI) (1) Massive parallel sequencing of host genome (1) Matched Placebo Hydroxychloroquine (1) Matched placebo (1) Maternal attachment, Edinburgh depression scoring and postpartum anxiety scale scores (1) Maternal stress (1) Matrix-M1 (1) Maximal effort test (1) McGrath videolaryngoscope (1) Measles-Mumps-Rubella Vaccine (1) Mechanical Trombectomy (1) Mechanical ventilation with the automated BVM compressor (1) Med-South Weight Loss Intervention (1) Media Intervention (1) Medical Mask (1) Medical Music (1) Medical Ozone procedure (1) Medical Record Review (1) Medical Record Review - Inpatient Treatment (1) Medical records-based recommendation (1) Medical/surgical mask (1) Medication Assisted Treatment (1) Medication Review (1) Meditation Therapy (1) Meditation and Anxiety Reduction Training (1) Meditation app usage (1) Mediterranean diet, no caloric restriction (1) Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule (1) Medium dose prednisolone (1) Medtronic Interstim II Model 3058 Neurostimulator (1) Mefloquine (1) Mefloquine + azithromycin + / - tocilizumab (1) MejoraCare (1) Melatonin 2mg (1) Melatonin intravenous (1) Melphalan (1) MenACWY (1) MenACWY boost (1) MenACWY prime & saline placebo boost + paracetamol (1) MenACWY single dose + paracetamol (1) MenACWY vaccine (1) MenCare+/Bandebereho fathers'/couples' group education (1) Mental Health questionnaire (1) Mental imagery (1) Menu label (1) Mepolizumab 100 MG [Nucala] (1) Merimepodib (1) Mesenchymal Stem Cell (1) Mesenchymal Stem Cells derived from Wharton Jelly of Umbilical cords (1) Mesenchymal Stromal Cells infusion (1) Mesenchymal Stromal Stem Cells - KI-MSC-PL-205 (1) Mesenchymal cells (1) Mesenchymal stem cell (1) Mesenchymal stem cell therapy (1) Mesenchymal stem cells (1) Mesenchymal stromal cell-based therapy (1) Message directing subjects to information on COVID-19 vaccine safety and efficacy (1) Messaging (1) MetaNeb® System (1) Metacognitive therapy and work-focused interventions (1) MetfoLiquid GeriaSan® (1) Metformin Glycinate (1) Metformin XR (1) Methotrexate-LDE phase 1 (1) Methotrexate-LDE phase 2 (1) MethylPREDNISolone 80 Mg/mL Injectable Suspension (1) Methylene Blue (1) Methylene Blue 5 MG/ML (1) Methylene-Blue Photodisinfection (1) Methylprednisolone Injectable Product (1) Methylprednisolone Injection (1) Metoprolol 100 mg (1) Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) (1) Microcrystalline Cellulose, NF (1) Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension (1) Microscopy of defined brain regions on autopsy specimens (1) Midazolam 5 mg (2.5 mL) (1) Midazolam injection (1) Middle-dose (1) Milk of magnesia (1) MindRhythm Harmony (1) Mindful Self-Compassion (1) Mindfullness based cognitive program (1) Mindfulness + Compassion Intervention (MC) (1) Mindfulness Alone (MO) Intervention (1) Mindfulness Based Cognitive Therapy for Resilience During COVID-19 plus CHAMindWell (1) Mindfulness Meditation (1) Mindfulness Rounds (1) Mindfulness Training (1) Mindfulness based intervention (1) Mindfulness exercises (1) Mindfulness intervention (1) Mindfulness program (1) Mindfulness session(s) (1) Mindfulness training (1) Mindfulness training (MT) Connect (1) Mindfulness-Based Cognitive Therapy (1) Mindfulness-based "STOP touching your face" practice (1) Minimal Attention Control Intervention (1) MinnRAP Peer Support Program (1) Minocycline (1) Mixture 3,6% H2 in N2 (96.4%) (1) Mobile Enhanced Prevention Support (1) Mobile Mental Health App - 1 (1) Mobile Mental Health App - 10 (1) Mobile Mental Health App - 2 (1) Mobile Mental Health App - 3 (1) Mobile Mental Health App - 4 (1) Mobile Mental Health App - 5 (1) Mobile Mental Health App - 6 (1) Mobile Mental Health App - 7 (1) Mobile Mental Health App - 8 (1) Mobile Mental Health App - 9 (1) Model Building (1) Model validation (1) Moderate Intensity Aerobic Exercises (1) Moderate-intensity continuous training (1) Modified Bai He Gu Jin Tang (1) Modified Rankin score (1) Molgramostim nebuliser solution (1) Mometasone furoate (1) Monalizumab (1) Monitoring Visit - Baseline (1) Monitoring Visit - Week 4 (1) Monitoring Visit - Week 8 (1) Monitoring for aggravation (1) Monitoring physiological data with the Hexoskin smart shirt (1) Monodose RS01 (1) Montelukast 10 mg (1) Montelukast 10mg (1) Montelukast Oral Granules (1) Montmorrillonite (1) Morning Bright Light Therapy (1) Mother Provides MOM (1) Motivational social support from nurse (1) Motivational social support from nurse with additional support from significant other (1) Motivational telephone intervention (1) Motor-based treatment (1) Moxibustion plus Cupping (1) Moxifloxacin or Levofloxacin (1) Mucodentol (1) Multi Modal Balance Training (1) Multi-target Dietary Supplement (MTDS) (1) Multi-tasking Training (1) MultiStem (1) Multicapillary column coupled ion mobility spectrometry (1) Multifrequency Bioimpedance Spectroscopy (1) Multimodal intervention strategy (1) Multiple Doses of Anti-SARS-CoV-2 convalescent plasma (1) Multivitamin placebo (1) Mupirocin (1) Muscle Relaxation Therapy (1) Muscle ultrasound (1) MuscleSound Ultrasound (1) Museum virtual guided tours (1) Music Therapy (1) MyPath tool (1) MySafeRx Inspire Flex (1) MySafeRx Inspire Plus (1) N terminal pro B type natriuretic peptide (NTproBNP), D-Dimer, and serum Tropinin - I (1) N-803 (1) N-95 Respirator (1) N-acetyl cysteine (1) N95 Respirator (1) N95 respirator (1) NA (no intervention) (1) NA-831 (1) NA-831 and Atazanavir (1) NA-831and Dexamethasone (1) NAD+ (1) NBT-NM108 (1) NETosis markers (1) NG Biotech (1) NG test (1) NGM621 (1) NHANES smell and taste tests (1) NICU Acquires MOM (1) NIO® (Intraosseous access) (1) NIVOLUMAB (1) NK Cells (1) NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells (1) NK-1R antagonist (1) NL-201 (1) NO gas (1) NO intervention planned due to the observational study design - only a diagnostic testing (1) NO intervention planned due to the observational study design only a diagnostic testing (1) NO-Immunosuppressive (1) NOX66 (1) NP-120 (Ifenprodil) (1) NRICM101 (1) NT-I7 (1) NaCl (1) NaCl 0.9% (1) NaCl Solution (1) Nafamostat Mesylate (1) Naltrexone 380 MG (1) Narrative Exposure Therapy (1) Nasal Brushing (1) Nasal Dexamethasone (1) Nasal Irrigation (1) Nasal Spray (1) Nasal Swab (1) Nasal lavage (1) Naso pharyngeal swab (1) NasoVAX (1) Nasopharyngeal (NP) swab (1) Nasopharyngeal Swab (1) Nasopharyngeal and throat/oropharyngeal swabs analyses by RT-PCR and ddPCR (1) Nasopharyngeal swab and main laboratory (1) Nasopharyngeal, oropharyngeal, or saliva swab (1) Natural Honey (1) Natural Killer Cells infusion (1) Nebulised heparin (1) Nebulised unfractionated heparin (UFH) (1) Nebulized Furosemide (1) Nebulized Platelet Lysate (1) Nebulized Saline (1) Nebulized Sterile Saline (1) Nebulized administration of RLF-100 or Placebo (1) Negative COVID Test Result - Hypothetical Scenario (1) Negative Ion Generator (1) Nemolizumab (1) NestaCell® (1) Neural network diagnosis algorithm (1) Neurocognitive assessment (1) Neurofeedback (1) Neuromuscular Electrical Stimulation (1) Neuromuscular evaluation (1) Neutral Aspheric Monofocal IOL (1) Neutral writing control (1) Neutralizing antibodies (1) New QIAstat-Dx fully automatic multiple PCR detection platform (1) New screening strategy (1) Newsfeed function (1) Next generation Sequencing (NGS) analysis (1) Niclosamide suspension (1) Nicorette White Ice Mint nicotine polacrilex gum (1) Nicotinamide riboside (1) Nicotine 7 mg/ 24h Transdermal Patch - 24 Hour (1) Nicotine patch (1) Nigella sativa (1) Nil intervention (1) Nintedanib (1) Nintedanib 150 MG (1) Nintedanib 150 MG [Ofev] (1) Nitazoxanide 500 MG (1) Nitazoxanide 500Mg Oral Tablet (1) Nitazoxanide Tablets (1) Nitazoxanide and atazanavir/ritonavir (1) Nitazoxanide with ivermectin (1) Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation (1) Nitric Oxide delivered via LungFit™ system (1) Nitric Oxide lozenges, 30 mg (1) Nitric Oxide-Continuous and Sessions (1) Nitric Oxide-Releasing Drug (1) Nitric Oxide-Sessions (1) Nivolumab Injection (1) No Intervention - Observational Study (1) No Messaging (1) No Personal protective equipment (PPE) (1) No Racial Inequality Highlighting (1) No Treatment (1) No intervention (survey study for medical doctors). (1) No intervention - exposure is to COVID-19 (1) No intervention - quality of life measure (1) No intervention / Compare the difference in respiratory rate between H0 and H12 of the initiation of morphine between the control and interventional groups (1) No intervention / Evaluation of the ferritin and glycosylated ferritin by standard approved serological tests (1) No intervention on patients (1) No intervention, observational (1) No intervention, this is an observational study that uses validated questionnaires and qualitative interviews.. (1) No interventions (1) No interventions planned (1) No interverntion (1) No research related technology based social interactions (1) No special intervention (1) No treatment (waitlist control) (1) Non Extracorporeal Membrane Oxygenation (1) Non Intervention (1) Non applicable (1) Non interventional study (1) Non invasive visual acuity testing (1) Non-ACEI/ARB (1) Non-Anchoring Strategy Control (1) Non-Heated Vest (1) Non-Interventional (1) Non-Mindfulness intervention (1) Non-contact ECG (1) Non-contact MCE system (1) Non-convalescent Plasma (control plasma) (1) Non-convalescent fresh frozen plasma (Standard plasma) (1) Non-enhanced CT scan of the chest (1) Non-food Ads (1) Non-hospitalization procedures (1) Non-interventional (1) Non-interventional study (1) Non-invasive brainstem stimulation (1) Non-invasive cardiac imaging (1) Non-invasive red LLLT treatment to chest of patient. (1) Non-invasive ventilatory support (1) None - NA (1) Norketotifen (1) Normal (9%) Saline (1) Normal Saline 0.9% (1) Normal Saline Infusion + standard of care (1) Normal Saline intranasal (1) Normal saline 0.9% (1) Normal saline solution (NSS), Placebo - Phase 1 (1) Normal saline solution (NSS), Placebo - Phase 2 (1) Normal saline solution (NSS), Placebo, Day 189 - Phase 2 (1) Normal saline solution (NSS), Placebo, Day 21 - Phase 1 (1) Normal saline solution (NSS), Placebo, Day 21 - Phase 2 (1) Norovirus Bivalent (GI.1 / GII.4) Vaccine(high) (1) Norovirus Bivalent (GI.1 / GII.4) Vaccine(low) (1) Norovirus Bivalent (GI.1 / GII.4) Vaccine(middle) (1) Not bravery message (1) Novel laser inferometry test for CORONA virus (1) Ntombi Vimbela! intervention (1) NuSepin® 0.1 mg (1) NuSepin® 0.2 mg (1) Nudge (1) Nursing care to reduce anxiety, fear and loneliness (1) Nutrition (1) Nutrition Consult and Protein Supplementation (1) Nutrition and Exercise Strategies (1) Nutrition education (1) Nutrition support (1) Nutritional assessment (1) Nutritional counseling (1) Nutritional education (1) Nutritional support system (NSS) (1) Nuvastatic (1) NİCaS (1) OCTAPLAS (1) OLO-1 Medical Molecular Sieve Oxygen Generator (1) ONC201 (1) OP-101 (1) OPT101 (1) ORIN1001 (1) OT Guided Cognitive Interventions (1) Obesity (1) Observation for study group (1) Observation of Virtual Actions (1) Observation of Virtual Actions (step 4) (1) Observation of behavior and COVID-19 infection will be conducted. (1) Observation of patients with known, suspected, or at risk for COVID-19 infection (1) Observation only (1) Observational (registry) (1) Observational Study (1) Observational cohort study on the natural history of hospitalized SARS-COV-2 patients. (1) Observational measurement of biometric data. No change to health care provided. (1) Observational only (1) Observational study only (1) Obtainment of nasopharyngeal, oropharyngeal, buccal, nasal and saliva samples (1) Obvio-19 app (1) Occupational health workers (1) Octagam (1) Octagam 10% (1) Odd/Even birth year intervention groups (1) Office FU (1) Olaparib Oral Tablet [Lynparza] (1) Olfaction testing (1) Olfactometry (1) Olfactory retraining (1) Omega 3/Nigella Sativa Oil (1) Omega 3/Nigella Sativa Oil/Anise seed capsule (1) Omega 3/Nigella Sativa Oil/Deglycyrrhizinated Licorice (1) Omega 3/Nigella Sativa Oil/Indian Costus (1) Omega 3/Nigella Sativa Oil/Quinine pills (1) Omega-3 Fatty Acid Supplement (1) Omegaven® (1) Omeprazole 20mg (1) Omeprazole 40 mg (1) Omnibiotic AAD (1) On-Line Survey (1) On-line exercise and education (1) On-site exercise and education (1) OnabotulinumtoxinA 100 UNT [Botox] (1) One COVID-19 vaccine candidate (TMV-083) administration - High dose (1) Online 1-Day Cognitive Behavioural Therapy (CBT)-Based Workshop (1) Online Intervention Grief COVID-19 (1) Online Intervention Mental Health COVID-19 (1) Online Questionnaires (1) Online Survey about Dietary and Lifestyle Habits (1) Online bibliotherapy programme (1) Online cognitive behavioral therapy (CBT) (1) Online educational intervention to enhance cultural competance (1) Online educational intervention to reduce ageism (1) Online exercise (1) Online instruction (1) Online questionnaire and interviews (1) Online real-time feedback video-based CPR training without quality measurement (1) Online real-time quality measurement and feedback video-based CPR training (1) Online support Group (1) Online training (1) Only Standard Treatment (1) Ophtamesone (1) Ophthalmologic exam (1) Opt-in Recruitment Email (1) Opt-out Recruitment Email (1) Optical Coherence Tomography (OCT) (1) Optical coherence tomography angiography (1) Optifast VLCD Program (1) Optifast VLCD Transition Phase (1) Optimal-Massive Intervention (1) Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience from the Middle East (1) Optional blood completion (1) Optional questionnaire completion (1) Oral (1) Oral 25-Hydroxyvitamin D3 (1) Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions (1) Oral fluid swab (1) Oral load of oxalate and sucralose (1) Oral supplement enriched in antioxidants (1) Oral-B Mouth Sore mouthwash (1) Oropharyngeal Swab (1) Orthopaedic Surgical Procedures (1) Oseltamivir 75mg (1) Osimertinib (1) Others(No intervention) (1) Otilimab (1) Outpatient MRI (1) Ovotransferrin (1) Oxaloacetate Medical Food/Dietary Supplement (1) Oxidative Stress ELISA Kit (1) Oxycodone and Midazolam (1) Oxycodone, Paroxetine, and Quetiapine (1) Oxygen Hood (1) Oxygen Therapy (1) Oxygen gas (1) Oxygen supply (1) Oxygen-ozone therapy, probiotic supplementation and Standard of care (1) Oxytocin (1) Ozone auto-hemotherapy (1) Ozonized oil (HOO (1) P2Et (Caesalpinia spinosa extract) (1) PACE-Life (1) PARTNER-MH (1) PCL COV05 - COVID 19 Ag Rapid FIA test (Rapid Antigen Test) (1) PCR Value (1) PCR for COVID-19 (1) PCR, lung ultrasound (1) PD-1 blocking antibody+standard treatment (1) PDS-08 (1) PEAR-008 (1) PEEP trial (1) PEP flute (1) PET-CT of 18F-FDG (1) PET/CT Scan (1) PF-06650833 (1) PF-06882961 20 mg (1) PF-06882961 20MG (1) PF-06939999 dose escalation (1) PF-06939999 in combination with docetaxel (1) PF-06939999 monotherapy (1) PF-07104091 + palbociclib (1) PF-07104091 + palbociclib + letrozole (1) PF-07104091 monotherapy (1) PF-07209960 (1) PF-07304814 (1) PH-combination therapy (1) PH-monotherapy (1) PH94B (1) PHQ-9 (9-item Patient Health Questionnaire) (1) PHQ-9 (Patient Health Questionnaire) Depression Scale (1) PHQ-9 Depression Scale (1) PHR160 Spray (1) PLACEBO GROUP (1) PLN-74809 (1) POOL LAMP (1) POOL RT-PCR (1) PP-MI Intervention (1) PRAYER (1) PRO questionnaire (1) PRO-SERO-COV (1) PROStep Dashboard (clinicians) (1) PROTECTIVE VENTILATION (1) PRV-015 (1) PSC-04 (1) PSG (1) PSQI (1) PSS (Perceived Stress Scale) (1) PT-PCR test for SARS-CoV-2 (1) PT-Pal (1) PT-X and IMT (1) PTC299 (1) PTSD (1) PWV (1) Pacebo: Calcium citrate (1) Pacel BPC (1) Pacel FDPC (1) Pacing + mindfulness (1) Package Quantity (cigarillos) (1) Paclitaxel (PTX) (1) Pacritinib (1) Palliative care assessment (1) Pamrevlumab (1) Pandemic control measures (1) Paraclinical examination (1) Paramedic Coaching (1) Parents and Infants Engaged (1) Part 1 - TL-895 (1) Part 2 - Placebo (1) Part 2 - TL-895 (1) Partially HLA-matched SARS-CoVSTs (1) Partner-assisted intervention (1) Passed infection of SARS-CoV-2 (1) Passive Microwave Radiometry (1) Patch, Nicotine (1) Patch, Placebo (1) Pathogen-specific aAPC (1) Pathways for Parents after Incarceration (1) Patient Characteristics (1) Patient Education (1) Patient Health Questionnaire (PHQ-9) (1) Patient Health Questionnaire-9 (PHQ-9) (1) Patient Navigation Program (1) Patient Status Engine (1) Patient management suffering of coronavirus infection (1) Patient sampling (1) Patient with SAR-CoV-2 infection (1) Patient-centred advice on Telephone Consultation in TB Patients: (1) Patient-only intervention (1) Patients admitted in Intensive Care Units (1) Patients admitted to Intensive Care Unit with SARS-CoV2 (1) Patients received standard of care treatment during hospitalization (1) Patients with the treatment agains COVID19 (1) Pectin (1) Peer Education on Exercise for Recovery (1) Peer Resilience Champion (1) Peginterferon Lambda-1a (1) Peginterferon lambda alfa-1a subcutaneous injection (1) Pegylated Interferon-α2b (1) Pegylated interferon lambda (1) Pembrolizumab (MK-3475) (1) Pemziviptadil (PB1046) (1) Pen injector (1) Penn Microbiome Therapy - 001 (1) Penn Microbiome Therapy - 002 (1) Penn Microbiome Therapy - 003 (1) Percutaneous Coronary Revascularization for STEMI (1) Percutaneous Transluminal Angioplasty (PTA) Device (1) Performance of WHEELS-I in promoting DASH/SRD adoption (1) Performance of the test antigenic and test RT-PCR (1) Performing Virtual Actions (1) Performing of lung ultrasound (1) Performing routine care (clinical and paraclinical tests) (1) Peripheral Blood (1) Peripheral blood sampling (1) Peripheral venous ultrasound (1) Peroxyl Mouthwash (1) Personal Exercise Intervention (1) Personal Protective Testing Booth (1) Personal behaviours (1) Personal freedom message (1) Personal identity recruitment (1) Personal protective equipment (1) Personal protective equipment (PPE) (1) Personal protective equipment from biological hazard (1) Personalized Anchoring Strategy (1) Personalized ambulatory training (1) Personalized health education (1) Phage Therapy (1) Phentermine 37.5 Mg (1) Philips Lumify Ultrasound System (1) Phlebotomy (1) Phone Administration of Questionnaires (1) Phone call interview (1) Phone interviews (1) Phone-call screening and management by a medical student/general practitioner tandem (1) Phosphate buffered saline Placebo (1) Photobiomodulation (1) Phsyiotherapy (1) Physical Activities & Activity Booklets (1) Physical Activity (1) Physical Exam (1) Physical Exercises (1) Physical Therapy (1) Physical Therapy Exercise (1) Physical examination (1) Physical exercise (1) Physician Survey (1) Physiological saline solution (1) Physiological serum (1) Physiology (1) Physiotherapy - Manual Therapy (1) Piclidenoson (1) Pico G2 4K Headset with Applied VR software (1) Pilot a rapid SARS-CoV-2 testing strategy (1) Pioglitazone (1) Pioglitazone 30 mg (1) Pioglitazone 45 mg (1) Pipeline™ Flex Embolization Device with Shield Technology™ (1) Piperacillin-tazobactam (1) Piperacillin/tazobactam (1) Pitolisant (1) Placebo (0.9% normal saline) (1) Placebo (1 tablet daily during 60 days) + Personal Protective Equipment (PPE) (1) Placebo (Methylcellulose) capsule (1) Placebo (PB0) (1) Placebo (PBO) (1) Placebo (Plasma-Lyte 148) (1) Placebo (carrier control) (1) Placebo (for Zonisamide) (1) Placebo (human albumin 1%) (1) Placebo (potato starch and magnesium stearate) (1) Placebo (saline) (1) Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%) (1) Placebo - Phase I (1) Placebo - Starch Powder Soft gels (1) Placebo 0.10 mg + 1.00 mg/kg (1) Placebo 0.20 mg + 2.00 mg/kg (1) Placebo 0.9% NaCl solution (1) Placebo 250 cc 24 hours continuous infusion for 15 days (1) Placebo Atazanavir (1) Placebo Atrovastatin (1) Placebo Control (1) Placebo Daclatasvir 60 mg (1) Placebo EC-18 (1) Placebo Glycerin SLIT (1) Placebo Group (1) Placebo Hydroxychloroquine (1) Placebo Infusion (1) Placebo LSF (1) Placebo Mouthwash (1) Placebo Mucoadhesive Buccal Tablet (1) Placebo Nitazoxanide (1) Placebo Oil (1) Placebo Oral Tablet (1) Placebo PBMT/sMF (1) Placebo Ribavirin (1) Placebo Saline (1) Placebo Sofusbuvir + Daclatasvir 60 mg (1) Placebo Starch (1) Placebo Subcutaneous Solution (1) Placebo Tablet (1) Placebo Vaccine (1) Placebo comparator: DW-NI (1) Placebo comparator: DW-NS (1) Placebo control (non-behavioral infographic) (1) Placebo control + best supportive care (1) Placebo for ABBV-47D11 (1) Placebo for ABBV-951 (1) Placebo for Azithromycin (1) Placebo for Hydroxychloroquine (1) Placebo for Levodopa/Carbidopa (LD/CD) (1) Placebo for Risankizumab IV (1) Placebo for Risankizumab SC (1) Placebo for Upadacitinib (1) Placebo for liposomed resveratrol and curcumin (1) Placebo injection (1) Placebo intravenous (1) Placebo matching to GSK3858279 (SC or IV) (1) Placebo matching to GSK3858279 (SC) (1) Placebo matching to gepotidacin (1) Placebo microcrystalline methylcellulose (1) Placebo mouthwash (water) (1) Placebo nebuliser solution (1) Placebo of FX06 (1) Placebo of Hydroxychloroquine (1) Placebo of LPV/r Tablets (1) Placebo of NICOTINE Transdermal patch (1) Placebo of excipient(s) will be administered (1) Placebo on a 0- and 14-day schedule (1) Placebo oral (1) Placebo oral capsule; From August 2020 'no additional treatment' (1) Placebo pMDI (1) Placebo patch (1) Placebo plus standard preventive measures (1) Placebo solution (1) Placebo tablet (1) Placebo to Match RDV (1) Placebo videos (1) Placebo- 0.10 mg/kg (1) Placebo- 0.20 mg/kg (1) Placebo- 1.00 mg/kg (1) Placebo- 2.00 mg/kg (1) Placebo-LDE phase 2 (1) Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine (1) Placebo/Control (1) Placebo: Emtricitabine/tenofovir disoproxil Placebo (1) Placebo: Hydroxychloroquine (1) Placenta-Derived MMSCs; Cryopreserved Placenta-Derived Multipotent Mesenchymal Stromal Cells (1) Placental Mesenchymal Stem Cells seeded on a commercially available dural graft extracellular matrix (1) Plant Polyphenol (1) Plaquenil 200Mg Tablet (1) Plasma Donation (1) Plasma Exchange (1) Plasma IgG levels (1) Plasma exchange (1) Plasma exchange and convalescent plasma (1) Plasma expansion with Ringer's Acetate (1) Plasma from COVID-19 convalescent patient (1) Plasma from a volunteer donor (1) Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19 (1) Pleth variability index (1) Plethysmography & DLCO (1) Plitidepsin 1.5 mg/day (1) Plitidepsin 2.0 mg/day (1) Plitidepsin 2.5 mg/day (1) Pneumococcal 13 - valent conjugate vaccine (1) Pneumococcal Conjugate Vaccine - formulation 1 (1) Pneumococcal Conjugate Vaccine - formulation 2 (1) Pneumococcal Conjugate Vaccine - formulation 3 (1) Pneumococcal Vaccine Polyvalent (1) Pneumococcal vaccine (1) Point of care ultrasound (1) Point-of-Care Ultrasonography (POCUS) (1) Point-of-care test for SARS-CoV-2 (1) Poly I: Poly C12U (Rintatolimod) (1) Polymorphism of the HSD3B1 (1) Polyoxidonium (1) Positive COVID Test Result - Hypothetical Scenario (1) Positive Emotion Skills Course (1) Positive Minds Strong Bodies Enhanced (1) Positive Peer Journaling (PPJ) (1) Positive feedback (1) Post COVID-19 Functional Satus Scale (1) Post Traumatic Stress Disorder questionnaire (PTSD-8) (1) Post-intensive Care unit syndrome (1) Post-mortem tissue collection (1) Postpartum women under investigation for Coronavirus or diagnosed with COVID-19 (1) Postural Positioning (1) Povidine iodine nasal swabs (1) Povidone-Iodine (PVP-I) (1) Povidone-Iodine 0.4% NI (1) Povidone-Iodine 0.5% (1) Povidone-Iodine 0.5% NI (1) Povidone-Iodine 0.5% NS (1) Povidone-Iodine 0.6% NI (1) Povidone-Iodine 0.6% NS (1) Povidone-Iodine 2% (1) Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP (1) Povidone-iodine (1) Powered Air purifying respirator (1) PrEP (1) Prasugrel (1) Prasugrel Hydrochloride 10 MG Oral Tablet (1) Pravastatin (1) Pravastatin 40 mg (1) Pre-operative breast magnetic resonance imaging (1) Prediction Market (1) Predictive factors for clinical response in patients with COVID-19. (1) Predictors adverse evolution (1) Predictors of health care provide (1) Prednisolone (1) Prednisolone 5 mg (1) Prednisone tablet (1) Pregnant women under investigation for Coronavirus or diagnosed with COVID-19 (1) Preload meals that are solid or texture modified and are fortified with protein or not fortified with protein (1) Premier Biotech COVID-19 IgG/IgM Rapid test Cassette (1) Presatovir placebo (1) Prescription Opioid Management App (1) Presence of specific anti-SARS-CoV-2 antibodies (1) Present Tense Talk (PTT) (1) PreserVision AREDS formulation gel tabs (1) Preservative-free saline (1) PressureWire X (1) Prevalence of COVID-19 (1) Prevenar 7 and Prevenar 13 (1) Preventive information (1) Previfenon® (1) Primary care (1) Primary care professionals reports of potential patient safety incidents, non-COVID-19 related (1) PrimePro (1) Pro BNP , Vitamin D (1) Probiorinse (1) Probiotic and LC-PUFA (1) Probiotics (1) Probiotics (2 strains 10x10^9 UFC) (1) Problem Management Plus (1) Problem-solving and relationship improvement intervention. (1) Produce prescription program (1) Progesterone 100 MG (1) Prognostic score (1) Progressive Exercise Training (1) Progressive cycling exercise test to exhaustion (1) Project ECHO (1) Project Health (1) Prolastin (1) Prolectin-M; a (1-6)-alpha-D-Mannopyranose class (1) Prolonged Exposure (PE) (1) Prolonged Exposure Therapy (1) Prolonged Proned Positioning (1) Promotion of flour (1) Prone (1) Prone Positioning (PP) (1) Prone decubitus (1) Prone position ventilation (1) Prone positioning (PP) (1) Prophylactic/Intermediate Dose Enoxaparin (1) Propofol (1) Propranolol Hydrochloride (1) Proprietary extract of Nerium oleander (1) Prosocial acts (1) Prospective Chart Review (1) Prospective oberservational registry (1) Prospective observation (1) Prospective study across two time-points examining the impact of viral mitigation protocols on mental health (1) Prospective study with two measurement points investigating the impact of viral mitigation protocols on parental burnout (1) Protocolised mechanical ventilation strategy (1) Proton Therapy (1) Prototype BMS-986165 (1) Prototype medical device (SEA CtV) (1) Prototype swab (1) Provision of flour (1) Proxalutamide (1) Psilocybin (1) Psychiatric counseling (1) Psycho-Social Questionnaire (1) Psycho-education (1) Psychoeducation and Safety (1) Psychoeducational intervention (1) Psychological and Behaviour Change Support (1) Psychological and physical rehabilitation based humanistic care (1) Psychological stress and adaptation at work score (PSAS) (1) Psychological treatment (1) Psychosocial stimulation and healthy eating education (1) Public Health England Gold Standard (1) Public space exposure (1) Pulmonary Function Tests (PFT) (1) Pulmonary Physiotherapy Techniques (1) Pulmonary Vascular Permeability Index (1) Pulmonary and Motor Rehabilitation (1) Pulmonary function test (1) Pulmonary function testing (1) Pulmonary function tests (1) Pulmonary tele-rehabilitation (1) Pulmonary ultrasound (1) Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase) (1) Pulse CO-Oximetry Hemoglobin measurement transcutaneous (1) Pulse Oximeter (1) Pulse oximeter (1) Pulse oximetry (1) Pyridostigmine Bromide (1) Pyronaridine-Artesunate (1) Pyronaridine-artesunate (1) Q-NRG Metobolic Cart Device (1) Q16 testing (1) QFR (1) QL0605 (1) QMF149 (1) QUANTIFERON (1) QazCovid-in® - COVID-19 inactivated vaccine (1) QuadraMune(TM) (1) Quadrivalent RIV with 2018-2019 NH H3 strain (1) Quadrivalent RIV with 2018-2019 NH H3 strain and adjuvant (1) Quadrivalent RIV with H3 strain 1 (1) Quadrivalent RIV with H3 strain 1 and adjuvant (1) Quadrivalent RIV with H3 strain 2 (1) Quadrivalent RIV with H3 strain 2 and adjuvant (1) Qualitative Interview (1) Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19) (1) Quality Improvement (1) Quality of Life (1) Quality of life assessment (1) Quality of life promotion (1) Quantitative IgG Test (1) Quantitative analysis of SARS-CoV-2 antibodies (1) Quantitative analysis of anti-SARS-CoV-2-antibodies (1) Quantitative and qualitative assessments of mental health (1) Quantra System (1) Quercetin (1) Quercetin Phytosome (1) Quercetin Prophylaxis (1) Quercetin Treatment (1) Questionaire (1) Questionnaire : Preparedness for Caregiving Scale (1) Questionnaire and interview (1) Questionnaire by phone call (1) Questionnaire collection (1) Questionnaire for evaluation of confinement on deviant sexual fantasies (1) Questionnaire forms (1) Questionnaire including validated tools such as Patient Health Questionnaire (PHQ-9), the 7-item Generalised Anxiety Disorder (GAD- 7), the 7-item insomnia severity index (1) Questionnaire with precaution information (1) Questionnaire, phone call (1) Questionnaire, same tools as before, with inclusion of PCL5 questionnaire too. (1) Questionnaire-based observational study (1) Questionnaires for specific phobia (1) Questionnaires on psychological quality of life (1) Questionnaires, spirometry (1) Questionnary (1) Quetiapine (1) Quick Defense (1) Quidel Sofia SARS Antigen FIA (1) Quinquina-Stevia/Azythromycin (1) RAAS inhibitor [continued standard of care] (1) RAPA-501-Allo off-the-shelf Therapy of COVID-19 (1) RAPID-3 (1) RBA-2 (1) RBT-9 (90 mg) (1) RD-X19 (1) RDV (1) RECHARGE (1) REGN10933 + REGN10987 (1) REGN10933+REGN10987 (1) REGN3048 (1) REGN3051 (1) RESP301, a Nitric Oxide generating solution (1) REmotely Monitored, Mhealth (REMM) supported High Intensity Interval Training (HIIT) (1) RIA-device (Remote Investigation and Assessment) (1) RISE (1) RO6953958 (1) RO7234292 (RG6042) (1) RPH-104 80 mg (1) RS blend (1) RSV LID/ΔM2-2/1030s (1) RSV Mobile Application (1) RSV vaccine formulation 1 (1) RSV vaccine formulation 2 (1) RSVPreF3 formulation 2 (1) RSVPreF3 formulation 3 (1) RT PCR SARS-CoV-2 (1) RT-PCR Covid-19 (1) RT-PCR SARS-Cov2 (1) RT-PCR and antibody testing (1) RT-qPCR test (1) RTLS data (1) RUC-4 Compound (1) RUTI® vaccine (1) Rabies Vaccine (1) Racial Inequality Highlighted (1) Racial/Ethnic Frame (1) Radiological Detection (1) Radspherin (1) Raman analysis of saliva, characterization of the Raman database and building of the classification model (1) Ramelteon 8mg (1) Ramipril 2.5 MG Oral Capsule (1) Random Donor Plasma (1) Randomized to Delayed Cord Clamping at birth (1) Randomized to Umbilical Cord Milking at birth (1) Ranitidine (1) Rapid Antigen Test (1) Rapid Diagnostic Test vs PCR (1) Rapid Onsite COVID-19 Detection (1) Rapid detection test (1) Rapid diagnostics using Anyplex TMII RV16 Detection (1) Rapid molecular test (1) Rarefaction (1) Rayaldee 30Mcg Extended-Release (ER) Capsule (1) Razuprotafib (1) Razuprotafib Subcutaneous Solution (1) ReWalk 6.0 (1) Reading a Book (1) Real cTBS to the vmPFC (1) Real iTBS to the dlPFC (1) Real-time chat-based support through IM Apps (1) Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) (1) Recombinant Bacterial ACE2 receptors -like enzyme of B38-CAP (rbACE2) plus Aerosolized 13 cis retinoic acid (1) Recombinant Human Interferon α2b Spray (1) Recombinant Interferon Alfa-2b (1) Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) -placebo (1) Recombinant S protein SARS vaccine (1) Recombinant human alkaline phosphatase (1) Recombinant human angiotensin-converting enzyme 2 (rhACE2) (1) Recombinant human interferon α1β (1) Recombinant human plasma gelsolin (Rhu-pGSN) (1) Recombinant influenza vaccines (1) Recombinant new coronavirus vaccine (CHO cell) group (1) Recombinant novel coronavirus vaccine (Adenovirus type 5 vector) (1) Recombinase aided amplification (RAA) assay (1) Reconsolidation of Traumatic Memories (RTM) (1) Reduced Dose Bevacizumab (1) Reference Treatment- BMS-986165-01 (1) Reference: Favipiravir 200 mg (Avigan) (1) Referral card (1) Regadenoson (1) Regadenoson myocardial perfusion imaging stress test (1) Registery Data Collection (1) Regular Inpatient Medical Care (1) Regular messages through Instant Messaging (IM) (1) Rehabilitation (1) Rehabilitation by Concentric exercises (1) Rehabilitation by Eccentric exercises (1) Rehabilitation exercise protocol (1) Rehabilitation-focused program (1) Reinforcement learning message delivery (1) Relamorelin 10 μg (1) Relation between frailty and clinical outcomes in elderly patients with COVID-19. (1) Relaxation (1) Relaxation Breathing (1) Relaxation Meditation (1) Relaxation Therapy (1) Remain COVID Free SSI (1) Remdesivir (RDV) (1) Remdesivir-HU (1) Remimazolam (1) Remote Automated Monitoring System (1) Remote Behaviour Modification Program (1) Remote Caregiver Training (1) Remote Cognitive Behavioral Therapy for Insomnia (1) Remote Intensive Group Behavioral Treatment (IGBT) (1) Remote Ischemic Conditioning (1) Remote Photoplethysmography (rPPG) vital sign acquisition (1) Remote Problem Management Plus (1) Remote consultation (1) Remote controlled exercise (1) Remote pulmonary rehabilitation (1) Removal of dead space filter (1) Renin-angiotensin system inhibitors (1) Repeat SARS-CoV-2 IgG antibodies at 45-65 days (1) Repetitive Transcranial Magnetic Stimulation (rTMS) (1) Replenish protein group (1) Reporting of anosmia, ageusia and other clinical symptoms (1) Repository Corticotropin Injection (1) ResCure™ (1) Resilience Program (1) Resilient, Empowered, Active Living-Telehealth (REAL-T) (1) Resolute Onyx (1) Respiratory Exercise Training (1) Respiratory Mechanics (1) Respiratory Training (1) Respiratory and psychological rehabilitation (1) Respiratory filter in-line placed with the standard mouthpiece (1) Respiratory infections (1) Respiratory mechanics measurement (1) Respiratory physiotherapy (1) Respiratory rehabilitation (1) Respiratory rehabilitation program (RR). (1) Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening (1) Respiratory tele-rehabilitation program (TRR). (1) Response and Attention Training (1) Responsive training with no video feedback (1) Responsive training with video feedback (1) Resting 12 lead ECG (1) Resveratrol (1) Resveratrol Placebo (1) Retrospective case-control analysis (1) Retrospective data collection (1) Revefenacin (YUPELRI) & Formoterol (Perforomist) (1) Reverse transcription polymerase chain reaction (1) Reverse-transcription polymerase chain reaction (RT-PCR) (1) Review of medical patient file (1) Reward Re-Training (1) RhACE2 APN01 (1) Rhea Health Tone® (1) Riboflavin Placebo (1) Rifaximin Novel Formulation (1) Rilematovir (1) Rilematovir X mg/kg (1) Rilpivirine Injectable Suspension (RPV LA) (1) Rilpivirine extended release suspension for injection (long-acting) (1) Ringer solution (1) Ringer's lactate (1) Rintatolimod (1) Risankizumab IV (1) Risankizumab SC (1) Risk factors (1) Risk of MERS infection (1) Risk reduction (1) Risperidone (1) Ritonavir (1) Ritonavir+Oseltamivir (1) Ritonavir/lopinavir (1) Rivaroxaban 10 MG (1) Rivaroxaban 2.5 MG (1) Rivaroxaban 2.5 Mg Oral Tablet (1) Rivaroxaban placebo tablets (1) RoActemra iv (1) RoActemra sc (1) Robot Assisted Percutaneous Cardiovascular Intervention (1) Robotic therapy (1) Rosuvastatin (Inhibitor arm) (1) Rosuvastatin (Placebo arm) (1) Rosuvastatin + BAY1817080 (1) Rosuvastatin + BI 1323495 (1) Rosuvastatin calcium (1) Routine Oral Care and Analgesia (1) Routine care (no SARS-CoVSTs) (1) Routine standard of care (1) Roxadustat (1) Rt PCR (1) Ruconest (1) Run-in medications (ICS-LABA combination) (1) Ruxolitinib 5 MG (1) Ruxolitinib administration (1) Ruxolitinib plus simvastatin (1) SAB-301 (1) SAMBA II (Diagnostic for the Real World) (1) SAR443122 (1) SARILUMAB (1) SARS-CoV (1) SARS-CoV 2 RNA PCR Semen (1) SARS-CoV 2 RNA PCR Urine (1) SARS-CoV-2 Ab (1) SARS-CoV-2 Antibody Analysis (1) SARS-CoV-2 IgG (1) SARS-CoV-2 IgG Antibody Testing Kit (1) SARS-CoV-2 S1/S2 IgG (1) SARS-CoV-2 Specific T Cells (1) SARS-CoV-2 and/or MIS-C Exposure (1) SARS-CoV-2 antibody based IVIG therapy (1) SARS-CoV-2 antibody immunoassays (1) SARS-CoV-2 antibody test (1) SARS-CoV-2 antibody testing (1) SARS-CoV-2 convalescent plasma treatment (1) SARS-CoV-2 inactivated vaccine (1) SARS-CoV-2 non-immune Plasma (1) SARS-CoV-2 plasma (1) SARS-CoV-2 questionnaire survey (1) SARS-CoV-2 rS - Phase 1 (1) SARS-CoV-2 rS/Matrix M1-Adjuvant (1) SARS-CoV-2 rS/Matrix-M Adjuvant - Day 189 - Phase 2 (1) SARS-CoV-2 rS/Matrix-M Adjuvant - Phase 1 (1) SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 1 (1) SARS-CoV-2 rS/Matrix-M Adjuvant, Day 0 - Phase 2 (1) SARS-CoV-2 rS/Matrix-M Adjuvant, Days 0 and 21 - Phase 2 (1) SARS-CoV-2 rapid diagnostic test (COVID-PRESTO® IgM/IgG, AAZ, Boulogne-Billancourt, France) (1) SARS-CoV-2 research in nasopharyngeal swab, sperm and serologics (1) SARS-CoV-2 serological assessment (IgG) (1) SARS-CoV-2 serology (1) SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen (1) SARS-CoV-2 vaccine (inactivated) (1) SARS-CoV-2 vaccine formulation 1 with adjuvant 1 (1) SARS-CoV-2 vaccine formulation 1 with adjuvant 2 (1) SARS-CoV-2 vaccine formulation 2 with adjuvant 1 (1) SARS-CoV-2 vaccine formulation 2 with adjuvant 2 (1) SARS-CoV-2 vaccine formulation 2 without adjuvant (1) SARS-CoV-2 viral composition (1) SARS-CoV-2-test (1) SARS-CoV2 Autoantibody detection (1) SARS-CoV2 Infection (1) SARS-CoV2 nasal swab (1) SARS-CoV2 serum antibody testing (1) SARS-Cov-2 infection (1) SARSCoV2 Convalescent Plasma (1) SBI-101 (1) SBRT (1) SCB-2019 (1) SCB-2019 with AS03 adjuvant (1) SCB-2019 with CpG 1018 adjuvant plus Alum adjuvant (1) SCD (1) SCH Intervention (1) SECRET questionnaire (1) SELF-BREATHE (1) SF12, EQ-5D-5L and work status standardized quantitative assessments (1) SHG (1) SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted) (1) SHR3680 (1) SIR1-365 (1) SJX-653 (1) SKILLZ-Girl Enhanced football curriculum (1) SLEDD with a L-MOD (1) SMBI digital app (1) SMS message support (1) SMS messages (1) SMS-based support (1) SNDX-6352 (1) SNG001 (1) SNO (1) SOC + IFX-1 (1) SOC + Intravenous Famotidine (1) SOC plus 15mg/kg EB05 IV (1) SOC plus Placebo IV (1) SOC: Temozolomide (1) SPEQ (Specific Psychotic Experiences Questionnaire) - Paranoia and Grandiosity Subscales (1) SPIN-CHAT Program (1) SPIRIT-in person (1) SPIRIT-remote (1) SSE educational intervention (1) ST-2427 (1) STC-19 score (1) STI-5656 (1) STP + COVID-19 Convalescent Plasma (CP) (1) STP + Standard Plasma (SP) (1) SYNB8802 (1) Saline Control (1) Saline Nasal Irrigation (1) Saline containing 1% Human serum albumin(solution without UC-MSCs) (1) Saline nasal and throat spray (1) Saline oral/nasal rinse (1) Saline placebo (1) Saline with Baby Shampoo Nasal Irrigation (1) Saline-sodium citrate (SSC) buffer (1) Saliva (1) Saliva Assay (1) Saliva and NPS test (1) Saliva based assay: crude RNA extraction (1) Saliva sample (1) Saliva specimen (1) Saliva test kit (1) Saliva-based testing (1) Sample (1) Sample Collection/Performance Evaluation (A) (1) Sample Collection/Performance Evaluation (B) (1) Sampler skills (1) Sampling (EDTA blood, pharyngeal and nose swabs, bronchoalveolar lavage ,urine) (1) Sampling of SARS-CoV-2 RNA from nasopharyngeal swab specimen or saliva collected via Salivette Cortisol (1) Sampling of tissue (1) Sampling salivary (1) Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA] (1) Sarilumab 400 MG/2.28 ML Subcutaneous Solution [KEVZARA] (1) Sarilumab Prefilled Syringe (1) Sarilumab SAR153191 (1) Sars-Cov-2 serology (1) Sars-Cov2 serology (1) Satisfaction evaluation (1) Savicell's ImmunoBiopsy™ (1) Saxagliptin (1) Scanning Chest X-rays and performing AI algorithms on images (1) Schirmer Test I (1) Screening breast magnetic resonance imaging (1) Screening digital breast tomosynthesis (1) Screening digital mammography (1) Screening test for covid ( RT PCR and CT Chest) (1) Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX] (1) Sedentary behaviour (1) Self Study (1) Self measurement with pulse oximeter (1) Self-Compassion for Chronic Pain Virtual Group Treatment Program (1) Self-Help Therapy (1) Self-System Therapy (1) Self-acupressure (1) Self-administered questionnaires (1) Self-awareness Control (1) Self-focused acts (1) Self-guided exercises (1) Self-help booklet (1) Self-help guided by a lay provider (1) Self-interest message (1) Self-management booklet (SWitCh: Stay well during COVID-19) (1) Self-prone position recommendation (1) Self-questionnary (1) Selitrectinib (BAY2731954) (1) Semen Qualitative Analysis (1) Semi-structured telephone questionnaire (1) Sending thorax ct video images via smartphone applications (1) Senicapoc (1) Sensbiosys (1) Sensitivity Intervention (1) Sensitivity and Couples' Intervention (1) SensiumVitals wearable sensor (1) Sequencing (1) Seraph®-100 Microbind® Affinity Blood Filter (1) Serelogy testing, RT PCR (1) Serial seroconversion measurements in hospital employees during the COVID-19 pandemic (1) Serologic SARS-CoV-2 screening (1) Serologic assays for antibodies to SARS-CoV-2 (1) Serologic immunoassays to SARS-CoV-2 antibodies (1) Serologic testing (1) Serological Assay or IgG for SARS-CoV-2 (1) Serological analyses to be lead on a pre-existing biobank (1) Serological screening for IgG and IgM antibodies against COVID-19 (1) Serological test and phone interview (1) Serological test for COVID-19. (1) Serological testing (1) Serological tests will be applied on patients blood sampling (1) Serology (1) Serology Test (1) Serology for Covid-19 (1) Serology test follow-up (1) Seroprevalence of SARS-CoV-2 infection in patients with HIV infection (1) Serum SARs COV 2 IGg screening in health care workers (1) Serum protein level analysis (1) Serum test (1) Serum tube collection (1) Serum zinc, vitamin d vitamin b12 levels . (1) Setanaxib (1) Severe Acute Respiratory Syndrome CoronaVirus 2 detection (1) Sevoflurane inhalant product (1) Sham (1) Sham Attention Training (1) Sham Device Treatment (1) Sham Stimulation (1) Sham cTBS to the vmPFC (1) Sham iTBS to the dlPFC (1) Sham intervention (1) Sham irradiation (1) Shanshamani Vati Plus (1) Shared Decision Making (1) Shock-dependent hydrocortisone (1) Short acting beta agonist (SABA) (rescue medication) (1) Sildenafil (1) Sildenafil citrate tablets (1) Silmitasertib (1) Silymarin (1) Simha Kriya (1) Simple chest tomography (1) Simplified Geriatric Evaluation (1) Simulation Airway Coaching (1) Simulation Intervention (1) Simulation of Repurposed Drugs for COVID-19 (1) Simultaneous EGD and colonoscopy (1) Singing for Lung Health group attendance (1) Single Session Problem-Solving Intervention (1) Single fraction whole lung radiotherapy (1) Single high dose vitamin D (1) Single passive leg movement (1) Sintilimab (1) Sirolimus 1 MG/ML (1) Sirukumab (1) Sit-to-stand care (1) Sitagliptin (1) Six Minute Walk Test (6MWT) (1) Six-minute walk test (6MWT) (1) Six-month ARV dispensing (1) Skin biopsy (1) Sleep App (1) Sleep Education (1) Sleepio (1) Slef questionnaires fulfilment (1) Small Gift (1) Smartphone application LiPAT (1) Smartphone-based voice and self-reported symptom collection (1) Smokefree Homes (1) Snorkel-based improvised personal protective equipment (1) Social ABCs (1) Social Communication and Emotional Skill Development (SCESD) module (1) Social Distancing Advertisements (1) Social Incentive (1) Social comparison Intervention (1) Social media & news consumption (1) Socialization (1) Sodium Bicarbonate (1) Sodium Bicarbonate 150Meq/L/D5W Inj (1) Sodium Chloride 9mg/mL (1) Sodium Nitrite (1) Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase (1) Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1) (1) Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2) (1) Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3) (1) Sodium Zirconium Cyclosilicate (SZC) Reduced Dose Level (1) Sodium bicarbonate (1) Sodium chloride (1) Sofosbuvir (1) Sofosbuvir 400 MG plus Daclatasvir 200mg (1) Sofosbuvir and Ledipasvir (1) Sofosbuvir ledipsavir (1) Sofosbuvir plus Ledipasvir (1) Sofosbuvir/Daclatasvir (1) Sofosbuvir/daclatasvir (1) Software Messaging (1) Sofusa DoseConnect (1) Sofusbuvir + Daclastavir 60 mg (1) Solaraze (1) Solcera (1) Soluble Urokinase Plasminogen Activator Receptor (1) Solution-Focused Support Program (1) Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA (1) Soterix taVNS model 0125-LTE Stimulator - Active-Active Group (1) Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group (1) Spartan COVID-19 System (1) Spartan COVID-19 Test (1) Spartan COVID-19 v2 System (1) Spartan Cube Point-of Care Covid-19 test (1) Spasticity Take Control (1) Specific anti-SARS-CoV-2 antibodies (1) Specimen Collection (1) Spectrila® (1) Speed of Processing Training (1) Sphenopalatine Ganglion Block with Local Anesthetic (1) Sphenopalatine Ganglion Block with Placebo (Isotone NaCl) (1) Spironolactone 100mg (1) Sputum analysis (1) Sputum and blood sampling (1) Sputum collection (1) Sputum sample (1) St. George's Respiratory Questionnaire (SGRQ) (1) Staff Wellbeing Centres (1) Stakeholder of TIP-OA Program (1) Stamaril (live attenuated yellow fever vaccine) (1) Standar medical treatmen (1) Standar of care (1) Standard (specific) therapy for COVID-19 (1) Standard 12-lead ECG, NT-proBNP, echocardiography (1) Standard COVID-19 therapies (1) Standard Care Plus Monitoring (1) Standard Care Therapy (1) Standard Dissemination Practice (1) Standard Donor Plasma (1) Standard Dose Bevacizumab (1) Standard Dose Quadrivalent Inactivated Influenza Vaccine (1) Standard Dose of Unfractionated Heparin (1) Standard Incentive (1) Standard Mask (1) Standard Of Care (SOC) (1) Standard Of Care (SOC) + Placebo (1) Standard Oxygen Delivery System (1) Standard Plasma (FFP) (1) Standard Public Health measures (1) Standard SII SBCC (1) Standard Therapy Protocol (STP) (1) Standard Treatment (1) Standard Ventilation Strategy (1) Standard administration of oxygen flow (1) Standard care delivered in the isolation hospitals. (1) Standard care therapy (1) Standard charity resources (1) Standard communication email (1) Standard diagnosis test (1) Standard diagnostic procedures (1) Standard interface (1) Standard medical care (1) Standard mouthpiece (1) Standard of Care (Intravenous access) (1) Standard of Care (SOC) + ANG-3777 (1) Standard of Care (SOC) and Colchicine+Rosuvastatin (1) Standard of Care (SOC): Radiation Therapy (1) Standard of Care Triple IS (1) Standard of Care thromboprophylaxis (1) Standard of care (Paracetamol) (1) Standard of care (SOC) plus placebo (1) Standard of care for SARS-CoV-2 infection (1) Standard of care management (1) Standard of care therapies (1) Standard of care therapy (1) Standard of care. (1) Standard oxygen therapy (1) Standard protein group (1) Standard screening strategy (1) Standard smoking cessation therapy for TUD plus Chess-based cognitive treatment (1) Standard supportive care (1) Standard therapeutic protocol (1) Standard therapy (1) Standard therapy for AUD (1) Standard therapy for AUD plus Chess-based cognitive treatment (1) Standard therapy for COVID-19 according to the stablished hospital protocols. (1) Standard therapy for TUD (1) Standard therapy of COVID-19 (1) Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin inhalation (1) Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection (1) Standard therapy recommended by the Ministry of Health of the Russian Federation and Dalargin intramuscular injection combined with Dalargin inhalation (1) Standard therapy recommended by the Ministry of Health of the Russian Federation. (1) Standard treatment according to the Clinical protocols (1) Standard treatment for COVID-19 (1) Standard-of-care (1) Standard-of-care treatment (1) Standard-titer Convalescent COVID-19 plasma (CCP2) (1) Standardised questionnaires (1) Standardized crisis management and coping protocol plan toward Coronavirus disease 2019 (COVID-19) (1) Standards of Care (1) Standart Care given during normal examination (1) Starling (1) State-trait anxiety inventory scale (1) Statins (Cardiovascular Agents) (1) Stem Cell Educator-Treated Mononuclear Cells Apheresis (1) Stem Cell Product (1) Step monitoring (1) Stereotactic Radiotherapy (1) Sterile Normal Saline for Intravenous Use (1) Sterile Water for Injection (1) Sterile normal saline (0.9%) (1) Stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by COVID-19 infection (1) Stool collection (1) Stool collection or fecal swab (1) Stools (1) Storage of operating waste (1) Streptokinase (1) Stress and emotion management (1) Stretching for People with MS: An Illustrated Manual (1) Study A (1) Study Arm (1) Study B (1) Study C (1) Study D (1) Study Group (1) Study of immune-mediated mechanisms in patients tested positive for SARS-CoV-2 (1) Subacute rehabilitation (1) Subcutaneous Placebo (1) Subject Usual Brand ENDS (1) Sublingual Methylene blue (1) Suboxone (1) Sudarshan Kriya Yoga (SKY) (1) Sulfonatoporphyrin(TPPS) plus Sunlight exposure. (1) Sulfur hexafluoride lipid-type A microspheres (1) Sulodexide (1) Sumifilam (PTI-125), 100 mg tablet (1) Supera 7.5 OD stent (1) Supine Positioning (1) Supine position (1) Supplement Drink (1) Support treatment (1) Supported Adopted Intervention 1 (1) Supported Adopted Intervention 2 (1) Supported Adopted Intervention 3 (1) Supportive Therapy (1) Supportive tratment (1) Supraflex Cruz 60 Micron (1) Suramin (1) Surfactant (1) Surfactant assessment (1) Surge capacity (1) Surgery (1) Surgery: Dynamic Hip Screw, hemiarthroplasty, hip replacement, intramedullary nail (1) Surgical Management (1) Surgical Management + Treatment (1) Surgical Mask (1) Surgical Stripping (1) Surgical face mask use only (1) Surgical facial mask (1) Surgical mask (1) Surgical procedures performed under general anesthesia (1) Surveillance card (1) Survey Group (1) Survey administration (1) Survey and Questionnaire (1) Survey to assess Post traumatic stress and anxiety at inclusion and 6 months later (1) Surveys (1) Susceptibility to infection (1) Suspension or Maintenance of Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors (1) Sustained attention (1) Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST) (1) SyB V-1901 (1) Symptom Survey (1) Symptom and Exposure Surveys (1) Symptomatic drugs (1) Symptomatic treatment (paracetamol or best symptomatic treatment based on doctor recommendations) (1) Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA) (1) Symptoms entered into the CovidX application (1) Symptoms questionnare (1) Synchronous large group online workshop (1) Synthetic neutralising antibodies (1) Syringe (1) Systemic indirect endovenous ozone therapy (1) T memory cells and NK cells (1) T-Detect™ SARS-CoV-2 Assay (1) T-cell receptor (TCR) repertoire (1) T3 solution for injection (1) T89 (1) T89 capsule (1) TAK-018 (1) TAK-018 Placebo (1) TAK-671 (1) TAK-671 Placebo (1) TAK-788 (1) TAK-906 Maleate (1) TAK-906 Maleate Placebo (1) TAK-981 (1) TAPE-Software (1) TAVR or SAVR (1) TBD Compound 1 (1) TBD Compound 2 (1) TBD Compound 3 (1) TCC-COVID mHealth solution (1) TCM prescriptions (1) TD-1058 (1) TD-1473 [Tablet A] (1) TD-1473 [Tablet B] (1) TD139 (1) TDCS (1) TDR (1) TEACCH School Transition to Employment and Postsecondary Education (T-STEP) (1) TEAM Wheels (1) TEM-tPA (1) TERA Intervention (1) TERN-101 (1) TGplPTH1-34 in fibrin (1) TJ003234 (1) TLRs activation measurement (1) TM5614 (1) TMS (1) TNKase (1) TOF protocol (1) TRIIM Treatment (1) TRV027 (1) TXA127 (1) Table Setting Training (1) Tacrolimus (1) Tafenoquine Oral Tablet (1) Take Control (1) Taking Time (1) Taking biological samples (1) Taking blood samples for analyzing progesterone levels (1) Talabostat Mesylate (1) Talabostat Mesylate plus Pembrolizumab (1) Tap water (1) Taste and olfactory function evaluation (1) Taste test (1) Team Intervention (1) Tear Collection (1) Tears swab (1) Technology based social interactions (1) Technology-assisted Index (1) Teduglutide (1) Tele-Pulmonary rehabilitation (1) Tele-Yoga Therapy (1) Tele-coaching (1) Tele-delivered psychological intervention (1) Tele-interventions related to diabetes management and mental well-being (1) Tele-medicine platform (1) Tele-yoga therapy (1) TeleCAM (1) Teleconsultation either by phone or by computer consultation (1) Telehealth CBT (1) Telehealth Consultation (1) Telehealth coaching sessions (1) Telehealth monitoring (1) Telehealth phone calls (1) Telemedicine FU (1) Telemedicine follow-up visit (1) Telemedicine to remote outpatient visit in bariatric patient (1) Telemedicine visit (1) Telemental Health Sessions, Support Groups and Questionnaires (1) Telephone Coaching (1) Telephone follow-up (1) Telephone interview (1) Telephone survey (1) Telephonic interview during the Italian lockdown. (1) Telephonic medical visit (1) Telepsychoeducation (1) Telepsychoeducation with personalized videos (1) Telepsychoeducation without personalized videos (1) Telerehabilitation-Based (1) Telesimulation (1) Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg (1) Telmisartan 20 mg/amlodipine 2.5 mg . (1) Telmisartan 20 mg/indapamide 1.25 mg (1) Telmisartan 40Mg Oral Tablet (1) Telmisartan 40mg (1) Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care. (1) Temporarily holding the RAAS inhibitor [intervention] (1) Temsirolimus (1) Ten-days oseltamivir (1) Tenecteplase (1) Tenofovir/ Emtricitabine ( 300 mg / 200 mg daily during 60 days) + Personal Protective Equipment (PPE) (1) Test Group: experimental - UVC Therapy applied (1) Test PCR (1) Test for SARS-CoV-2 (1) Test: Favipiravir 200 mg (LOQULAR) (1) TestNPass (1) Tested for SARS-CoV-2 (regardless of the result) (1) Testing Sensitivity for SARS-CoV-2 Virus in Symptomatic Individuals (1) Testing for SARS-CoV-2 (1) Testing of SARS-CoV-2 antibodies (1) Testing procedure for Binding antibodies (1) Tests (1) Tetrandrine (1) Text Messaging Reminder (1) Text material for psychoeducation and audio for relaxation techniques (1) Text message (1) Tezacaftor/Ivacaftor + Ivacaftor (1) Thalidomide (1) The CRAFT program (adapted due to COVID-19) (1) The DryShield (1) The MBSR program (adapted due to COVID-19) (1) The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: (1) The PREPARE program (1) The STOP intervention (1) The Vie Scope laryngoscope (1) The control group will not receive hydroxychloroquine (1) The demographic, clinical, laboratory, and instrumental data (1) The high-volume evacuator (1) The saliva ejector (1) The standard Macintosh laryngoscope (1) The standard of care (1) The standard therapy (1) The study does not required (1) The use of the MentalPlus® digital game for assessment and rehabilitation of cognitive function after remission of the symptoms of COVID-19 (1) The usual treatment (1) Therapeutic Anticoagulation (1) Therapeutic Exercise and Education (1) Therapeutic Plasma Exchange (TPE) (1) Therapeutic Plasma exchange (1) Therapeutic plasma exchange (1) Therapeutic plasma exchange (TPE) (1) Therapist Guided E-Therapy (1) Therapist-guided one-session online exposure therapy according to (Öst, 1989) (1) Therapy Intervention (1) There is no intervention (1) There is no intervention in this study (1) Thermography (1) Thiazide or Thiazide-like diuretics (1) This is an online survey with no intervention. (1) Thoracic CT Scan (1) Thorax CT (1) Thoraxic computed tomography (1) Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28 (1) Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28 (1) Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28 (1) Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group# (1) Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group# (1) Three doses of placebo at the schedule of day 0, 14, 28(high-dose group) (1) Threshold IMT device (1) Throat swab and/or nasopharyngeal swab (1) Throat swab sample for measuring current infection with SARS-CoV-2 (1) Thrombin Generation Assay (TGA) (1) Thrombin generation test assay (1) Thrombomodulin Modified Thrombin Generation Assay (TGA-TM) (1) Thromboprophylaxis (1) Thymosin+standard treatment (1) Thyroidectomy (1) Ticagrelor (1) Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine (1) Tigerase® and best available care (1) Tinzaparin or unfractionated heparin (1) Tirofiban Injection (1) Tislelizumab (1) Tissue plasminogen activator (1) Titanium blood test (1) To assess for development of IgG antibodies against SARS-CoV2 (1) Tociliuzumab (1) Tocilizumab +/- ruxolitinib (stages 2b/3) (1) Tocilizumab 180 MG/ML (1) Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA] (1) Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (1) Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1 (2 doses) (1) Tocilizumab Injection [Actemra] (1) Tocilizumab Prefilled Syringe (1) Tocilizumab and Ruxolitinib (Advanced stage 3) (1) Toffee Full Face Mask (1) Tomeka® (1) Toraymyxin PMX-20R (PMX Cartridge) (1) Toremifene (1) Tracheal intubation and cardiopulmonary resuscitation (1) Tracheal suction (1) Tracheostomy (1) Tracheostomy with aerosol box in COVID-19 positive patients (1) Tracheotomy (1) Tradipitant (1) Traditional Chinese Medicine Prescription (1) Traditional Proning Arm (1) Traditional antirheumatic drugs (1) Training (1) Training and Technical Assistance (1) Training clinicians in basic critical care and the management of severe COVID-19 cases (1) Training for Awareness, Resilience, and Action (TARA) (1) Training load (1) Training of youth, community health assistants and community health workers. (1) Training on tailored Quality Improvement measures (1) Training session adressing information and health literacy (1) Training video on anxiety, fear and loneliness in the COVID-19 environment. (1) Training, Tech. Assistance, Quality Assurance/Improvement (1) Tramadol (1) Tranexamic acid (1) Tranexamic acid tablets (1) Trans Sodium Crocetinate (1) Transcendental Meditation (1) Transcendental meditation (1) Transcranial Electrical Stimulation (1) Transcutaneous Auricular Vagus Nerve Stimulation (1) Transfer Package from CI Therapy (1) Transfusion of COVID-19 convalescent plasma (1) Transfusion of SARS-CoV-2 Convalescent Plasma. (1) Transfusion of standard Plasma. (1) Transitional Online Peer Support Group (n=20) (1) Transparent, reusable respirator (1) Transplant patient (1) Transpulmonary pressure measurements (1) Transpulmonary thermodilution (1) Transthoracic echocardiogram (TTE) (1) Trauma Informed Psychotherapy (1) Trauma Informed Yoga (1) Trauma-informed yoga video recording (1) Travelan OTC (1) Treadmill electrocardiographic stress test (1) Treamid (1) Treatment (1) Treatment A (1) Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 3 (1) Treatment A (Dymista): Fixed drug combination of azelastine hydrochloride and fluticasone propionate nasal spray at Visit 5 (1) Treatment As Usual (1) Treatment B (1) Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 3 (1) Treatment B (Placebo): Nasal spray with no active dose (Dymista vehicle) at Visit 5 (1) Treatment C (1) Treatment and prophylaxis (1) Treatment as usual (1) Treatment as usual vitamin D (1) Treatment for COVID-19 (1) Treatment group: will receive a combination of Nitazoxanide, Ribavirin and Ivermectin for a duration of seven days : (1) Treatment with Dexmedetomidine (1) Tremelimumab (1) TriCor® 145mg tablets (1) Triazavirin (Riamilovir) (1) Triazolam 0.25 MG Oral Tablet (1) Trier Social Stress Test (1) Trimethoprim Sulfamethoxazole (TMP/SMX) (1) Trimodulin (1) Trivia Training (1) Trust in science message (1) Tuberculin test (1) Two COVID-19 vaccine candidate (TMV-083) administrations - High dose (1) Two COVID-19 vaccine candidate (TMV-083) administrations - Low dose (1) Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL (1) Two dose ChAdOx1 nCoV-19/Covishield 0.5mL (1) Two dose MenACWY vaccine (1) Two dose MenACWY vaccine min. 4 weeks apart (1) Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 (1) Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule (1) Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule (1) Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28 (1) Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14 (1) Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28 (1) Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule (1) Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule (1) Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14 (1) Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28 (1) Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 (1) Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly (1) Two doses of placebo at the emergency vaccination schedule (1) Two doses of placebo at the routine vaccination schedule (1) Two doses of placebo at the schedule of day 0, 14 #High-dose group# (1) Two doses of placebo at the schedule of day 0, 14 #middle-dose group# (1) Two doses of placebo at the schedule of day 0, 28(high-dose group) (1) Two doses of placebo at the schedule of day 0, 28(middle-dose group) (1) Tympanic Temperature (1) UB-612 (1) UCB9741 (1) UCMSCs (1) UCPVax + Nivolumab (1) ULTRAPROTECTIVE VENTILATION (1) UNI911 INHALATION (1) UNIKINON (Chloroquine phosphate) 200mg tablets (1) US Neulasta (1) UTTR1147A (1) UTTR1147A-matched Placebo (1) UV Light Treatment (1) Ulinastatin (1) Ultimaster Tansei 80 Micron (1) Ultra Brief Online Mindfulness-based Intervention (1) Ultra low-dose computer thermography (1) Ultra-Low-dose radiotherapy (1) Ultra-rapid molecular point-of-care testing (1) Ultrasonography (1) Ultrasound lung imaging as part of FAST+ evaluation (1) Ultrasound of the lower limbs (1) Umbilical Cord Lining Stem Cells (ULSC) (1) Umbilical Cord Mesenchymal Stem Cells (1) Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care. (1) Umbilical cord Wharton's jelly-derived human (1) Umbilical cord derived mesenchymal stem cells (1) Umifenovir (1) Unavailable COVID Test Result - Hypothetical Scenario (1) Unfractionated Heparin IV (1) Unfractionated heparin SC (1) Unfractionated heparin nebulized (1) Unified Protocol for COVID-19 Parenting Stress (UP-COVID) (1) Uniform random message delivery (1) Universal Screening Arm (1) Unsupervised exercise (1) Unsupervised physical activities (1) Upadacitinib (1) Upadacitinib (ABT-494) (1) Urinary Incontinence (1) Urine Test (1) Urine collection (1) Urine sample (1) Use of ECOBICI (public bicycle sharing program) (1) Use of Facetime with child and parents during induction (1) Use of mobile application (1) Use of social media during COVID-19 (1) Use of the pinpointIQ solution (physIQ, Inc.) (1) Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures (1) Usual Brand Cigarette (1) Usual Care Only (1) Usual Care plus Customized Referrals (1) Usual antibiotic treatment (1) Usual care positioning with no instructions (1) V-SARS (1) V/Q SPECT-CT (1) V/Q Vest (1) V590 (1) V591 (1) VB119 (1) VC (1) VCPM (1) VESTA respirator (1) VIB4920 (1) VIB7734 (1) VIP4SCI (1) VIR-7831 (1) VITROS Anti-SARS-CoV-2 IgG test (1) VR for psychoeducation and relaxation (1) VRC-FLUNPF0103-00-VP VRC-FLUNPF0103-00-VP (H10ssF-6473) (1) VRC-MALMAB0100-00-AB (1) VRC-SRSDNA015-00-VP (1) VXA-CoV2-1 (1) Vaccinated with polio vaccine (IPV) (1) Vaccine (1) Vaccine Therapy (1) Vaccine coverage assessment (1) Vaginal fluid Covid-19 PCR test (1) Valbenazine (1) Validation of the LAMP assays (1) Validation of the NGS method (1) Validation of the POCT Antigen tests (1) Valoctocogene Roxaparvovec (1) Valproate (1) Valsartan (Diovan) (1) Values Clarification and Attitudes Transformation (VCAT) Workshop (1) Vancomycin (1) Vancomycin with Taper/Pulse (1) Vascular surgery (1) Vehicle (1) Vehicle + Heparin along with best supportive care (1) Vehicle Control (1) VenaSeal™ Closure System (1) Venepuncture (1) Venous Draw & Testing (1) Venous blood was collected for biochemistry testing (1) Venous blood was collected for biochemistry testing. (1) VentaProst (inhaled epoprostenol delivered via a dedicated delivery system) (1) Ventil - a gas flow divider (1) Verapamil (1) Veru-111 (1) VibroLUNG (1) Video (1) Video Chat + Basic Feedback (1) Video Chat +Personalized Feedback (1) Video Dance classes (1) Video Default (1) Video Visit (1) Video about safety and effectiveness of adult seasonal flu vaccination (1) Video based aerobic exercise (1) Video based exercise (1) Video-Based (1) Video-Based intervention (1) Videofluoroscopic Swallowing Study (VFSS) (1) Videofluoroscopy (1) Vie Scope laryngoscopy (1) Vielight RX Plus (1) Views and experiences of health care professionals working in intensive care units during the COVID-19 pandemic (1) Viral Specific T-cells (VSTs) (1) Virtual ACT Workshop for Emotional Eating (1) Virtual Assistant first, then Human Coach (1) Virtual Care and Remote Automated Monitoring (1) Virtual Care at Home (1) Virtual ELM (1) Virtual Group Exercise (1) Virtual Group Intervention (1) Virtual Peer Support Platform (1) Virtual Reality Behavioral Activation (1) Virtual Reality Goggles (1) Virtual Reality Pain Neuroscience Education (1) Virtual cOaching in making Informed Choices on Elder Mistreatment Self-Disclosure (VOICES) (1) Virtual home visits (1) Virtual reality therapy first (1) Virtual-Care Cognitive Behavioural Therapy (1) Viruxal Oral and Nasal Spray (1) Visual-acoustic biofeedback (1) Vit D (1) Vital sign measurement (1) VitalConnect Vital Sign Patch (1) VitalTalk communication skills training (1) Vitamin B12 (1) Vitamin C tablets (1) Vitamin D 1000 IU (1) Vitamin D3 (cholecalciferol) (1) Vitamin D3 or Placebo (1) Vitamin E (1) Vitamins (1) Vitamins and Minerals (1) Viusid and Asbrip (1) VivaDiag™ COVID-19 lgM/IgG Rapid Test (1) ViviGen® Cellular Bone Matrix (1) Voice Symptom Scale (VoiSS) (1) Volunteer of TIP-OA Program (1) Voraxaze (1) Voriconazole Inhalation Powder (1) WALC-R (1) WEB BASED EDUCATION (1) WFI 5% glucose (1) WFI water nebulization (1) WFIT (1) WHO recommendations (waiting condition) (1) WHOQOL-BREF (1) WHOQOL-BREF survey (1) WJ-MSCs (1) WW (1) Wait list time (1) Wait-list control (1) Waiting list (1) Waiting list where participants wait for delayed treatment (1) Waitlist (1) Walk Test (1) Water Without an Elevated Level of KELEA (1) Wearable Activity Trackers, Exercise Prescription and Virtual Care (1) Wearable Medical Device (Empatica E4) (1) Wearing surgical face mask sprayed with hypertonic saline (1) Web + text smoking cessation intervention (1) Web Based Questionnaire (1) Web Based Survey (1) Web application users (1) Web-based REDCap survey (1) Web-based psychosocial peer-to-peer support (1) Web-based self-report questionnaires (1) WebEx Physical Activity Program (1) Website (1) Weck-cel Swab Collection (1) Weekly Assessment (1) Weight Counseling (1) Weight Loss (1) Wellness (1) Wharton's jelly derived Mesenchymal stem cells. (1) White Sender in Acknowledgement (1) White Sender in Informational Videos (1) Whole Exome Sequencing (1) Whole Genome Analysis (1) Whole Health Program (1) Whole exome sequencing (1) Withings ScanWatch (1) Without haptic stimulation (1) Woebot Substance Use Disorder (1) WofB (1) Women receiving extra remembering by healthcare (1) Workshops control group LiPAT (1) Wrist-worn feedback physical activity monitor (1) Written Information (1) Written Summary of Rounds (1) XAV-19 (1) XC221 (1) XCEL-UMC-BETA (1) XIENCE PRIME BTK stent (1) XatJove Anoia Aplication (1) Xiyanping injection (1) Xpert Pro stent (1) Yin Hu Qing Wen Granula(low does) (1) YinHu QingWen Decoction (1) YinHu QingWen Decoction(low dose) (1) Yinhu Qingwen Granula (1) Yoga Nidra (1) Yoga Therapy (1) Yoga group (1) Zanubrutinib (1) Zaritt Burden Interview (1) Zavegepant (BHV-3500) (1) Zilucoplan® (1) Zinc (Placebo) (1) Zinc (zinc gluconate) (1) Zinc (zinc gluconate) & Vitamin D (cholecalciferol) (1) Zinc Citrate (1) Zinc Gluconate (1) Zinc Picolinate (1) Zinc Picolinate Placebo (1) Zinc Sulfate (1) Zinc Sulfate 220 MG (1) Zinc gluconate (1) Zithromax Oral Product (1) Zofin (1) ZofinTM (OrganicellTM Flow) (1) Zolpidem + PAP therapy (1) Zonisamide (1) Zotatifin (1) [14C]-GSK3640254 intravenous infusion (1) [14C]-GSK3640254 powder (1) [14C]-NT-814 (1) [14C]-radiolabelled BI 1358894 (1) [14C]AZD9833 Solution for Infusion, (NMT 22.8 kBq/5mL) (1) [14C]CC-90001 (1) [18F]FP-R01-MG-F2 (1) [68Ga]Ga-DOTA-(RGD)2 PET/CT (1) [TIMP-2]*[IGFBP-7] (1) a specifically designed self-administered questionnaire (1) a survey (1) acetylsalicylic acid (1) actigraphy (1) acute kidney injury (1) additional blood tubes (1) aerosol box (1) aerosolized DNase (1) after-each-case room disinfection (1) agenT-797 (1) airway management during sedation or general anesthesia (1) all treatment about COVID-2019 (1) allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC) (1) allogeneic mesenchymal stem cell (1) alpha one antitrypsin inhalation (1) alveolar recruitment (1) amlodipine 5 mg/indapamide 2.5 mg (1) amoxicillin/clavulanate (1) anti-CD40 antibody (CDX-1140) (1) anti-SARS-CoV-2 IgY (1) anti-SARS-CoV-2 human convalescent plasma (1) anti-SARS-CoV-2 plasma (1) antidiabetic treatment (1) antithymocyte globulin (rabbit) (1) appendectomy (1) artus Influenza A/B RT-PCR Test (1) assessment of the sequelae after hospitalization for Sars-COV-2 (1) attendance by ambulance crew (1) auscultation by using traditional stethoscope and electronic stethoscope under full PPE (1) autologous adipose-derived stem cells (1) autopsy (1) avdoralimab (1) azithromycin (1) azoximer bromide (1) bacTRL-Spike (1) bamlanivimab (1) behavioral lifestyle intervention (1) belatacept (1) bidirectional oxygenation mouthpiece (1) biochemical analysis (1) biological assays in particular on the lipid metabolism (1) biological sample (1) biological samples collection (1) biological samples day of delivery (1) biological samples, questionnaires and interviews (1) biopsies of subcutaneous adipose tissue (1) blastocyst-stage embryo transfer (1) blood collection via fingerprick (1) blood sample for seroepidemiological investigation (1) blood sampling for biobank (1) blood test for SARS-COV2 serology (1) blood tests (1) bovhyaluronidase azoxymer (1) bromelain (1) bronchoscopy examination (1) canakinumab (1) captopril 25mg (1) cardiac magnetic resonance (1) cardiovascular and respiratory systems monitoring (1) care as usual (1) care modalities (1) carotid-femoral pulse-wave velocity (1) cellulose-containing placebo capsules (1) cenicriviroc (1) chest radiography (1) chest x-ray (1) chiropractic team (1) chlorine dioxide (1) chlorine dioxide 3000 ppm (1) chloroquine (1) cholecalciferol 200,000 IU (1) cholecalciferol 50,000 IU (1) chronic pain team (1) cleavage-stage embryo transfer (1) clinical features and laboratory values (1) collection of biological samples (1) collection of mucosal lining fluid (1) collection of swabs (1) community health worker support (1) comparison of sample collection methods (1) complication (1) computerized cognitive training (CCT) (1) congenital malformation (1) conjunctival RT PCR (1) consultation (1) control (1) control group (1) convalescent plasma application to SARS-CoV-2 infected patients (1) convalescent plasma from recovered COVID 19 donor (1) conventional management of patients (1) conventional oxygen (1) corticosteroid nasal irrigation (1) covid-19 positive pregnant women (1) ctDNA blood sampling (1) current IPAC-UHN PPE (1) daily room disinfection (1) daily syndromic surveillance (1) dapansutrile capsules (1) data record (1) decisions of limitations and stop processing (1) demographic and clinical data obtained from hospital's electronic medical record. (1) diagnostic (1) diagnostic tests for COVID-19 infection (1) dialysis (1) double gloves (1) draw blood (1) e-Psychotherapy (1) e-ink screen (1) eHealth (1) eHealth +counselling contacts (1) eM2M (1) ePNa-CheXED (1) echocardiogram 2D (1) eculizumab (1) efgartigimod IV (1) efgartigimod PH20 SC (1) electrolytes (1) ensoETM device (1) ensoETM. Esophageal cooling during AF ablation (1) enzalutamide (1) enzalutamide Placebo (1) epidemiological and demographic characteristics (1) evaluation of skin microvascular flow and reactivity (1) everolimus (1) exchange blood transfusion from normal donor (1) exercise brochure (1) exercise group (1) exposure (1) fMRI (1) faecal sample collector (1) famotidine (1) favipiravir (1) favipiravir tablets+chloroquine phosphatetablets tablets (1) favorable outcome (1) feces samples (COVI-BIOME ancillary study) (1) fingertip tests for POC assays (1) food-specific go/no-go computerized training (1) fostamatinib (1) fsfi survey (1) further processing of health data (1) gammaCore® (Vagus nerve stimulation) (1) gammaCore® Sapphire (non-invasive vagus nerve stimulator) (1) geko T3 (1) glenzocimab (1) global survey (1) gym-based training (1) hAd5-S-Fusion+N-ETSD vaccine (1) high flow nasal cannula (HFNC) (1) high flow nasal cannula device (1) high-flow high humidity oxygen device with tracheostomy adapter (1) high-titer anti-Sars-CoV-2 plasma (1) home care monitoring (1) home spirometry (1) hormones (1) hospitalisation, necessity of ICU, mortality rate, lung involvement (1) hospitalization for premature birth (1) hospitalized children with Covid19 (1) human cord tissue mesenchymal stromal cells (1) hydrocortisone (1) hydroxychloroquine + azithromycin (1) hydroxychloroquine in combination with camostat mesylate (1) hydroxychloroquine placebo (1) hydroxychloroquine sulfate 200 MG (1) hyper immunoglobulins containing anti-Corona VS2 immunoglobulin (1) hyperbaric oxygen therapy (HBOT) (1) hyperimmune plasma (1) hypoxia : 14.3 and 12.7% FIO2, hypercapnia 7% CO2, inspiratory mechanical constraint (1) iAMP test (1) iNO (inhaled nitric oxide) delivered via the INOpulse Delivery System (1) identify SARS-CoV-2 infection by serology (1) imPulse™ Una e-stethoscope (1) imaging, blood tests (1) immune plasma (1) immunoSEQ Dx (1) impliminting Online Distance Learning (1) in-hospital mortality rate (1) indirect calorimetry (1) inhalable hydroxychloroquine (HCQ) (1) inhaled hydroxychloroquine (1) inhaled type I interferon (1) inspiratory muscle traiing (1) insurance navigation (1) integrated clinical evaluation (1) intensive care unit admission ratio (1) interleuken 6 level measurment (1) intermediate dose Enoxaparin/ unfractionated heparin (1) intermittent theta burst stimulation (iTBS) (1) intradermal injection of BCG Vaccine (1) intramuscular accine (1) intravenous immunoglobulin therapy (1) intubation (1) ioveraº (1) ioveraº sham (1) it is a survey (1) iv Tocillizumab (TCZ) (1) laboratory biomarkers (1) labs (1) lactoferrin, green tea extract (1) lanadelumab (1) laparoscopic or open appendicectomy (1) lay telephone coaching (1) less-frequency hemodialysis (1) leucovorin (1) life questionnaires (1) lifestyle modification (1) liposomal lactoferrin (1) lopinavir/ritonavir (1) lopinavir/ritonavir group (1) lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate (1) low-dose (1) low-molecular-weight heparin (1) lulizumab pegol (1) lung mechanics at different PEEP (1) lung ultrasound (LUS) (1) mHealth Assessments (1) mMRC (Modified Medical Research Council) Dyspnea Scale (1) mRNA in urine test (1) management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia (1) mavrilimumab (1) measurement of circulating sFlt1 concentration (1) mechanical ventilation (1) mechanical ventilator settings and position (1) media multi-task (1) media package (1) melatonin (1) meplazumab for injection (1) mesenchymal stem cells (1) metenkefalin + tridecactide (1) metformin glycinate (1) metformin hydrochloride (1) methylprednisolone (1) methylprednisolone therapy (1) microcirculation recording (1) mind. body. voice (1) mindfulness, emotion didactics, interpersonal skills, experiential learning (1) miniprobe Alveoflex (1) mobile internet survey on self-test (1) modification of the planned therapeutic management (1) modified IPAC-UHN PPE (1) molecular testing for virus RNA using RT-PCR (1) mometasone furoate nasal spray (1) monthly serologic IgM/G test (1) morning Yoga-based breathing support (1) mortality (1) mouthrinse with bêta-cyclodextrin and citrox (1) mouthrinse without bêta-cyclodextrin and citrox (1) multipeptide cocktail (1) muscle ultrasound (1) mycophenolate mofetil (1) mycophenolic acid (1) n/a - samples collected along routine care samples only (1) nCapp, a cell phone-based auto-diagnosis system (1) nangibotide (1) nasal pharyngeal (NP) swab samples (1) nasopharyngeal Covid 19 RT-PCR (1) nasopharyngeal and throat swab (1) nebulised recombinant tissue-Plasminogen Activator (rt-PA) (1) nebulization (1) newborns from covid 19 positive mothers (1) no intervention-mechanistic study (1) no intervention. observational cohort study (1) no interventional study (1) non (1) non applicable (1) non e-cigarette TV commercials (1) non interventional (1) non interventional study (1) non-RAS blocking antihypertensives (1) non-contact magnetically-controlled capsule endoscopy (1) non-interventional (1) none - observational (1) none, this study is observational (1) nonfood-specific go/no-go computerized training (1) noninvasive ventilation (1) normal saline (1) nosocomial infection/hospital acquired infection (1) not applicable (observational study) (1) nutritional intervention (1) oSOC (1) observation (1) observation of covid 19 pneumonia (1) olfactory and gustatory tests (1) olfactory device (1) online KKH Sports Singapore Program with Usual Care (1) online mindfulness group (1) online questionnaires (1) oral co-trimoxazole (1) oral polio vaccine + information (1) oropharyngeal swabs (1) oxygen treatment (1) oxyhydrogen (1) pathogen reduced SARS-CoV-2 convalescent plasma (1) patients COVID 19 (1) patients receiving nasal high flow (1) performance evaluation study of RealDetect RT-PCR Kit for COVID-19 detection (1) peripheral blood draw (1) phone call (1) photobiomodulation and photodynamic therapy (1) physical activity program (1) physiological effects of awake prone position in COVID 19 patients (1) pirfenidone (1) placebo (hartmann plus albumine) (1) placebo capsules (1) placebo for clazakizumab (1) placebo for risankizumab IV (1) placebo rinse (1) placebo+rHuPH20 (1) plasma from convalescent patients with COVID-19 (1) plasma hyperimmune (1) plasma therapy using convalescent plasma with antibody against SARS-CoV-2 (1) poractant alfa (1) positive psychological intervention (1) power breathe (1) prayer (1) pre-operative screening (1) pre_dinner Yoga-based breathing support (1) pre_lunch Yoga-based breathing support (1) predict admission of covid-19 patients to ICU and death with routine and quickly avalaible clinical, biological and radiological variables? (1) prednisolone (1) procalcitonin (1) proper diet (1) prophylactic heparin (1) prophylactic lactoferrin daily (1) psycho-education video (1) psychological and sociological interviews (1) psychological assessment (1) pulmonary anomalies 4 months after documented COVID-19 pneumonia (1) pulmonary rehabilitation (1) pulmonary ultrasound (1) pulse oximeter (1) qRT-PCR and serology (1) quality of life questionnaires (1) quality of live assessment (1) quesionnair (1) questionaire to husband and wife (1) questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality (1) questionnaire and optional interview (1) questionnaire filling (1) quetionnary (1) rDirectCAM (1) rHuEPO (1) rNAPc2 (1) rapid salivary test (1) rapid serological test (1) reSET-O (1) real-time multiplex PCR (1) realtime PCR (1) recombinant human interferon Alpha-1b (1) recovered covid 19 patients plasma (1) rectal swab (1) regular care (1) research specific blood sample (1) respiratory function rehabilitation training (1) retrospective metagenomics on clinical samples collected during hospitalization (1) revised HOME-CoV score (1) rhDNase I (1) rhPTH(1-84) (1) ricolinostat (1) risankizumab (1) risk factors (1) rosuvastatin (1) saint george respiratory questionnaire (1) saliva collection (1) saliva sample (1) samling of oropharynx and nasopharynx (1) sample of blood and saliva (1) self-administered structured questionnaire (1) self-care tools (1) semaglutide (1) semen analysis (1) serological test (1) serology test (1) sertraline (1) serum NGAL and cystatin c (1) serum chemistry analysis (1) serum inflammatory biomarkers (1) service of questionnaire (1) severe covid-19 pneumonia with ET (1) severity of lung involvement with COVID-19. (1) sham TMS (1) slow-wave disruption (1) smell household Items (1) smell the odors of the olfactory rehabilitation kit according to the classic or intensive method (1) sodium chloride 0.9% (1) sofosbuvir (1) some risk factors that might be correlated with TMD (1) specific exercise rehabilitation treatment (1) spirometry (1) spirometry, thoracic CT, CPET, 6 minute walking test, SF-36 questionnaire (1) standard chemotherapy (1) standard concomitant therapy (1) standard medical treatment (1) standard newborn and infant care (1) standard operating procedures (1) standard procedure (1) standard prophylactic dose Enoxaparin/ unfractionated heparin (1) standard protocol (1) standard treatment (1) standard western medicine treatment (1) standardized Lung Ultrasound (LUS) examination (1) stem cells (1) strain CVD 1208S-122 (1) stress and anxiety questionnaire (1) supportive and symptomatic treatment (1) surveys and questionnaires (1) suspected of COVID-19 infection (1) sweat samples (COVIDOG ancillary study) (1) systemic treatment (1) tacrolimus (1) teleconsultation (1) telehealth applications (1) telemedicine (1) telephone consult (1) telmisartan 40 mg/amlodipine 5 mg (1) telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg (1) telmisartan 40 mg/indapamide 2.5 mg (1) test (1) thalidomide (1) therapeutic plasmaexchnage (1) theraputic heparin (1) this study is non- interventional (1) thoracic CT-scan (1) thoracic computed tomography scan (1) thoracic lung ultrasound (1) thromboprofylaxis protocol (1) thromboprophylaxis with low-molecular-weight heparin or fondaparinux (1) thymosin alpha 1 (1) topical steroids and cyclosporin-A (1) tracheostomy (1) traditional communication tools (1) transparent sheet (1) treated with hyperimmune plasma (1) turkish physicians (1) unfractionated heparin (1) urinary NGAL, TIMP-2, IGFBP7, IL-6, viral load and metabolomic (1) use and exposure to disinfectants during the coronavirus pandemic (1) vaccine (1) vaccine BCG (1) vaccine candidate MVA-MERS-S (1) vadadustat (1) venipuncture in peripheral vein (1) ventilatory support with oxygen therapy (1) virgin coconut oil (VCO) (1) visual analogue scale (1) vitamin D (1) vitamin d (1) von Willebrand factor (Recombinant) (1) vv-ECMO (1) washed microbiota transplantation (1) web based survey (1) web-based COMPASS intervention (1) wedged insole (1) zinc (1) zinc acetate (1) zinc gluconate and ascorbic acid (1) ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF. (1) γ-Globulin (1) Оxygen therapy (1)

    Convalescent plasma

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (61)


    Name (Synonyms) Correlation
    drug3501 Questionnaire for evaluation of confinement on deviant sexual fantasies Wiki 0.21
    drug2158 Interferon-β1a Wiki 0.21
    drug4418 Ticagrelor Wiki 0.21
    Name (Synonyms) Correlation
    drug5081 nebulization Wiki 0.21
    drug3351 Prasugrel Wiki 0.21
    drug4678 Virtual Reality Pain Neuroscience Education Wiki 0.21
    drug2073 Imaging by thoracic scanner Wiki 0.21
    drug1535 Eritoran Wiki 0.21
    drug1909 High-flow nasal cannula Wiki 0.21
    drug2863 Non-invasive cardiac imaging Wiki 0.21
    drug248 Aerosolized 13 cis retinoic acid Wiki 0.21
    drug2085 Immunoglobulin Wiki 0.21
    drug1676 Five-days oseltamivir Wiki 0.21
    drug294 Amoxicillin-clavulanate Wiki 0.21
    drug5011 intubation Wiki 0.21
    drug5276 tracheostomy Wiki 0.21
    drug1680 Fixed-duration higher dose Hydrocortisone Wiki 0.21
    drug3450 Pulmonary function test Wiki 0.21
    drug4631 Values Clarification and Attitudes Transformation (VCAT) Workshop Wiki 0.21
    drug2066 IgG antibodies immunoassay Wiki 0.21
    drug2684 Moxifloxacin or Levofloxacin Wiki 0.21
    drug2839 No interverntion Wiki 0.21
    drug4209 Surgical mask Wiki 0.21
    drug3424 Protocolised mechanical ventilation strategy Wiki 0.21
    drug931 Ceftriaxone Wiki 0.21
    drug3114 Patients with the treatment agains COVID19 Wiki 0.21
    drug1679 Fixed-duration Hydrocortisone Wiki 0.21
    drug4344 Ten-days oseltamivir Wiki 0.21
    drug251 Aerosolized All trans retinoic acid Wiki 0.21
    drug3191 Piperacillin-tazobactam Wiki 0.21
    drug5094 non-interventional Wiki 0.21
    drug930 Ceftaroline Wiki 0.21
    drug1958 Hydroxychloroquine + lopinavir/ritonavir Wiki 0.21
    drug4869 bronchoscopy examination Wiki 0.21
    drug4229 Symptomatology, Treatment. daily Activities and Anxiety for Cardiovascular patients Survey (STRATA) Wiki 0.21
    drug1949 Hydroxychloroquin with Azithromycin Wiki 0.21
    drug3965 Shock-dependent hydrocortisone Wiki 0.21
    drug4233 Synthetic neutralising antibodies Wiki 0.21
    drug2501 Macrolide administered for 3-5 days Wiki 0.21
    drug2502 Macrolide administered for up to 14 days Wiki 0.21
    drug382 Aspirin Wiki 0.19
    drug1662 Fiberoptic Endoscopic Evaluation of Swallowing Wiki 0.15
    drug2376 Lopinavir-Ritonavir Wiki 0.15
    drug3052 PLX-PAD Wiki 0.15
    drug4387 Therapeutic anticoagulation Wiki 0.15
    drug1174 Corticosteroid Wiki 0.15
    drug3980 Simvastatin Wiki 0.15
    drug1015 Clopidogrel Wiki 0.12
    drug364 Apremilast Wiki 0.12
    drug2821 No Intervention Wiki 0.12
    drug2366 Lopinavir / Ritonavir Wiki 0.10
    drug3876 Sarilumab Wiki 0.09
    drug2385 Lopinavir/ritonavir Wiki 0.08
    drug4429 Tocilizumab Wiki 0.07
    drug297 Anakinra Wiki 0.06
    drug1950 Hydroxychloroquine Wiki 0.06
    drug1043 Colchicine Wiki 0.06
    drug4690 Vitamin C Wiki 0.06
    drug4112 Standard of care Wiki 0.04
    drug453 Azithromycin Wiki 0.03
    drug3195 Placebo Wiki 0.02

    Correlated MeSH Terms (20)


    Name (Synonyms) Correlation
    D002318 Cardiovascular Diseases NIH 0.24
    D006819 Hyaline Membrane Disease NIH 0.21
    D003289 Convalescence NIH 0.16
    Name (Synonyms) Correlation
    D000073296 Noncommunicable Diseases NIH 0.15
    D014029 Tobacco Use Disorder NIH 0.11
    D003680 Deglutition Disorders NIH 0.09
    D003327 Coronary Disease NIH 0.08
    D011665 Pulmonary Valve Insufficiency NIH 0.07
    D050177 Overweight NIH 0.06
    D006331 Heart Diseases NIH 0.06
    D016638 Critical Illness NIH 0.05
    D045169 Severe Acute Respiratory Syndrome NIH 0.04
    D018352 Coronavirus Infections NIH 0.04
    D012127 Respiratory Distress Syndrome, Newborn NIH 0.04
    D011014 Pneumonia NIH 0.03
    D012128 Respiratory Distress Syndrome, Adult NIH 0.03
    D003141 Communicable Diseases NIH 0.03
    D007239 Infection NIH 0.02
    D013577 Syndrome NIH 0.02
    D055371 Acute Lung Injury NIH 0.02

    Correlated HPO Terms (4)


    Name (Synonyms) Correlation
    HP:0001626 Abnormality of the cardiovascular system HPO 0.24
    HP:0002015 Dysphagia HPO 0.09
    HP:0010444 Pulmonary insufficiency HPO 0.07
    Name (Synonyms) Correlation
    HP:0002090 Pneumonia HPO 0.03

    Clinical Trials

    Navigate: Correlations   HPO

    There are 22 clinical trials


    1 Anti-MERS-COV Convalescent Plasma Therapy

    Since the first report of the Middle East Respiratory Syndrome Corona virus (MERS- CoV) in September 2012, more than 800 cases have been reported to the World Health Organization (WHO) with substantial mortality.

    NCT02190799
    Conditions
    1. Respiratory Distress Syndrome (
    2. Respiratory Distress Syndrome (&
    3. Respiratory Distress Syndrome (& [Hyaline Membrane Disease
    4. Respiratory Distress Syndrome (& [Hyaline Membrane Disease]
    5. Respiratory Distress Syndrome (& [Hyaline Membrane Disease])
    Interventions
    1. Biological: Convalescent plasma
    MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Hyaline Hyaline Membrane Disease

    Primary Outcomes

    Description: Hospital mortality will be death in the ICU during the same hospital admission

    Measure: Hospital mortality

    Time: Death in the Hospital (ICU or ward) before or at 6 months after enrollment

    Secondary Outcomes

    Description: Death in the ICU during the same hospital admission.

    Measure: ICU mortality

    Time: Death in the ICU at or after 90 days of enrollment

    Description: Number of calendar days between admission and final discharge from ICU.

    Measure: ICU Length of Stay

    Time: Number of days in ICU with an average expected duration of 10 days.

    Description: Number of calendar days between start and final liberation from mechanical ventilation.

    Measure: Duration of Mechanical Ventilation

    Time: Number of days of mechanical ventilation with an expected average duration of 8 days

    Description: viral clearance from all sampled sites by day 3 after administration of CP

    Measure: Viral load in tracheal aspirate

    Time: Serial levels in the first 28 days of enrollment

    Description: Epidermal Growth Factor (EGF), Eotaxin, Granulocyte colony-stimulating factor (G-CSF), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), Interferon(IFN)-γ, IFN-a2, Interleukin (IL)-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17, IL-1ra, IL-1a, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, Interferon gamma-induced protein (IP)-10, Monocyte Chemotactic Protein (MCP)-1, Macrophage Inflammatory Protein (MIP)-1a, MIP-1β, Tumor Necrosis Factor-α (TNF-a), TNF-β, Vascular Endothelial Growth Factor (VEGF)

    Measure: Inflammatory markers,

    Time: Serial levels in the first 28 days of enrollment

    Description: anti-MERS-CoV antibody level before and after administration of CP.

    Measure: Anti-MERS-CoV antibodies

    Time: Serial levels in the first 28 days of enrollment

    Other Outcomes

    Description: X ray changes at day 0, 1, 3, 7, 14, 21 and 28

    Measure: Chest X ray

    Time: Serial changes in the X ray till day 28
    2 Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

    REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic resulting in critical illness. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19.

    NCT02735707
    Conditions
    1. Community-acquired Pneumonia, Influenza, COVID-19
    Interventions
    1. Drug: Fixed-duration Hydrocortisone
    2. Drug: Shock-dependent hydrocortisone
    3. Drug: Ceftriaxone
    4. Drug: Moxifloxacin or Levofloxacin
    5. Drug: Piperacillin-tazobactam
    6. Drug: Ceftaroline
    7. Drug: Amoxicillin-clavulanate
    8. Drug: Macrolide administered for 3-5 days
    9. Drug: Macrolide administered for up to 14 days
    10. Drug: Five-days oseltamivir
    11. Drug: Ten-days oseltamivir
    12. Drug: Lopinavir/ritonavir
    13. Drug: Hydroxychloroquine
    14. Drug: Hydroxychloroquine + lopinavir/ritonavir
    15. Drug: Interferon-β1a
    16. Drug: Anakinra
    17. Drug: Fixed-duration higher dose Hydrocortisone
    18. Drug: Tocilizumab
    19. Drug: Sarilumab
    20. Drug: Vitamin C
    21. Drug: Therapeutic anticoagulation
    22. Drug: Simvastatin
    23. Biological: Convalescent plasma
    24. Other: Protocolised mechanical ventilation strategy
    25. Drug: Eritoran
    26. Drug: Apremilast
    27. Drug: Aspirin
    28. Drug: Clopidogrel
    29. Drug: Prasugrel
    30. Drug: Ticagrelor
    MeSH:Pneumonia
    HPO:Pneumonia

    Primary Outcomes

    Measure: All-cause mortality

    Time: Day 90

    Description: Primary end-point for patients with suspected or proven COVID-19 pandemic infection

    Measure: Days alive and not receiving organ support in ICU

    Time: Day 21

    Secondary Outcomes

    Measure: ICU Mortality

    Time: Day 90

    Measure: ICU length of stay

    Time: Day 90

    Measure: Hospital length of stay

    Time: Day 90

    Measure: Ventilator free days

    Time: Day 28

    Measure: Organ failure free days

    Time: Day 28

    Measure: All-cause mortality

    Time: 6 months

    Description: EQ5D-5L and WHODAS 2.0 (not completed in all regions)

    Measure: Health-related Quality of life assessment

    Time: 6 months

    Measure: Proportion of intubated patients who receive a tracheostomy

    Time: Day 28

    Description: Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital

    Measure: Destination at time of hospital discharge

    Time: Free text Day 90

    Measure: Readmission to the index ICU during the index hospitalization

    Time: Day 90

    Measure: World Health Organisation 8-point ordinal scale outcome

    Time: Hospital discharge

    Other Outcomes

    Description: Antibiotic Domain specific outcome

    Measure: Occurrence of multi-resistant organism colonisation/infection

    Time: Day 90, censored at hospital discharge

    Description: Antibiotic Domain specific outcome

    Measure: Occurrence clostridium difficile

    Time: Day 90, censored at hospital discharge

    Description: Macrolide Duration domain specific outcome, and COVID-19 Antiviral Domain specific outcome.

    Measure: Occurrence of serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death

    Time: Day 90, censored at hospital discharge

    Description: Antiviral Domain specific outcome. Only required at selected sites.

    Measure: Change from baseline influenza virus levels in upper and lower respiratory tract specimens

    Time: Day 3, up to Day 7

    Description: COVID-19 Antiviral Domain and COVID-19 Immune Modulation Domain specific endpoint

    Measure: Serial detection of SARS-CoV-2 in upper or lower respiratory tract specimens (using only specimens collected for routine clinical testing)

    Time: Day 90, censored at hospital discharge
    3 Convalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19

    Passive immunization with immunoglobulins is occasionally used as therapy for the treatment of viral infectious diseases. Immunoglobulins are used for the treatment of CMV disease, and is effective as prophylaxis when given soon after exposure to varicella zoster virus, rabies, and hepatitis B virus. Neutralizing antibodies against MERS, SARS-CoV-1 and SARS-CoV-2 have been shown to be present in patients previously infected with MERS, SARS-CoV-1 and SARS-CoV-2 respectively. During the 2003 SARS outbreak in Hong-Kong,a non-randomized study in hospitalized SARS patients showed that treatment with convalescent plasma (convP) from SARS-recovered donors significantly increased the day 22 discharge rate and decreased mortality. A study in non-human primates showed that rhesus macaques could not be re-infected with SARS-CoV-2 after primary infection. With no proven effective therapy against COVID, this study will evaluate the safety and efficacy of convalescent plasma from COVID-recovered donors as a treatment for hospitalized patients with symptomatic COVID-19. The study will focus on patients who tested positive for SARS-CoV-2 in the last 96 hours before inclusion Primary objectives • Decrease overall mortality in patients within COVID disease Study design: This trial is a randomized comparative trial. Patients will be randomized between the infusion of 300mL of convP with standard of care. Patient population: Patients with PCR confirmed COVID disease, age >18 years Donors will be included with a known history of COVID who have been asymptomatic for at least 14 days. Intervention: 300mL of convP Duration of treatment: ConvP will be given as a one-time infusion Duration of follow up: For the primary endpoint: until discharge or death before day 60, whichever comes first. For the secondary endpoints (with separate consent) up to 1 year. Target number of patients: 426 Target number of donors: 100 Expected duration of accrural: 36 months

    NCT04342182
    Conditions
    1. COVID-19
    Interventions
    1. Biological: Convalescent plasma

    Primary Outcomes

    Description: the mortality in the 300ml convP group will be compared with the control arm

    Measure: Overall mortality until discharge from the hospital or a maximum of 60 days after admission whichever comes first

    Time: until hospital discharge or a maximum of 60 days whichever comes first

    Secondary Outcomes

    Description: the hospital days in the 300ml convP group will be compared with the control arm

    Measure: Impact of 300ml convP therapy on hospital days

    Time: until hospital discharge or a maximum of 60 days whichever comes first

    Description: A patient will be considered weaned from oxygen therapy when the patient did not receive oxygen for at least 24 hours.

    Measure: Impact of 300ml convP on weaning from oxygen therapy

    Time: until hospital discharge or a maximum of 60 days whichever comes first

    Description: the overall mortality in hospital days in patients admitted tot the ICU within 24 hours after admission in the 300ml convP group will be compared with the patients admitted tot the ICU within 24 hours after admission in the control arm

    Measure: Impact of 300ml convP on overall mortality in patients admitted to the ICU within 24 hours after admission

    Time: until hospital discharge or a maximum of 60 days whichever comes first

    Description: The mortality in patients with a duration of symptoms less than the median duration of symptoms in the study population will be compared with the mortality in patients with a duration of symptoms more than the median duration of symptoms in the study population

    Measure: Difference in the effect of convP on mortality in patients with a duration of symptoms less or more the median duration of symptoms in the study population

    Time: hospital discharge or a maximum of 60 days whichever comes first

    Description: the ICU days in hospital days in patients admitted to the ICU within 24 hours after admission in the 300ml convP group will be compared with the patients admitted tot the ICU within 24 hours after admission in the control arm

    Measure: Impact of 300ml convP therapy on ICU days in patients admitted to the ICU within 24 hours after admission

    Time: Until hospital discharge, estimated average 4 weeks

    Description: airway samples will be taken on day 1 - 3 - 5 - 7 - 10 - 14 - and at discharge

    Measure: Impact of plasma therapy on the decrease in SARS-CoV2 shedding from airways

    Time: until hospital discharge, estimated average 2 weeks

    Description: Blood wil be drawn at day 1, day 7 and day 14

    Measure: Impact of CTL and NK cell immunity on the likelihood of being protected from immune serum transfer

    Time: until hospital discharge, extimated average 2 weeks

    Description: Evaluation of Severe Adverse Events and transfusion related adverse events

    Measure: Safety of convP therapy

    Time: until hospital discharge or a maximum of 60 days whichever comes first

    Description: The WHO COVID19 disease severity scale on day 15 will be compared with the WHO COVID19 disease severity scale on day 1

    Measure: Change of the 8-point WHO COVID19 disease severity scale on day 15

    Time: until day 15

    Description: The WHO COVID19 disease severity scale on day 30 will be compared with the WHO COVID19 disease severity scale on day 1 and day 15

    Measure: Change of the 8-point WHO COVID19 disease severity scale on day 30

    Time: until day 30

    Description: The WHO COVID19 disease severity scale on day 15 will be compared with the WHO COVID19 disease severity scale on day 1 in patients with a baseline neutralizing antibody titer (PRNT50) <80.

    Measure: Change of the 8-point WHO COVID19 disease severity scale on day 15 in the subgroup of patients with a baseline neutralizing antibody titer (PRNT50) <80.

    Time: until day 15

    Description: Low dose CT and lung function is done 6 weeks after discharge and if abnormal again 3 months after discharge.

    Measure: Impact of plasma therapy on risk of long-term structural lung damage and lung function

    Time: up to 12 months after plasma transfusion
    4 A Randomized Open-Label Trial of CONvalenscent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness (CONCOR-1)

    There is currently no treatment available for COVID-19, the acute respiratory illness caused by the novel SAR-CoV-2. Convalescent plasma from patients who have recovered from COVID-19 that contains antibodies to the virus is a potential therapy. On March 25th, 2020, the FDA approved the use of convalescent plasma under the emergency investigational new drug (eIND) category. Randomized trials are needed to determine the efficacy and safety of COVID-19 convalescent plasma for acute COVID-19 infection. The objective of the CONCOR-1 trial is to determine the efficacy of transfusion of COVID-19 convalescent plasma to adult patients admitted to hospital with COVID-19 infection at decreasing the frequency of in-hospital mortality in patients hospitalized for COVID-19. It is hypothesized that treating hospitalized COVID-19 patients with convalescent plasma early in their clinical course will reduce the risk of death, and that other outcomes will be improved including risk of intubation, and length of ICU and hospital stay. This pan-Canadian clinical trial has the potential to improve patient outcomes and reduce the burden on health care resources including reducing the need for ICU beds and ventilators.

    NCT04348656
    Conditions
    1. COVID-19
    Interventions
    1. Biological: Convalescent plasma

    Primary Outcomes

    Description: Endpoint of the need for intubation or patient death in hospital

    Measure: Intubation or death in hospital

    Time: Day 30

    Secondary Outcomes

    Description: Endpoint of the need for intubation before 30 days

    Measure: Need for Intubation

    Time: Day 30

    Description: Time in hours to intubation from randomization

    Measure: Time to intubation

    Time: Day 30

    Description: Endpoint of the number of days off ventilator at 30 days

    Measure: Ventilator-free days

    Time: Day 30

    Description: In-hospital death censored at 90 days

    Measure: In-hospital death

    Time: 90 days

    Description: Time to in-hospital death at 90 days

    Measure: Time to in-hospital death

    Time: Day 90

    Description: Death at 30 days

    Measure: Death at 30 days

    Time: 30 days

    Description: Date of intensive care unit admission (first date and total number of days)

    Measure: Length of stay in intensive care unit (ICU)

    Time: Day 30

    Description: Date of hospital admission (first date and total number of days)

    Measure: Length of stay in hospital

    Time: Day 30

    Description: First date on ECMO and total number of days

    Measure: Need for extracorpeal membrane oxygenation (ECMO)

    Time: Day 30

    Description: Need for renal replacement therapy

    Measure: Need for renal replacement therapy

    Time: Day 30

    Description: New myocarditis

    Measure: Development of myocarditis

    Time: Day 30

    Description: Transfusion-associated adverse events, Grade 3 and 4 serious adverse events, and cumulative incidence of Grade 3 and 4 adverse events and serious adverse events (using medDRA)

    Measure: Adverse events and serious adverse events

    Time: Day 30

    Description: CCP transfusion-associated adverse events (AE)

    Measure: CCP transfusion-associated adverse events (AE)

    Time: 30 days
    5 COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma

    COVID-19 disease has become a very serious global health problem. Treatments for severe forms are urgently needed to lower mortality. Any procedure that improves these forms should be considered, especially those devoid of serious side effects.There is not enough published information on the use of allogeneic convalescent plasma (ACP) in the treatment of severe forms of COVID-19. The use of ACP can be combined with other treatments and has very few adverse effects. It takes 10-14 days for SARS-CoV2-infected patients to produce virus-neutralizing antibodies: within that time they can develop serious complications and die. Injecting PAC into patients with severe forms of COVID-19 shortens the period of risk while the patient produces the antibodies.

    NCT04357106
    Conditions
    1. COVID-19
    Interventions
    1. Biological: Convalescent plasma
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: PaO2/FiO2 relation

    Measure: Lung injury

    Time: 7 days

    Description: Patients survival after therapy

    Measure: Overall survival

    Time: 15-30 days

    Secondary Outcomes

    Description: Determine the incidence of side effects from plasma administration

    Measure: Adverse reactions to plasma

    Time: 7 days
    6 Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome in Referral Hospitals in Indonesia

    Corona virus disease 2019 (COVID-19) has been declared as a Pandemic by the World Health Organization (WHO). According to WHO report on March 31st 2020, globally COVID-19 have infected over 750,000 people and caused over 36,000 deaths with case fatality rate of 4.85%. In Indonesia, COVID-19 have infected 1,414 people and caused 122 deaths with case fatality rate of 8.63%. In severe cases, COVID-19 causes complications, such as acute respiratory distress syndrome (ARDS), sepsis, septic shock, and multi-organ dysfunction syndrome (MODS), where age and comorbid illnesses as a major factor to these complications. Up to this point there are several promising therapies for COVID-19 but is not yet recommended and in need of further research. The use of convalescent plasma has been approved by the US Food and Drug Administration (FDA) through the scheme of emergency investigational new drug (eIND). This method has been used as the treatment in several outbreak or plague cases over the years, such as the flu epidemic in 1918, polio, measles, mumps, SARS (severe acute respiratory syndrome), EVD (Ebola virus disease) and MERS (middle-eastern respiratory syndrome) and this treatment shows better outcome. Several case report on the use of convalescent plasma for COVID-19 patients with ARDS and mechanical ventilation has been reported and shows promising outcome. Nevertheless, larger and multicenter research need to be done to assess and evaluate the effectiveness and safety of convalescent plasma therapy on for COVID-19 patients with ARDS.

    NCT04380935
    Conditions
    1. COVID
    2. Acute Respiratory Distress Syndrome
    Interventions
    1. Biological: Convalescent plasma
    2. Drug: Standard of care
    MeSH:Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Syndrome

    Primary Outcomes

    Description: Proportion of all-cause mortality

    Measure: All-cause mortality

    Time: up to 28 days

    Secondary Outcomes

    Description: Mean length of stay in intensive care unit

    Measure: Length of stay in intensive care unit

    Time: up to 28 days

    Description: Mean duration of mechanical ventilation

    Measure: Duration of mechanical ventilation

    Time: up to 28 days

    Description: Mean change from baseline using time series analysis

    Measure: Body temperature (degree in Celsius)

    Time: Day 1, 3, 5, and 7 after administration of therapy

    Description: Mean change from baseline using time series analysis

    Measure: The Sequential Organ Failure Assessment (SOFA) Score

    Time: Day 1, 3, 5, and 7 after administration of therapy

    Description: Mean change from baseline using time series analysis

    Measure: PAO2/FIO2 ratio

    Time: Day 1, 3, 5, and 7 after administration of therapy

    Description: Mean change from baseline using time series analysis

    Measure: C-Reactive Protein (CRP) in mg/L

    Time: Day 1, 3, 5, and 7 after administration of therapy

    Description: Mean change from baseline using time series analysis

    Measure: D-Dimer in ng/mL

    Time: Day 1, 3, 5, and 7 after administration of therapy

    Description: Mean change from baseline using time series analysis

    Measure: Procalcitonin in ng/mL

    Time: Day 1, 3, 5, and 7 after administration of therapy

    Description: Mean change from baseline using time series analysis

    Measure: Interleukin 6 (IL-6) in pg/mL

    Time: Day 1, 3, 5, and 7 after administration of therapy

    Description: Number of participants with allergic/ anaphylaxis transfusion reaction

    Measure: Allergic/ anaphylaxis transfusion reaction

    Time: 24 hours post-transfusion

    Description: Number of participants with Hemolytic transfusion reaction

    Measure: Hemolytic transfusion reaction

    Time: 24 hours post-transfusion

    Description: Number of participants with Transfusion Related Acute Lung Injury

    Measure: Transfusion Related Acute Lung Injury

    Time: 24 hours post-transfusion

    Description: Number of participants with Transfusion associated Circulatory Overload

    Measure: Transfusion associated Circulatory Overload

    Time: 24 hours post-transfusion
    7 Randomised Evaluation of COVID-19 Therapy

    RECOVERY is a randomised trial investigating whether treatment with Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids, Azithromycin, Colchicine, IV Immunoglobulin (children only), Convalescent plasma, Synthetic neutralizing antibodies (REGN-COV2), Tocilizumab or Aspirin prevents death in patients with COVID-19.

    NCT04381936
    Conditions
    1. Severe Acute Respiratory Syndrome
    Interventions
    1. Drug: Lopinavir-Ritonavir
    2. Drug: Corticosteroid
    3. Drug: Hydroxychloroquine
    4. Drug: Azithromycin
    5. Biological: Convalescent plasma
    6. Drug: Tocilizumab
    7. Biological: Immunoglobulin
    8. Drug: Synthetic neutralising antibodies
    9. Drug: Aspirin
    10. Drug: Colchicine
    MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections

    Primary Outcomes

    Description: For each pairwise comparison with the 'no additional treatment' arm, the primary objective is to provide reliable estimates of the effect of study treatments on all-cause mortality.

    Measure: All-cause mortality

    Time: Within 28 days after randomisation

    Secondary Outcomes

    Description: To assess the effects of study treatment on number of days stay in hospital

    Measure: Duration of hospital stay

    Time: Within 28 days and up to 6 months after the main randomisation

    Description: Among patients not on invasive mechanical ventilation at baseline, the number of patients with a composite endpoint of death or need for invasive mechanical ventilation or ECMO.

    Measure: Composite endpoint of death or need for mechanical ventilation or ECMO

    Time: Within 28 days and up to 6 months after the main randomisation

    Other Outcomes

    Description: To assess the effects of study treatment on number of patients who needed ventilation and the number of days it was required

    Measure: Need for (and duration of) ventilation

    Time: Within 28 days and up to 6 months after the main randomisation

    Description: To assess the effects of study treatment on number of patients who needed renal replacement therapy

    Measure: Need for renal replacement

    Time: Within 28 days and up to 6 months after the main randomisation

    Description: To assess the effects of study treatment on number of patients who develop new major cardiac arrythmias

    Measure: Development of new major cardiac arrythmias

    Time: Within 28 days and up to 6 months after the main randomisation
    8 The Use of Convalescent Plasma for Patients Hospitalized With COVID-19 Disease

    Pilot study of tolerability and efficacy of transfusion of 200mL of convalescent plasma in patients with COVID-19 respiratory disease.

    NCT04385199
    Conditions
    1. Coronavirus Infection
    2. Coronavirus
    3. COVID
    Interventions
    1. Biological: Convalescent plasma
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: For intubated patients improvement in PaO2/FiO2

    Measure: Improvement in respiratory disease

    Time: day 1 post transfusion

    Description: For intubated patients improvement in PaO2/FiO2

    Measure: Improvement in respiratory disease

    Time: day 3 post transfusion

    Description: For intubated patients improvement in PaO2/FiO2

    Measure: Improvement in respiratory disease

    Time: day 5 post transfusion

    Description: For intubated patients improvement in PaO2/FiO2

    Measure: Improvement in respiratory disease

    Time: day 7 post transfusion

    Description: For intubated patients improvement in PaO2/FiO2

    Measure: Improvement in respiratory disease

    Time: day 14 post transfusion

    Description: For intubated patients improvement in PaO2/FiO2

    Measure: Improvement in respiratory disease

    Time: day 28 post transfusion

    Description: For non intubated patients time to intubation post transfusion

    Measure: Improvement in respiratory disease

    Time: 7 days

    Secondary Outcomes

    Description: ICU length of stay

    Measure: ICU Length of Stay

    Time: 28 days

    Description: Hospital length of stay

    Measure: Length of Stay

    Time: 28 days

    Description: Duration of time on ventilator

    Measure: Ventilator days

    Time: 28

    Description: Adverse transfusion events

    Measure: Tolerability of convalescent plasma

    Time: During transfusion, 1 day post-transfusion

    Description: Improvement in Chest X Ray

    Measure: Radiographic improvement

    Time: 3 days post transfusion

    Description: Improvement in Chest X Ray

    Measure: Radiographic improvement

    Time: 28 days post transfusion
    9 Efficacy of Convalescent Plasma for the Treatment of Severe SARS-CoV-2 Infection: A Randomized, Open Label Clinical Trial

    Convalescent plasma has been used for over 100 years in the treatment of severe acute respiratory infections of viral origin. There are not pharmacological treatments for the actual outbreak for SARS-Cov-2 and it is necessary to evaluate the efficacy of treatment options, including convalescent plasma transfusion. The hypothesis is that convalescent plasma is efficacious and safe for reducing mortality in patients with COVID-19 treated in ICU

    NCT04391101
    Conditions
    1. SARS-Cov-2
    Interventions
    1. Drug: Convalescent plasma

    Primary Outcomes

    Description: Proportion of patients who die while being hospitalized

    Measure: Intrahospital mortality from any cause

    Time: Up to 28 days

    Secondary Outcomes

    Description: Number of days hospitalized

    Measure: Length of hospital stay

    Time: Up to 60 days

    Description: Number of days without ventilatory support

    Measure: Free time for ventilatory support on day 60

    Time: Day 60

    Description: Proportion of patients alive on day 60

    Measure: Overall survival at day 60 since hospitalization

    Time: Day 60

    Description: Proportion of adverse events related with convalescent plasma

    Measure: Cumulative incidence of adverse events: transfusion reactions (fever, flare), TRALI (transfusion-associated lung injury), TACO (transfusion-related circulatory overload), transfusion- related infections

    Time: Up to 28 days
    10 Convalescent Plasma Transfusion Therapy in Severe COVID-19 Patients- a Tolerability, Efficacy and Dose-response Phase II RCT

    As of March 18, 2020, COVID-19 cases were reported in approximately 195 countries. No specific therapeutic agents or vaccines for COVID-19 are available. Several therapies, such as remdesivir and favipiravir, are under investigation, but the antiviral efficacy of these drugs is not yet known. The use of convalescent plasma (CP) was recommended as an empirical treatment during outbreaks of Ebola virus in 2014. A protocol for treatment of Middle East respiratory syndrome coronavirus (MERS-CoV) with CP was established in 2015. This approach with other viral infections such as SARS-CoV, H5N1 avian influenza, and H1N1 influenza also suggested that transfusion of CP was effective. In previous reports, most of the patients received the CP by single transfusion. In a study involving patients with pandemic influenza A(H1N1) 2009 virus infection, treatment of severe infection with CP (n = 20 patients) was associated with reduced respiratory tract viral load, serum cytokine response, and mortality. In another study involving 80 patients with SARS, the administration of CP was associated with a higher rate of hospital discharge at day 22 from symptom onset compared with patients who did not receive CP. Accordingly, these findings raise the hypothesis that use of CP transfusion could be beneficial in patients infected with SARS-CoV-2. The objective of this study is to describe the initial clinical experience with CP transfusion administered to severe COVID-19 patients. The primary endpoint of this trial would be to assess the tolerability, efficacy, and dose-response of CP in severe COVID-19 patients. The secondary endpoint would be to assess the clinical and laboratory parameters after therapy, in-hospital mortality, length of hospital stay, reduction in the proportion of deaths, length of ICU stay, requirement of ventilator and duration of ventilator support. All RT-PCR positive cases with features of severe infection will be enrolled in this study. Apheretic CP will be collected from a recovered patient (consecutive two RT-PCR samples negative) between day 22 to 35 days of recovery and those with the antibody titre above 1:320. This RCT will consist of three arms, a. standard care, b. standard care and 200 ml CP and c. standard care and 400 ml CP as a single transfusion. Twenty (20) patients will be enrolled for each arm. Randomization will be done by someone not associated with the care or assessment of the patients by means of a random number table. Allocations will be concealed in sequentially numbered, opaque, sealed envelopes. Clinical parameters [fever, cough, dyspnea, respiratory rate, PaO2/ FiO2 level, pulse, BP, the requirement of O2, and others] will be recorded before and after CP. Laboratory parameters such as complete blood count, CRP, chest X-ray, SGPT, SGOT, S. Ferritin, and serum antibody titre will be measured before and after transfusion. Allergic or serum sickness-like reactions will be noted and adjusted with outcome. Laboratory tests including RT-PCR will be done at BSMMU virology and laboratory medicine department. Apheretic plasma will be collected at the transfusion medicine department of SHNIBPS hospital, ELISA, antibody titre will be done at CMBT, and patients will be enrolled at DMC and MuMCH. All necessary screening tests will be done before transfusion. Graphpad Prism v 7.0 will be used for analysis. One way ANOVA test, a non-parametric Mann-Whitney test, and a Kruskal-Wallis test will be performed to compare the arms. For parametric outcomes, the investigators will compare the odds ratios across the pairs.

    NCT04403477
    Conditions
    1. Covid19
    2. Convalescence
    Interventions
    1. Biological: Convalescent plasma
    MeSH:Convalescence

    Primary Outcomes

    Description: % of patients died after enrolment

    Measure: Proportion of In-hospital mortality

    Time: 7 days

    Description: Time to death in hours after enrolment

    Measure: Time to death

    Time: 7 days

    Secondary Outcomes

    Description: Temperature in degree Fahrenheit at Day 0, 1, 3, 7

    Measure: Fever

    Time: 7 days

    Description: Respiratory rate per minute at Day 0, 1, 3, 7

    Measure: Respiratory distress

    Time: 7 days

    Description: Saturation of oxygen in % at Day 0, 1, 3, 7

    Measure: Saturation of oxygen

    Time: 7 days

    Description: Blood pressure in mm of Hg at Day 0, 1, 3, 7

    Measure: Blood pressure

    Time: 7 days

    Description: Oxygen requirements in liter/min at Day 0, 1, 3, 7

    Measure: Oxygen requirement

    Time: 7 days

    Description: CRP level in mg/litre

    Measure: C-reactive Protein

    Time: Day 0, 3 and 7

    Description: Serum Ferritin level in ng/ml

    Measure: Ferritin

    Time: Day 0, 3 and 7

    Description: Serum SGPT level in I/U

    Measure: SGPT

    Time: Day 0, 3 and 7

    Description: Serum SGOT level in I/U

    Measure: SGOT

    Time: Day 0, 3 and 7

    Description: Duration of ICU stay in days

    Measure: ICU stay

    Time: 14 days

    Description: Requirement of ventilator support in hours

    Measure: Ventilator support

    Time: 14 days

    Description: Duration of hospital stay in days

    Measure: Hospital stay

    Time: 14 days

    Description: % of patients developed early transfusion reaction like fever, sweating, rash, abdominal pain, urticaria, vomiting, wheezing, chest tightness and hypotension

    Measure: Proportion of Transfusion reaction

    Time: 24 hours
    11 Convalescent Plasma Therapy in Patients With COVID-19

    Scientists and medical workers all around the world were running out of time to manage COVID-19. Several studies have been done to understand the disease and ultimately to find possible treatment. Based on those studies, one of the potential treatment was antibody transfer from recovered COVID-19 patients. Passive antibody transfer was a fast and easy choice. The rational use of antibody from the patient's plasma is a natural neutralizing protein to the cell-infected virus and could possibly slow the active infection down. Investigators initiate an intervention study with purposes to produce quality convalescent plasma from the recovered patients, define the safety of plasma for human use and as an alternative treatment to improve the clinical outcomes of severe COVID-19 patients. The study hypothesis is convalescent plasma is safe and could possibly improve outcome of severe (non-critical) COVID-19 patients. This research will conduct the plaque reduction neutralizing test (PRNT) of recipient blood in vitro. The plasma will be collected in the blood transfusion unit (BTU) in Gatot Soebroto hospital. The storage, testing, transfer, and transfusion of eligible convalescent plasma are the authority of Gatot Soebroto BTU. PRNT and plasma antibody titer measurement from donor plasma will be conducted at Eijkman Institute of Molecular Biology. Investigators enroll approximately 10 patients consecutively, who will be admitted at Gatot Soebroto hospital. Baseline demographic characteristics of samples are recorded. Clinical dan laboratory data will be measured before and after plasma transfusion periodically. The measured variables are pharmacological therapy (antivirus, antibiotics, steroids), invasive oxygen therapy, oxygen index, sequential organ failure assessment (SOFA) score, and laboratory parameters such as leukocyte count, blood chemical panel include liver and renal function, C-reactive protein, procalcitonin, IL-6 and immunoglobulin titer of the recipient and also chest X-ray evaluation. The potential expected risk of plasma transfusions is transfusion reaction (immunological or non-immune related) and transferred foreign pathogen. Investigator will report and treat all adverse events after plasma transfusion has been done. A severe adverse event (SAE) will also report in a special form to sponsor and data safety monitoring board (DSMB). There is theoretically antibody-dependent enhancement (ADE) mechanism from COVID-19 whom will receive plasma transfusion to progress to severe immune response. This preliminary study is supposed to provide supporting data and experience of plasma processing to a larger study in the near future.

    NCT04407208
    Conditions
    1. Convalescence
    2. Corona Virus Infection
    3. Plaque
    Interventions
    1. Biological: Convalescent plasma
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Convalescence

    Primary Outcomes

    Description: PNRT50

    Measure: Plaque reduction neutralization test (PNRT)

    Time: day 7 after first transfusion

    Description: Change of D-dimer compared between pre and post transfusion

    Measure: D-dimer

    Time: day 1,4,7,14 after first transfusion

    Description: Change of CRP compared between pre and post transfusion

    Measure: C-Reactive Protein (CRP)

    Time: day 1,4,7,14 after first transfusion

    Description: Change of INR compared between pre and post transfusion

    Measure: International Normalized Ratio (INR)

    Time: day 1,4,7,14 after first transfusion

    Description: Change of OI compared between pre and post transfusion

    Measure: Oxygenation Index

    Time: day 1,4,7,14 after first transfusion

    Description: Change of CXR with CXR covid score compared between pre and post transfusion

    Measure: Chest X-ray

    Time: day 1,4,7,28 after first transfusion

    Secondary Outcomes

    Description: every adverse event that cause patient to die, prolonged hospitalization or worsening clinical stage of illness

    Measure: severe adverse event

    Time: from day 0 to 14 days after plasma transfusion
    12 CONCOR-1: A Randomized Open-Label Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness

    There is currently no treatment available for COVID-19, the acute respiratory illness caused by the novel SAR-CoV-2. Convalescent plasma from patients who have recovered from COVID-19 that contains antibodies to the virus is a potential therapy. On March 25th, 2020, the FDA approved the use of convalescent plasma under the emergency investigational new drug (eIND) category. Randomized trials are needed to determine the efficacy and safety of COVID-19 convalescent plasma for acute COVID-19 infection. The objective of the CONCOR-1 trial is to determine the efficacy of transfusion of COVID-19 convalescent plasma to adult patients admitted to hospital with COVID-19 infection at decreasing the frequency of in-hospital mortality in patients hospitalized for COVID-19. It is hypothesized that treating hospitalized COVID-19 patients with convalescent plasma early in their clinical course will reduce the risk of death, and that other outcomes will be improved including risk of intubation, and length of ICU and hospital stay. WCM is a U.S. sub-site to this pan-Canadian clinical trial (NCT04348656) which has the potential to improve patient outcomes and reduce the burden on health care resources including reducing the need for ICU beds and ventilators.

    NCT04418518
    Conditions
    1. COVID-19
    Interventions
    1. Biological: Convalescent plasma

    Primary Outcomes

    Description: Endpoint of the need for intubation or patient death in hospital

    Measure: Intubation or death in hospital

    Time: Day 30

    Secondary Outcomes

    Description: Endpoint of the need for intubation before 30 days

    Measure: Need for Intubation

    Time: Day 30

    Description: Time in hours to intubation from randomization

    Measure: Time to intubation

    Time: Day 30

    Description: Endpoint of the number of days off ventilator at 30 days

    Measure: Ventilator-free days

    Time: Day 30

    Description: In-hospital death censored at 90 days

    Measure: In-hospital death

    Time: 90 days

    Description: Time to in-hospital death at 90 days

    Measure: Time to in-hospital death

    Time: Day 90

    Description: Death at 30 days

    Measure: Death at 30 days

    Time: 30 days

    Description: Date of intensive care unit admission (first date and total number of days)

    Measure: Length of stay in intensive care unit (ICU)

    Time: Day 30

    Description: Date of hospital admission (first date and total number of days)

    Measure: Length of stay in hospital

    Time: Day 30

    Description: First date on ECMO and total number of days

    Measure: Need for extracorpeal membrane oxygenation (ECMO)

    Time: Day 30

    Description: Need for renal replacement therapy

    Measure: Need for renal replacement therapy

    Time: Day 30

    Description: New myocarditis

    Measure: Development of myocarditis

    Time: Day 30

    Description: Transfusion-associated adverse events, Grade 3 and 4 serious adverse events, and cumulative incidence of Grade 3 and 4 adverse events and serious adverse events (using medDRA)

    Measure: Adverse events and serious adverse events

    Time: Day 30

    Description: CCP transfusion-associated adverse events (AE)

    Measure: CCP transfusion-associated adverse events (AE)

    Time: 30 days
    13 The Therapeutic Potential of Convalescent Plasma Therapy on Treating Critically-ill COVID-19 Patients Residing in Respiratory Care Units in Hospitals in Baghdad, Iraq

    Out of 49 early-stage critically-ill COVID-19 patients, 21 patients are the experimental group who take convalescent plasma compared to 28 patients receive only conventional therapy without taking Convalescent plasma. Recovery or death, length of stay in hospital, and improvement in the clinical course of the disease are monitored in relation to monitoring through severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) RNA detection via poly chain reaction (PCR), and SARS-CoV-2 immunoglobulin G (IgG) and immunoglobulin M (IgM) serological monitoring.

    NCT04441424
    Conditions
    1. IMMUNOTHERAPY
    Interventions
    1. Biological: Convalescent plasma
    2. Drug: Hydroxychloroquin with Azithromycin
    MeSH:Critical Illness

    Primary Outcomes

    Description: evaluate the role of convalescent plasma in saving life of treated patients by measuring the final outcome whether treated patients survived or died

    Measure: Death versus survival of treated patients

    Time: Up to 8 weeks

    Secondary Outcomes

    Description: this outcome is about measuring the length of stay (in days) of treated patients with convalescent plasma versus tose who were treated with conventional therapies

    Measure: The length of stay in hospitals

    Time: Up to 8 weeks
    14 Infusion of Convalescent Plasma for the Treatment of Patients Infected With Severe Acute Respiratory Syndrome-Coronavirus-2 (COVID-19): A Double-blinded, Placebo-controlled, Proof-of-concept Study

    Patients who are ill with COVID-19 may benefit from receiving convalescent plasma infusions containing antibodies from donors who have recovered from the disease and are proven to no longer be infected. Given the current public health emergency due to COVID-19, the FDA has recently fast-tracked the use of convalescent plasma. The purpose for this study is to assess if convalescent plasma collected from donors previously infected with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, can provide clinical benefit to those acutely ill with the virus and to evaluate if such treatment is safe. There will be two arms in the interventional study, where subjects will either be treated with convalescent plasma or fresh frozen plasma in a randomized and blinded manner. As an additional comparison, the clinical course of subjects enrolled during the period of the study who do not receive an alternative treatment for COVID-19 will be assessed.

    NCT04442191
    Conditions
    1. COVID-19
    Interventions
    1. Biological: Convalescent plasma
    2. Biological: Placebo

    Primary Outcomes

    Description: The primary endpoint will be clinical response at 8 days, defined as no need for oxygen supplementation for the previous 24 hours.

    Measure: Oxygen supplementation

    Time: 8 days

    Secondary Outcomes

    Description: Mortality rate during the 28 days of follow-up and during the subjects' initial hospital stays

    Measure: 28-day and in-hospital mortality rate

    Time: 28 days

    Description: Transfer to an ICU bed during the 28 days following study enrollment

    Measure: Number of participants transferred to the Intensive Care Unit (ICU)

    Time: 28 days

    Description: Intubation within the 28 days following study enrollment

    Measure: Number of participants intubated

    Time: 28 days

    Description: Number of days admitted to the hospital during the 28-day follow-up period

    Measure: Length of hospital stay in days

    Time: 28 days

    Description: Type of respiratory support required during the 28-day follow-up period: intubation, high-flow oxygen by nasal canula, nasal canula

    Measure: Type of respiratory support

    Time: 28 days

    Description: Change in CRP following treatment

    Measure: C-reactive Protein (CRP)

    Time: 28 days

    Description: Change in lymphocyte count following treatment

    Measure: Lymphocyte count

    Time: 28 days

    Description: Number of days respiratory support is required

    Measure: Length or respiratory support required, in days

    Time: 28 days

    Description: Change in LDH following treatment

    Measure: Lactate dehydrogenase (LDH)

    Time: 28 days

    Description: Change in Ferritin level following treatment

    Measure: Ferritin

    Time: 28 days

    Description: Change in D-Dimer level following treatment

    Measure: D-Dimer

    Time: 28 days

    Description: Change in WBC count following treatment

    Measure: White Blood Cell (WBC) Count

    Time: 28 days

    Other Outcomes

    Description: Severe transfusion reaction will be defined as having any of the following occur within 6 hours of the infusion of blood product and not attributable to the underlying disease: 1) an increase of 2 L/minutes or more in supplemental oxygen requirement compared to the baseline requirement before transfusion, 2) oxygen saturations <93% despite oxygen via nasal canula, or 3) need for transfer to the ICU.

    Measure: Safety endpoint: Severe transfusion reaction

    Time: 6 hours following transfusion

    Description: Cumulative incidence of adverse events during the study period: transfusion reaction (fever, rash), transfusion related acute lung injury (TRALI), transfusion associated circulatory overload (TACO), transfusion related infection.

    Measure: Safety endpoint two: adverse events

    Time: 24 hours following transfusion
    15 Pilot Clinical, Statistical and Epidemiological Study on Efficacy and Safety of Convalescent Plasma for the Management of Patients With COVID-19

    The health contingency established against the Severe Acute Respiratory Syndrome associated type 2 Coronavirus (SARS-CoV-2) has promoted a race against the clock for the search on treatment against the disease related with coronavirus (COVID-19). There are no current approved therapeutic options against the virus, although there is a rush for the development of drugs, vaccines and even the passive immunization through plasma from convalescent patients. This passive immunization is made with the administration of antibodies from patients that went through the infectious state of the disease and progress to clinical remission. SARS-CoV-2, and its predecessor SARS-CoV-1, have great similarities between their genes and proteins; tis allow to hypothesize that the antibodies developed against SARS-CoV1 can recognize the antigens of SARS-CoV-2. In this manner, the transfusion of convalescent plasma to patients with the infection brings the probability on eliminating the infection, in this case SARS-CoV-2. There are evidence of this phenomenon observed in previous pandemics caused by SARS-CoV-1, Influenza AH1N1 and Ebola virus. The objective of the study is to develop a therapeutic strategy based on the administration of plasma from patients with COVID-19 with clinical remission to patients that are coursing with the infection. The expected results hopes to establish an effective treatment and satisfactory recovery of patients with COVID-19. Also, we expect to describe the respective antibodies related against the SARS-CoV-2 infection.

    NCT04452812
    Conditions
    1. COVID-19 Pneumonia
    2. Convalescent Plasma
    Interventions
    1. Biological: Convalescent plasma
    MeSH:Pneumonia
    HPO:Pneumonia

    Primary Outcomes

    Description: Any cause mortality during the first 30 days of treatment

    Measure: All-cause mortality

    Time: 30 days

    Description: Side effects associated with the administration of convalescent plasma

    Measure: Side effects

    Time: 30 days

    Secondary Outcomes

    Description: Time to discharge from the ICU

    Measure: Length of stay in Intensive Care Unit (ICU)

    Time: 14 days

    Description: Time for discharge from hospital

    Measure: Length of stay in hospitalization

    Time: 21 days

    Description: Number of days with ventilatory support

    Measure: Days of mechanical ventilation

    Time: 14 days

    Description: change in D-dimer (micrograms/L)

    Measure: Inflammatory biomarkers (d-dimer)

    Time: 21 days

    Description: change in C-reactive protein (milligrams/dL)

    Measure: Inflammatory biomarkers (c-reactive protein)

    Time: 21 days

    Description: Change in LDH (UI/L)

    Measure: Inflammatory biomarkers (lactate dehydrogenase)

    Time: 21 days

    Description: Change in ferritin (nanograms/mL)

    Measure: Inflammatory biomarkers (ferritin)

    Time: 21 days
    16 Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma

    This study aims to collect convalescent plasma and use it as experimental treatment in critically ill Covid-19 patients in order to reduce mortality and length of stay in intensive care unit.

    NCT04468009
    Conditions
    1. SARS-Associated Coronavirus
    2. Covid19
    3. SARS-CoV Infection
    Interventions
    1. Biological: Convalescent plasma
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

    Primary Outcomes

    Description: Mortality at 30 days of Intensive Care Unit (ICU) admission

    Measure: Mortality at ICU at 30 days

    Time: Mortality at 30 days

    Description: Mortality at 90 days of ICU admission

    Measure: Mortality at ICU at 90 days

    Time: Mortality at 90 days

    Secondary Outcomes

    Description: Sequential Organ Failure Assessment (SOFA) of study days 1, 3, 5, 7, 14 and 28

    Measure: SOFA score of study days 1, 3, 5, 7, 14 and 28

    Time: Study days 1, 3, 5, 7, 14 and 28

    Description: Duration (number of days) of supportive therapy (oxygen and ventilation, dialysis, vasopressors) after enrollment

    Measure: Need for supportive therapy after enrollment

    Time: Duration of supportive therapy through study completion, an average of 3 months

    Description: Duration (number of days) of stay in ICU between ICU admission and ICU final discharge

    Measure: Lenght of stay in ICU

    Time: Duration of stay in ICU through study completion, an average of 3 months

    Description: Duration (number of days) of mechanical ventilation between beginning and final liberation from mechanical ventilation

    Measure: Lenght of mechanical ventilation

    Time: Duration of mechanical ventilation through study completion, an average of 3 months

    Description: Duration (number of days) of hospitalization between hospital admission and final hospital discharge

    Measure: Lenght of hospitalization

    Time: Duration of hospitalization through study completion, an average of 3 months

    Other Outcomes

    Description: Duration (number of days) of hospitalization after ICU discharge

    Measure: Lenght of hospitalization after ICU discharge

    Time: Duration (number of days) of hospitalization through study completion, an average of 3 months

    Description: Number of days without ventilation after enrollment

    Measure: Days without ventilation after enrollment

    Time: Days without ventilation through study completion, an average of 3 months

    Description: Number of days without vasopressors after enrollment

    Measure: Days without vasopressors after enrollment

    Time: Days without vasopressors through study completion, an average of 3 months

    Description: Changes in Chest X-ray (unilateral, bilateral, unique, multiple, pleural effusion) after enrollment

    Measure: Changes in Chest X-ray

    Time: Changes in Chest X-ray through study completion, an average of 3 months
    17 Therapeutic Plasmapheresis in Critically Ill Adult Patients With COVID-19 Confirmed Diagnosis / Plasmaféresis terapéutica en Pacientes Adultos críticamente Enfermos Con diagnóstico Confirmado de COVID-19

    Introduction: The SARS-CoV-2 outbreak has left more than two million infected worldwide in the first four months of COVID-19 epidemic. To date, there is no specific treatment for the disease and in critically ill patients there is an additional challenge in controlling the systemic inflammatory response, which is characterized by cytokine storm, alteration in coagulation and endothelial activation in addition to infection. Strategies used in previous viral epidemics, such as convalescent plasma, are therapeutic options to rescue, especially in individuals with a critical presentation of the disease. Aim: To establish clinical response of critically ill patients with COVID-19 who received convalescent plasma from subjects recovered from SARS-CoV-2 during their stay in Intensive Care Unit at Fundación Cardiovascular de Colombia (Hospital Internacional de Colombia). Methodology: Quasi-experimental study (no randomization will be performed). Adult patients who meet selection criteria will receive 500 ml of ABO compatible convalescent plasma, obtained by apheresis from patients recovered from SARS-CoV-2 infection. The main outcome will be in-hospital mortality at 30 days, while indication for ventilatory support (intubation) and adverse events at thirty days will be evaluated as secondary outcomes, compared to subjects receiving usual treatment for clinical sign and symptoms given the absence of ABO compatible plasma units. A survival analysis will be performed using Kaplan-Meier method and association strength will be reported using HR and 95% CI crude and adjusted for confounding variables. Expected results: It is expected to know the clinical and paraclinical response of patients receiving convalescent plasma in our institution, as well as to establish their probability of survival and its associated factors.

    NCT04480632
    Conditions
    1. COVID-19
    Interventions
    1. Biological: Convalescent plasma
    MeSH:Critical Illness

    Primary Outcomes

    Description: In-hospital mortality after administration of ABO compatible convalescent plasma or indication (but not plasmapheresis for absence of compatible convalescent plasma) for comparison group

    Measure: In-hospital mortality

    Time: 30 days

    Secondary Outcomes

    Description: Number of patients with medical indication of hemodialysis or peritoneal dialysis for acute renal failure

    Measure: Incidence of renal replacement therapy

    Time: 30 days

    Description: Number of patients with Alergic reaction, Anaphylaxis, Severe thrombotic events, Transfusion-related acute lung injury (TRALI)], Transfusion-associated circulatory overload (TACO)], Antibody-Dependent Enhancement (ADE)]

    Measure: Incidece of adverse events

    Time: During tranfusion until 24 hours after.
    18 An International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed With SARS-CoV-2 Infection (COVID-19)

    An International Multi-Centre Randomised Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients Diagnosed with SARS-CoV-2 Infection (COVID-19).

    NCT04483960
    Conditions
    1. SARS-CoV-2 Infection (COVID-19)
    Interventions
    1. Drug: Hydroxychloroquine
    2. Drug: Lopinavir / Ritonavir
    3. Biological: Convalescent plasma
    MeSH:Infection Communicable Diseases

    Primary Outcomes

    Description: Morbidity

    Measure: Proportion of participants alive and not having required new intensive respiratory support (invasive or non-invasive ventilation) or vasopressors/inotropic support in the 28 days after randomisation.

    Time: 28 days

    Secondary Outcomes

    Description: Not hospitalized, no limitations on activities Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or ECMO; Death.

    Measure: World Health Organization (WHO) 7-point outcome scale (clinician assessed)

    Time: 28 days

    Description: All cause mortality

    Measure: Mortality

    Time: 7, 15, 28, and 90 days

    Description: Number of days

    Measure: Time to death

    Time: 90 days

    Description: Number of days

    Measure: Length of hospital stay

    Time: 90 days

    Description: Yes/No

    Measure: Receipt of invasive or non-invasive ventilation

    Time: 28 days

    Description: Number of days

    Measure: Length of receipt of invasive or non-invasive ventilation

    Time: 28 days

    Description: Number of days

    Measure: Length of intensive care unit (ICU) stay

    Time: 90 days

    Description: Yes/No

    Measure: Presence of chest infiltrates on chest x-ray (CXR) or CT

    Time: 3 and 7 days

    Description: Number of days

    Measure: Time to defervescence from randomisation

    Time: 28 days

    Description: C-reactive protein (CRP) and Lactate dehydrogenase (LDH) and D-dimer

    Measure: Biomarker levels

    Time: 28 days

    Description: number of days of use in first 10 days

    Measure: Antibiotic use

    Time: 10 days

    Description: Recording of the following adverse events: Diarrhoea, Nausea, Vomiting, Pancreatitis, QTc prolongation (>500ms) 24 hours, serious allergic reaction or anaphylaxis, transfusion-related acute lung injury, transfusion-associated circulatory overload

    Measure: Adverse Events

    Time: 10 days

    Description: Yes/No

    Measure: Serious ventricular arrhythmia (including ventricular fibrillation) or sudden unexpected death in hospital

    Time: 28 days

    Description: Yes/No - based on the modified Kidney Disease Improving Global Outcomes (KDIGO) criteria; serum creatinine increase by≥ 26.5mol/L within 48 hours OR to ≥1.5 times baseline, known or presumed to have occurred within the prior 7 days

    Measure: Acute Kidney Injury (AKI)

    Time: 28 days

    Description: Confirmed deep vein thrombosis, pulmonary embolus, ischemic cerebrovascular event, acute myocardial infarction or other thrombotic event during index hospitalisation.

    Measure: Thrombotic events

    Time: 28 days

    Description: Proportion of patients with negative SARS-CoV-2 real time - polymerase chain reaction (RT-PCR) at day 3 and day 7 from upper or lower respiratory tract samples.

    Measure: Viral clearance

    Time: 3 and 7 days
    19 PERUCONPLASMA: Randomized Clinical Trial to Evaluate Safety and Efficacy of the Use of Convalescent Plasma in Hospitalized Patients With COVID-19

    Open label controlled clinical trial to evaluate the safety and efficacy of the use of convalescent plasma in hospitalized patients with COVID-19 infection. This study will have two arms, one arm will receive convalescent plasma plus standard of care, and the other arm will receive standard of care only. Adults older than 18 years old, hospitalized with diagnosis of COVID-19 confirmed by a laboratory test (molecular or serology), with severe or life-threatening disease, will be included to the study after obtaining inform consent by the patient of a direct family member. Participants will be then randomized 1:1 to the experimental and the control groups. Participants at the experimental group will receive 1 to 2 units of ABO compatible COVID-19 convalescent plasma (200 ml to 250 ml each) within 48 hours, in addition to the standard of care. Participants at the control group will receive standard of care. Safety of convalescent plasma administration will be evaluated, as well as other indicators of clinical efficacy.

    NCT04497324
    Conditions
    1. COVID-19
    Interventions
    1. Biological: Convalescent plasma

    Primary Outcomes

    Description: Incidence of transfusion-related Serious Adverse Events, according to the Hemovigilance Module Surveillance Protocol v2.5.2

    Measure: Transfusion-related Serious Adverse Events

    Time: 14 days after randomization

    Secondary Outcomes

    Description: Death during hospitalization within the first 30 days after enrollment

    Measure: All-cause in-hospital mortality

    Time: 30 days after randomization

    Description: Number of days from date of enrollment to date of discharge

    Measure: Length of hospital stay

    Time: 30 days after randomization or until hospital discharge, whatever comes first

    Description: Number of days from date of admission to the ICU to date of discharge from ICU

    Measure: Length of ICU stay

    Time: 30 days after randomization or until hospital discharge, whatever comes first

    Description: Requirement of invasive mechanical ventilation (Yes/No). Evaluated only for those participants that were on non-invasive ventilatory support at time of randomization

    Measure: Need of invasive mechanical ventilation

    Time: 30 days after randomization or until hospital discharge, whatever comes first

    Description: Number of days from date of intubation to date of successful extubation

    Measure: Duration of mechanical ventilation

    Time: 30 days after randomization or until hospital discharge, whatever comes first

    Description: Improvement of 2 or more points in the WHO progression scale

    Measure: Clinical Improvement at 14 days

    Time: At 3, 14 and 30 days after randomization
    20 Efficacy and Safety of Using Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support

    The COVID-19 pandemic has been spreading continuously, and in Brazil, until August 18, 2020, there have been more than 3,359,000 cases with more than 108,536 deaths, with daily increases. The present study proposes to evaluate the efficacy and safety of using convalescent plasma for treating patients with COVID-19 pneumonia without indication of ventilatory support.

    NCT04528368
    Conditions
    1. COVID-19
    Interventions
    1. Biological: Convalescent plasma
    MeSH:Pneumonia
    HPO:Pneumonia

    Primary Outcomes

    Description: To evaluate the area under the curve of SARSCoV-2 viral load in nasopharyngeal and or oropharyngeal samples on days 0, 3, 6, 9, 12, 15, 18 and 15 after randomization.

    Measure: Area under the curve of SARS-COV-2 viral load obtained from nasopharyngeal and /or oropharyngeal swabs.

    Time: 0, 3, 6, 9, 12, 15, 18 and 21 days

    Secondary Outcomes

    Description: The seven-point scale is as follows: Death 7 points; Hospital admission for mechanical ventilation plus additional organ support (eg, pressors, RRT, ECMO) = 6 points; Hospital admission for mechanical ventilation = 5 points; Hospital admission for non-invasive ventilation or high-flow oxygen therapy = 4 points; Hospital admission for oxygen therapy (but not requiring high-flow or non-invasive ventilation) = 3 points; Hospital admission but not requiring oxygen therapy = 2 points; Discharged with limitations of activities = 1 point; Discharged with no limitations of activities = 0 point;

    Measure: Assessment of clinical improvement using an Ordinal Severity Scale

    Time: 0, 7, 10, 14, 21 and 28 days

    Measure: Evaluate oxygen saturation

    Time: 0, 3, 6, 9, 12, 15, 18 and 21 days

    Measure: Evaluate oxygen supplementation

    Time: 0, 3, 6, 9, 12, 15, 18 and 21 days

    Measure: Assess respiratory rate

    Time: 0, 3, 6, 9, 12, 15, 18 and 21 days

    Measure: Evaluate the PaO2 / FiO2 ratio (for patients on mechanical mechanisms)

    Time: 0, 3, 6, 9, 12, 15, 18 and 21 days

    Measure: Length of hospital stay

    Time: 21 days

    Measure: Length of stay in intensive care

    Time: 21 days

    Measure: Assess the rate of orotracheal intubation

    Time: 21 days

    Description: Quantification by ELISA the levels of 36 molecules determined simultaneously using the Human Cytokine Array Kit da R&D Systems (C5a, IL-4, IL-32 alpha, CD40 ligand, IL-5, CXCL10 / IP-10, G-CSF, IL-6, CXCL11 / I-TAC, GM-CSF, IL-8, CCL2 / MCP-1, CXCL1 / GRO alpha, IL-10, MIF, CCL1 / I-309, IL-12 p70, CCL3 / MIP-1 alpha, ICAM-1, IL-13, CCL4 / MIP-1 beta, IFN -gamma, IL-16, CCL5 / RANTES, IL-1 alpha, IL-17, CXCL12 / SDF-1, IL-1 beta, IL-17E, Serpin E1 / PAI-1, IL-1ra, IL-23, TNF-alpha, IL-2, IL-27 and TREM-1)

    Measure: Change in the profile of cytokines/chemokines in both groups

    Time: 0, 3, 6, 9, 12, 15, 18 and 21 days

    Measure: Presence of antibodies against SARS-CoV-2 in serum after convalescent plasma administration

    Time: 0, 3, 6, 9, 12, 15, 18 and 21 days

    Measure: Death rate

    Time: 7, 10, 14, 21 and 28 days

    Measure: Rate of transfusion reactions to convalescent plasma infusion

    Time: 21 days
    21 Real-time Evaluation of Safety and Efficacy of Convalescent Plasma Units Transfused to Elderly Patients With COVID-19

    The trend of the spread of the COVID-19 pandemic demonstrates in Lombardy, starting from 28.03.2020, a slowdown in the exponential phase of infections and the probable reaching of a plateau phase. However, a marked increase in infections was observed in the so-called "protected structures" such as nursing homes (RSA), both in health staff and in the residents of such facilities. The observed percentage of lethality, according to the more recent data provided by the National Institute of Health, is very high especially among residents. For these reasons, the city Hospital (ASST) of Mantua , already involved in the use of hyperimmune plasma as a therapy for COVID-19, designed this study in order to evaluate RSA patients and to identify the cases eligible for this treatment.

    NCT04569188
    Conditions
    1. COVID-19
    Interventions
    1. Biological: Convalescent plasma

    Primary Outcomes

    Description: Death from any cause

    Measure: Death

    Time: 15 days

    Secondary Outcomes

    Description: Naso-pharyngeal swab

    Measure: Viral load

    Time: 7 days
    22 Convalescent Plasma in the Treatment of Covid-19

    One hundred patients hospitalized and in need of oxygen treatment due to Covid-19 should be randomized and 50% treated with 200 ml convalescent plasma x 3 and 50% given ordinary treatment. Primary outcome is number of days the patients need oxygen within 28 days from inclusion. Secondary outcome is number of days in hospital, number of days in respirator and mortality. Side effects of treatment is monitored.

    NCT04600440
    Conditions
    1. Covid-19
    2. Respiratory Insufficiency
    Interventions
    1. Biological: Convalescent plasma
    MeSH:Respiratory Insufficiency Pulmonary Valve Insufficiency
    HPO:Pulmonary insufficiency

    Primary Outcomes

    Description: Number of days in need of oxygen within 28 days from inclusion

    Measure: Number of days in need of oxygen

    Time: 28 days

    Secondary Outcomes

    Description: number of days before discharge from hospital

    Measure: Number of days before discharge from hospital

    Time: 3 months

    Description: death of patient

    Measure: Mortality within 3 months

    Time: 3 months

    Description: number of days before need of assisted ventilation

    Measure: Number of days before need of assisted ventilation

    Time: 28 days

    Related HPO nodes (Using clinical trials)


    HP:0002090: Pneumonia
    Genes 280
    TLL1 CHD7 TGIF1 KMT2D ACP5 PIGN JAK3 NOS1 SFTPB SRP54 MS4A1 NODAL USB1 CD79B SGCG ACTC1 CASP8 TGFB1 OFD1 CD19 CD247 NHLRC1 SHH NTRK1 EGFR LAMA3 PLOD1 FANCF JAK3 RAG2 PGM3 CACNA1C BTK IL2RG PIK3CD CREBBP KCNJ6 FMO3 ACTA1 TNFSF12 GATA6 ZAP70 PLOD1 UNC119 FGF8 GAS1 DNAI1 WAS GNPTAB FOXH1 CYBC1 LAMC2 RAG1 PEPD PDHA1 PMM2 PAFAH1B1 CD19 CD3D SIX3 CD81 DLL1 LTBP3 EP300 TNFRSF13B SIX3 GLI2 SMARCD2 TIMM8A MYH6 DCLRE1C ABCA3 IL7R TBC1D24 STAT3 CFB FOXH1 FOXP3 FCGR2A P4HTM AP3B1 POLA1 TK2 CDON PKHD1 TAF1 CDON NIPBL GRHL3 GAS1 EFEMP2 CRLF1 SLC35A1 SLC25A24 DOCK8 ZIC2 LEP AFF4 DDR2 CD3E PTPRC BLM RNU4ATAC TNFRSF13C KNSTRN CDON SELENON FOXH1 ORC6 RAG1 RNF168 SHH DISP1 CYBA IL7R CARD11 LONP1 COL11A2 CR2 FGF8 ZIC2 CARD11 CYBB NBN ICOS DNAJC21 DNMT3B DISP1 TGIF1 HLA-DQB1 ADA SETBP1 MED25 FOXH1 SLC35C1 ACADVL TDGF1 PNP SP110 SMC1A ICOS SREBF1 TDGF1 NBN DCLRE1C ALMS1 GLI2 MCIDAS FGF8 NCF1 RAG1 PTCH1 NADK2 IL2RG ZBTB24 ZAP70 GLI2 FGFR1 GAS1 TNFRSF13B GAS1 IFNGR1 CFTR COL11A2 CR2 SAMD9 CD247 TGIF1 TREX1 CARMIL2 TCIRG1 BLNK UBB SRP54 LAMB3 DISP1 RMRP TNFRSF13C NFKB1 STAG2 IRF8 PTCH1 SIX3 KPTN TBX20 TDGF1 CSPP1 IGHM BTK NFIX RNU4ATAC CXCR4 NFKB2 RAC1 CD27 TGIF1 ADA TBX20 ZIC2 MTHFD1 RAG2 GATA4 TNFRSF11A DZIP1L FGF8 KIAA0586 SHH TDGF1 RYR1 ODAD1 WDR1 CREBBP CITED2 DLL1 NCF2 TBCD SHH NODAL RAC2 SIX3 GBA PTCH1 DNAI2 ZIC2 TNFRSF13C ALMS1 PURA STAG2 DLL1 SBDS ICOS EFL1 ACP5 SFTPC CFAP410 MASP2 IL2RG IGLL1 AFF4 BTK LIG4 NFKB2 WDR19 CD55 CDON GAS8 EPM2A NKX2-1 RNF125 DCLRE1C NODAL LRBA ELANE MAN2B1 DLL1 PTCH1 HLA-DQA1 EXTL3 SLC35C1 MAN2B1 FOXN1 PRKCD GLI2 RANBP2 MID1 IL2RG FBLN5 NKX2-5 NODAL GFI1 TNFSF12 RAG2 ADA IL21R KDM6A OSTM1 ASAH1 DISP1 PANK2 FGFR1
    SNP 0

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    Related HPO nodes (Using clinical trials)


    HP:0002090: Pneumonia
    Genes 280
    TLL1 CHD7 TGIF1 KMT2D ACP5 PIGN JAK3 NOS1 SFTPB SRP54 MS4A1 NODAL USB1 CD79B SGCG ACTC1 CASP8 TGFB1 OFD1 CD19 CD247 NHLRC1 SHH NTRK1 EGFR LAMA3 PLOD1 FANCF JAK3 RAG2 PGM3 CACNA1C BTK IL2RG PIK3CD CREBBP KCNJ6 FMO3 ACTA1 TNFSF12 GATA6 ZAP70 PLOD1 UNC119 FGF8 GAS1 DNAI1 WAS GNPTAB FOXH1 CYBC1 LAMC2 RAG1 PEPD PDHA1 PMM2 PAFAH1B1 CD19 CD3D SIX3 CD81 DLL1 LTBP3 EP300 TNFRSF13B SIX3 GLI2 SMARCD2 TIMM8A MYH6 DCLRE1C ABCA3 IL7R TBC1D24 STAT3 CFB FOXH1 FOXP3 FCGR2A P4HTM AP3B1 POLA1 TK2 CDON PKHD1 TAF1 CDON NIPBL GRHL3 GAS1 EFEMP2 CRLF1 SLC35A1 SLC25A24 DOCK8 ZIC2 LEP AFF4 DDR2 CD3E PTPRC BLM RNU4ATAC TNFRSF13C KNSTRN CDON SELENON FOXH1 ORC6 RAG1 RNF168 SHH DISP1 CYBA IL7R CARD11 LONP1 COL11A2 CR2 FGF8 ZIC2 CARD11 CYBB NBN ICOS DNAJC21 DNMT3B DISP1 TGIF1 HLA-DQB1 ADA SETBP1 MED25 FOXH1 SLC35C1 ACADVL TDGF1 PNP SP110 SMC1A ICOS SREBF1 TDGF1 NBN DCLRE1C ALMS1 GLI2 MCIDAS FGF8 NCF1 RAG1 PTCH1 NADK2 IL2RG ZBTB24 ZAP70 GLI2 FGFR1 GAS1 TNFRSF13B GAS1 IFNGR1 CFTR COL11A2 CR2 SAMD9 CD247 TGIF1 TREX1 CARMIL2 TCIRG1 BLNK UBB SRP54 LAMB3 DISP1 RMRP TNFRSF13C NFKB1 STAG2 IRF8 PTCH1 SIX3 KPTN TBX20 TDGF1 CSPP1 IGHM BTK NFIX RNU4ATAC CXCR4 NFKB2 RAC1 CD27 TGIF1 ADA TBX20 ZIC2 MTHFD1 RAG2 GATA4 TNFRSF11A DZIP1L FGF8 KIAA0586 SHH TDGF1 RYR1 ODAD1 WDR1 CREBBP CITED2 DLL1 NCF2 TBCD SHH NODAL RAC2 SIX3 GBA PTCH1 DNAI2 ZIC2 TNFRSF13C ALMS1 PURA STAG2 DLL1 SBDS ICOS EFL1 ACP5 SFTPC CFAP410 MASP2 IL2RG IGLL1 AFF4 BTK LIG4 NFKB2 WDR19 CD55 CDON GAS8 EPM2A NKX2-1 RNF125 DCLRE1C NODAL LRBA ELANE MAN2B1 DLL1 PTCH1 HLA-DQA1 EXTL3 SLC35C1 MAN2B1 FOXN1 PRKCD GLI2 RANBP2 MID1 IL2RG FBLN5 NKX2-5 NODAL GFI1 TNFSF12 RAG2 ADA IL21R KDM6A OSTM1 ASAH1 DISP1 PANK2 FGFR1
    SNP 0

    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook